Case Reports1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGFβ Receptor Mutations in Benign Joint Hypermobility by Mehta, Puja et al.
Tuesday 23 April 2013, 10.30–11.30
POSTER VIEWING I
CASE REPORTS
1. A LATE PRESENTATION OF LOEYS–DIETZ SYNDROME:
BEWARE OF TGFb RECEPTOR MUTATIONS IN BENIGN JOINT
HYPERMOBILITY
Puja Mehta1, Susan Holder2, Benjamin Fisher3 and Tonia Vincent1
1Rheumatology, Imperial College Healthcare NHS Trust, London,
2North West Thames Regional Genetics Service, NWLH NHS Trust,
London and 3Rheumatology Research Group, University of
Birmingham, Birmingham, UK
Background: Thoracic aortic aneurysms (TAA) and dissections are not
uncommon causes of sudden death in young adults. Loeys-Dietz
syndrome (LDS) is a rare, recently described, autosomal dominant,
connective tissue disease characterized by aggressive arterial aneur-
ysms, resulting from mutations in the transforming growth factor beta
(TGFb) receptor genes TGFBR1 and TGFBR2. Mean age at death is
26.1 years, most often due to aortic dissection. We report an unusually
late presentation of LDS, diagnosed following elective surgery in a
female with a long history of joint hypermobility.
Methods: A 51-year-old Caucasian lady complained of chest pain and
headache following a dural leak from spinal anaesthesia for an elective
ankle arthroscopy. CT scan and echocardiography demonstrated a
dilated aortic root and significant aortic regurgitation. MRA demon-
strated aortic tortuosity, an infrarenal aortic aneurysm and aneurysms
in the left renal and right internal mammary arteries. She underwent
aortic root repair and aortic valve replacement. She had a background
of long-standing joint pains secondary to hypermobility, easy bruising,
unusual fracture susceptibility and mild bronchiectasis. She had one
healthy child age 32, after which she suffered a uterine prolapse.
Examination revealed mild Marfanoid features. Uvula, skin and
ophthalmological examination was normal.
Results: Fibrillin-1 testing for Marfan syndrome (MFS) was negative.
Detection of a c.1270G>C (p.Gly424Arg) TGFBR2 mutation confirmed
the diagnosis of LDS. Losartan was started for vascular protection.
Conclusions: LDS is a severe inherited vasculopathy that usually
presents in childhood. It is characterized by aortic root dilatation and
ascending aneurysms. There is a higher risk of aortic dissection
compared with MFS. Clinical features overlap with MFS and Ehlers
Danlos syndrome Type IV, but differentiating dysmorphogenic features
include ocular hypertelorism, bifid uvula and cleft palate.
Echocardiography and MRA or CT scanning from head to pelvis is
recommended to establish the extent of vascular involvement.
Management involves early surgical intervention, including early
valve-sparing aortic root replacement, genetic counselling and close
monitoring in pregnancy. Despite being caused by loss of function
mutations in either TGFb receptor, paradoxical activation of TGFb
signalling is seen, suggesting that TGFb antagonism may confer
disease modifying effects similar to those observed in MFS. TGFb
antagonism can be achieved with angiotensin antagonists, such as
Losartan, which is able to delay aortic aneurysm development in
preclinical models and in patients with MFS. Our case emphasizes the
importance of timely recognition of vasculopathy syndromes in
patients with hypermobility and the need for early surgical intervention.
It also highlights their heterogeneity and the potential for late
presentation.
Disclosures: The authors have declared no conflicts of interest.
2. A CASE OF POSTERIOR REVERSIBLE ENCEPHALOPATHY
SYNDROME IN A PATIENT WITH SLE
Kavitha Nadesalingam1, Helen Maciver1 and Wendy Shingler1
1Rheumatology, Bradford Teaching Hospitals, Bradford, UK
Background: Posterior reversible encephalopathy syndrome (PRES)
is an increasingly reported condition identified by characteristic clinical
manifestations and MRI features. It is characterized by headache,
visual disturbances, seizures, altered mental status, hypertension (HT)
and radiological findings of oedema in the white matter of the brain.
Risk factors include HT, renal disease and immunosuppressive
therapies although the pathogenesis remains unclear.
Methods: We present a case of a 16-year-old girl, AR, with SLE,
treated with HCQ, mycofenolate and prednisolone since 15 years of
age, who went on to develop PRES.
Results: AR was reviewed in clinic in August 2011 with proteinuria,
haematuria, hypoalbuminaemia, rising creatinine and low complement.
She was normotensive at this point. An urgent renal biopsy confirmed
diffuse active LN, stage IVa.
AR was treated with cyclophosphamide (CYC) and commenced on
an ACE inhibitor. Despite two cycles of CYC, she became oedematous
and gained 10 kg in weight. Her blood pressure (BP) was 155/95. She
was started on furosemide and her ACE-inhibitor was increased.
AR was then admitted acutely with recurrent seizures, confusion
and visual loss. Blood pressure on admission was 166/100. WCC 14,
Cr 162 Ur 15, Alb 23, CRP <5. CT head—low density white matter
lesion in left and right occipital lobes. She was sedated and intubated
on ICU and required haemofiltration. Infection was excluded and she
was commenced on i.v. methylprednisolone (MTP) and IVIG. An MRI
showed extensive white matter oedema likely secondary to vasculo-
pathy. She remained hypertensive with reduced level of conscious-
ness, weakness and had further seizures. She was therefore given
rituximab. Following neurology review, a diagnosis of PRES was made
and MTP was stopped and labetalol and GTN started in an attempt to
improve BP. As AR had active SLE, hydrocortisone and RTX were
continued on advice of the rheumatology team. She continued to make
a slow recovery over 3 months and a repeat MRI showed improvement
in oedema. On discharge her vision and mobility had improved and
she had no further seizures. Cr 74 on discharge.
Conclusions: PRES occurs in young SLE patients often early in
disease. The mean systolic and diastolic BPs on presentation has
been reported at 187.6 and 113.5 mmHg respectively. It has been
documented that 76.5% of cases of PRES in SLE had recent initiation
or augmentation of immunosuppressants of a mean duration of 6.9
days prior to development of PRES. The major immunosuppressants
identified were i.v. MTP, i.v. CYC and cyclosporine.
Our case reiterates that multiple aetiologies may be responsible for
PRES in SLE patients.
The diagnosis of PRES needs to be considered when patients
present with typical symptoms and MRI findings so possible offending
agents can be withheld. However, in patients with active SLE,
augmentation of immunosuppression is still strongly warranted to
reduce lupus related organ damage.
Disclosures: The authors have declared no conflicts of interest.
3. RITUXIMAB THERAPY IN REFRACTORY MACROPHAGE
ACTIVATION SYNDROME SECONDARY TO SLE
Jyoti Bakshi1, Sadon Hassan2, David D’Cruz3 and Antoni Chan1
1Rheumatology, Royal Berkshire Hospital, Reading, 2Haematology,
Royal Berkshire Hospital, Reading and 3Rheumatology, St Thomas’s
Hospital, London, UK
Background: A 45-year-old Jamaican male with SLE (previously
meeting the ACR criteria) presented with a one-month history of fever
and feeling non-specifically unwell. Medications included a reducing
regimen of Prednisolone and Hydroxychloroquine. Examination
showed a tachycardia and fever only. Chest X-ray and ECG were
normal. Urine dipstick showed protein (1þ) and blood (3þ). Blood tests
were unremarkable other than an elevated AST 71 U/l (range 5–40),
ALT 139 U/l (range 10–35), CRP of 150 mg/l and ESR 100 mm/h.
Despite treatment with broad spectrum antibiotics and hydrocortisone
he continued to have fevers and developed a neutropenia (count 0.6)
requiring antibiotic cover for potential neutropenic sepsis.
Methods: He acutely deteriorated with the haemoglobin falling to
7.6 g/l, platelet count to 29 x 109/l with a rise in creatinine (352 mmol/l),
ALT (950 U/l) and AST (293 U/l). Anti-dsDNA was 627 U/ml and
complements were low. Serum ferritin was >2000 mg/dl, with raised
triglycerides (300 mg/dl) and a low fibrinogen (100 mg/dl). CT chest/
abdomen/pelvis commented on a possible atypical infection in the
lungs. Treatment was switched to meropenem, anti-viral and anti-
fungal agents to cover possible invasive opportunistic infections and
blood products were given. Despite 7 days of treatment the CRP
(280 mg/l) and ESR (132 mm/h) remained elevated with continued
pyrexias and cytopenias. Multiple blood and urine cultures, viral
serology, TB Elispot, echocardiogram and abdominal ultrasound were
unremarkable. Bone Marrow aspiration showed haemophagocytosis.
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CSF protein was 1.34 g/l (0.12–0.6) and CSF viral and bacterial cultures
were negative.
Results: Macrophage Activation Syndrome (MAS) secondary to acute
SLE was diagnosed based on laboratory, clinical and bone marrow
findings. Despite Methylprednisolone 1 g/day for 3 days followed by
1 mg/kg/day orally and IVIG 2 g/kg over 5 days, platelet and neutrophil
count remained low with significant renal dysfunction. Escalation
therapy to Cyclophosphamide or Cyclosporine was considered an
infection risk due to ongoing cytopenias and renal impairment.
Rituximab (1 g 2 weeks apart) therapy was commenced and within 6
days from the first infusion the platelet and neutrophil counts
recovered to normal. After two infusions a week apart, the patient
improved clinically with no further fevers and the cytopenias,
inflammatory markers and ferritin levels all normalizing. MMF 2 g/day
as maintenance therapy was commenced.
Conclusions: MAS is a life-threatening complication of rheumatic
disease. MAS secondary to SLE should be considered in a patient
presenting with fevers, pancytopenia, hyperferritinaemia, liver failure
and bone marrow marcophage haemophagocytosis, with active SLE in
the absence of infection. Rituximab use has been mainly reported in
MAS secondary to EBV infection but not SLE. We report the
successful use of Rituximab therapy in the treatment of resistant
MAS secondary to acute SLE.
Disclosures: The authors have declared no conflicts of interest.
4. NATURAL KILLER T-CELL LYMPHOMA: FATAL MIMIC OF
GIANT CELL ARTERITIS
Anna E. Litwic1 and Fiona McCrae2
1Rheumatology, Royal Bournemouth and Christchurch Hospitals
NHS Trust, Bournemouth and 2Rheumatology, Queen Alexandra
Hospital Portsmouth Hospitals NHS Trust, Portsmouth, UK
Background: Natural killer T cell lymphoma (NKTCL) is a type of non-
Hodgkin lymphoma (NHL). It is very rare; in Western populations, the
prevalence of nasal lymphomas is estimated at 0.17–1.5% of all NHL,
45% of which are thought to be NKTCL in origin. It can present with
systemic features and head and neck manifestations such as facial
pain, decreased visual acuity, nasal discharge, and epistaxis. Other
symptoms depend on system involved. NKTCL carries high mortality.
Prognosis is approximately 1 year from diagnosis.
We present the case of a 60-year-old Caucasian male whose
symptoms were considered typical of GCA. He responded to steroid
therapy initially, but then re-presented with periorbital symptoms
suggestive of alternative diagnosis
Methods: He presented with 2 weeks history of temporal headache,
scalp tenderness, jaw ache, fatigue and weight loss. He had been
treated in primary care for sinusitis when he reported cold like
symptoms, nasal discharge and nose bleed. These symptoms had
resolved with antibiotics. Blood test including FBC, renal, liver profile
and ANCA were normal, but CRP and ESR were elevated (27 mg/l,
47 mm/h respectively). He was commenced on 40 mg Prednisolone.
Temporal artery biopsy results were negative. His symptoms
improved, but his mental state deteriorated. He was admitted under
mental health act to a psychiatric hospital, diagnosed with steroid
induced psychosis and given a rapid steroid reducing regime
Results: With the steroid reduction his symptoms recurred. 4 months
after initial presentation he re-presented with severe headache,
swelling and redness of the right periorbital region and was admitted
for further investigations. Blood tests revealed mild anaemia, high ESR
92 mm/h and CRP 22 mg/l. CT and MRI scan of his brain, orbit and
sinuses showed soft tissue in the right ethmoid sinus and right nasal
cavity extending into right orbit. Differentiating between infection and
tumour was not possible and the patient underwent biopsy which
proved nasal NKTCL.
The tumour cells showed expression of Epstein-Barr virus (EBV).
Chronic active EBV infection may results in complications such as
EBV-positive lymphoid neoplasia mainly in T cell and NK cell lineage;
and large vessel arteritis with infiltration of EBV-positive lymphoid
cells.
As NKTCL of the head and neck is a very rare malignancy his
treatment regimen was based on consultation with specialist centre.
He received Methotrexate, Cyclophosphamide, Mesna, Dexametha-
sone, Etoposide and Asparginase. Despite chemotherapy he suffered
from recurrence and progression of the lymphoma and died
Conclusions: This case illustrates a very rare mimic of GCA.
Recurrence of symptoms on steroid reduction associated with
additional features: periorbital swelling and nasal discharge suggest
alternative diagnosis. When atypical features are present further
investigations including imaging and tissue biopsy should be con-
sidered to establish diagnosis and commence appropriate treatment
Disclosures: The authors have declared no conflicts of interest.
5. SILASTIC SYNOVITIS: A CASE AND REVIEW OF THE
LITERATURE
Rakhi Seth1 and Fiona McCrae1
1Rheumatology Department, Queen Alexandra Hospital,
Portsmouth, UK
Background: A 50-year-old lady presented with a 5-month history of
persistent left wrist pain and swelling. She was known to have
degenerative cystic changes in the base of the thumb metacarpal and
had had a left thumb carpometacarpal joint arthroplasty and resection
of the trapezium with insertion of a Swanson Silastic implant 4 years
previously in 2008.
Her past medical history included ovarian carcinoma 7 years ago.
For her wrist pain, she was taking naproxen and paracetamol which
helped provide some pain relief. Her niece has RA. She was a 30-pack
year smoker and drank a minimal amount of alcohol. She worked in a
warehouse, which involved heavy manual work.
Examination revealed left wrist synovitis with reduced range of
movement. She also had some tenderness around the left 3rd and
4th PIPJ. In comparison, examination of her right wrist was normal.
Examination of her nails, skin, and other joints was unremarkable.
Her cardiorespiratory and abdominal examinations were also
unremarkable.
Methods: Initial investigations including rheumatoid factor, anti-CCP,
ANA and inflammatory markers and radiographs of the hands and
wrists were performed. Further investigations included a MRI of the left
wrist and a synovial biopsy.
Results: Blood tests revealed a negative rheumatoid factor and ANA,
and her anti-CCP was normal. Her ESR 17, CRP<5 and normal full
blood count, renal and liver function.
A radiograph of the left wrist showed a previous left trapeziectomy
with a silastic prosthetic replacement. There was evidence of a
considerable erosive process affecting her carpometacarpal, carpal
and radiocarpal joints of the left wrist. This suggested that the
arthropathy was crossing ligamentous boundaries. Fracture was
excluded.
A MRI scan of her left wrist (with gadolinium) was performed and
confirmed the presence of an erosive process and a suggestion of
fragmentation of the implant. A synovial biopsy was then taken.
Histopathology of the left wrist synovium revealed multiple pale grey
fragments together measuring 0.7x0.7x0.3 cm. Microscopy showed a
florid giant cell reaction to refractile, granular material. The appear-
ances were consistent with previous surgery at this site with a giant
cell reaction to foreign material. The acid-fast bacilli culture was
negative.
Conclusions: This patient’s wrist pain was due to a giant cell synovitis
secondary to particulate silastic from a previous silastic implant.
Silastic synovitis can occur at any joint where there is a prosthetic
implant in place. Involvement of the hand and wrist is however most
common at the carpal bones which are more susceptible to stress
forces. An inflammatory process occurs in response to foreign
particles, which are sloughed off the implant, resulting in erosion of
bone and articular cartilage with intraosseous cystic changes.
Histopathology reveals an inflammatory infiltrate with giant cells
around silicone-elastomer particles. A review of the literature will
also be presented.
Disclosures: The authors have declared no conflicts of interest.
6. HEART FAILURE IN A WOMAN WITH SLE AND ANTI-
PHOSPHOLIPID SYNDROME AND FABRY’S DISEASE
Anupama Nandagudi1, Elizabeth Jury2 and David Isenberg1,2
1Department of Rheumatology, University College Hospital, London
and 2Centre for Rheumatology Research, Department of Medicine,
University College London, London, UK
Background: A 38-year-old woman with a background of SLE,
secondary anti-phospholipid syndrome and Sjo¨gren’s syndrome
presented with exertional chest pain and shortness of breath for
3 months. Her SLE symptoms were relatively stable and she showed
features of heart failure on examination.
Methods: Echocardiograph showed cardiomyopathy including con-
centric hypertrophy with posterior wall and interventricular septum
thickness of 2cms, increased from 0.9cms in a previous assessment.
Heart biopsy showed sarcoplasmic vacuolation, myofibrillary loss of
myocytes and massive deposition of electron dense glycosphingolipid
myelin figures in the myocyte sarcoplasm suggestive of Fabry’s
disease (FD).
Results: FD is an X-linked deficiency of the enzyme a-galactosidase A
(GLA), resulting in accumulation of the glycosphingolipid globotriao-
sylceramide (Gb3) in organs and tissues. GLA activity was low in this
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patient at 39 nmol/h/mg protein (normal range 33–134) and genetic
testing showed a rare P343L mutation in the GLA enzyme confirming
the diagnosis. The patient was treated with enzyme replacement
therapy (ERT), agalsidase beta, which reduced levels of serum Gb3
and normalized her heart function. She subsequently suffered a
myocardial infarction which was associated with increased anti-
cardiolipin (ACLA) and b2-GPI antibodies and a cerebrovascular
accident. ERT may contribute to endothelial damage which could
explain why strokes continue to occur in treated patients. Her lupus
disease activity remained relatively inactive clinically although ACLA,
anti-b2 GPI and double-stranded DNA antibodies continued to be
positive and complement levels low.
Conclusions: The pattern of organ involvement in patients with FD
and SLE can be similar (including eye, renal and cardiac involvement)
and the coexistence of FD and SLE has been described previously.
Furthermore, the presence of ‘lupus associated’ antibodies to dsDNA,
ENA and phospholipids can be features of patients with FD. Neonatal
screening shows late onset FD has an incidence of 1 in 3100,
suggesting the true prevalence is underestimated. Thus the co-
existence of FD and SLE may be more common than believed
previously.
If untreated, the accumulation of Gb3 leads to progressive organ
failure and premature death. Gb3 is immunogenic and creates an
environment that sustains autoimmune responses. We show increased
Gb3 expression in lymphocyte cell membranes from SLE patients. This
can increase cell activation, oxidative stress and the formation of
reactive oxygen species, factors that promote inflammation and
contribute to increased cardiovascular risk. There may be a case for
screening certain SLE patients for Gb3 and GLA enzyme activity, for
example, those with unexplained cardiac symptoms.
In summary, defects in lipid biosynthesis, such as in FD, could
contribute to development of autoimmunity and should be considered
in cases of unexplained organ damage in SLE patients.
Disclosures: The authors have declared no conflicts of interest.
7. REFRACTORY MULTISYSTEM SARCOIDOSIS INVOLVING
PELVIC BONE RESPONDING TO INFLIXIMAB
Uma Karjigi1 and Anupam Paul1
1Rheumatology, James Cook University Hospital, Middlesbrough, UK
Background: Chronic progressive multisystem granulomatous dis-
ease is seen in 10–30% of patients with sarcoidosis and can result in
end organ damage. Corticosteroids are the mainstay of treatment with
the addition of cytotoxic agents in severe cases. Some patients are
refractory to such treatment and therefore management is a challenge.
There is currently limited evidence for biologic agents such as
Infliximab, a monoclonal anti-TNF-a antibody in the treatment of
multisystem sarcoidosis. Aim of this case report is to disseminate
knowledge concerning successful treatment of multisystem sarcoido-
sis involving pelvis with the use of TNF-a blockers in refractory cases.
Methods: Case presentation: 33-year-old lady referred to rheumatol-
ogy with arthralgia, myalgia, malaise, headaches, facial swelling,
nausea, vomiting, ear and neck pain and tingling in her fingers. Her
past medical history revealed uveitis. Subsequently she developed
right facial palsy and noted to have bilateral parotid enlargement.
Chest X-ray and CT chest confirmed extensive mediastinal and
bilateral hilar lymphadenopathy. Serum ACE levels were elevated
and lymph node biopsy confirmed sarcoidosis. She was started on
oral prednisolone 40 mg daily with good response. However she
developed erythema nodosum, relapse of uveitis and repeated
episodes of hypercalcaemia needing hospital admission on trying to
reduce the dose of steroids. She complained of pain in hip joints. MRI
pelvis showed multiple bony lesions and bone biopsy confirmed bony
involvement of sarcoidosis. Intavenous zolendronic acid helped with
bone pain and hypercalcaemia. Commenced on AZA however unable
to tolerate because of headaches. Continued to have active disease
and started on infliximab and MTX. She improved on this combination
treatment and managed to reduce steroids gradually.
Results: Granulomatous bone involvement has an overall incidence of
1–13%. The small bones of hands and feet are the most common
localizations, while skull, knee, rib, pelvic and sternal localizations are
rarely reported. The diagnosis of the sarcoid is based on the clinical
presentation, radiological manifestations and histopathological assay.
Even though radiographic findings are characteristic, could be
challenging to distinguish from bony metastasis. On literature review
there are reported case of vertebral sarcoidosis treated with anti-TNF
agents, our case report suggests Infliximab can be effective in
treatment of refractory sarcoidosis involving pelvic bone.
Conclusions: This is first case reported on successful use of Anti-TNF
in treatment of multisystem sarcoidosis involving pelvic bone. There is
currently limited evidence for biologic agents such as Infliximab in the
treatment of multisystem sarcoidosis. Our case supports the need for
randomized controlled clinical trials of anti-TNF therapy in refractory
systemic Sarcoidosis.
Disclosures: The authors have declared no conflicts of interest.
8. A FATAL CASE OF ANTI-MDA5 CLINICALLY AMYOPATHIC
DERMATOMYOSITIS
Frances Rees1, Emma O’Dowd1, William Kinnear1, Simon Johnson1
and Peter Lanyon1
1Rheumatology Department, Nottingham University Hospitals NHS
Trust, Nottingham, UK
Background: Melanoma differentiation-associated gene 5 (MDA5) has
recently been identified as a novel auto-antigen in patients with
clinically amyopathic dermatomyositis (CADM) targeted by anti-
CADM-140 antibodies. The typical phenotype includes cutaneous
ulceration, palmar papules, oral mucosal pain and a high risk of rapidly
progressive ILD (RP-ILD). However, because the ANA and ENA are
typically negative, the clinical phenotype may not be identified initially.
We are reporting this case to raise awareness of this condition.
Methods: A man in his 7th decade was admitted with a 4 week history
of cough, breathlessness, small joint pain and malaise. He had
received prior treatment with amoxicillin and clarithromycin with no
response. He had no past medical or drug history. He was an ex-
smoker.
He had bilateral inspiratory crackles with oxygen saturations of
92% on air, synovitis of the hands and right knee. He had two
aphthous tongue ulcers and erythematous lesions on his fingers.
Full blood count, renal and liver function and CK were normal. CRP
was 9, ESR 40. Urine dipstick, ANA, ENA, ANCA, RF, dsDNA and anti-
GBM were negative. Skin biopsy findings were non-specific, but
suggestive of an eczematous process. Chest X-ray was normal.
Atypical pneumonia testing was negative. CTPA showed subpleural
interstitial opacities consistent with atelectasis or fibrosis. He was
treated with further antibiotics for atypical pneumonia and oral
prednisolone for presumed reactive arthritis.
Results: Six weeks later he had ongoing dyspnoea with exercise
tolerance 10 yards. The synovitis had resolved, but the digital lesions
were still present. Prednisolone was increased to 40 mg. He was
referred for consideration of an open lung biopsy to ascertain the exact
diagnosis.
He was re-admitted 6 weeks later with fever, confusion and
profound hypoxia requiring ventilation on ITU. CXR showed worsened
bilateral interstitial shadowing. Bronchoscopy and BAL were negative.
On review by rheumatology he had nail fold infarcts and purpuric
papules on the dorsal-ventral junction of his fingers. In view of his
finger lesions, oral ulcers and RP-ILD, anti-MDA5 CADM was
suspected. He was treated with intravenous methylprednisolone but
died within days of multi-organ failure. Subsequently, MDA5 anti-
bodies were identified by immunoprecipitation.
Conclusions: Rheumatologists need to be aware of the expanding
clinical phenotype of CADM, in particular the cutaneous features and
those antibody subsets which are associated with RP-ILD so that
treatment can be targeted appropriately. Typically patients are ANA
and ENA negative and therefore are often assumed not to have a CTD.
Previous reports have indicated the high prevalence of RP-ILD in this
condition and high mortality risk.
Disclosures: The authors have declared no conflicts of interest.
9. RITUXIMAB IN RECURRENT THROMBOEMBOLIC
DISEASE IN APS
Jyoti Bakshi1 and Richard Stevens1
1Rheumatology, Buckinghamshire Hospital NHS Trust,
Buckinghamshire, UK
Background: We describe the use of Rituximab in a patient with APS
with recurrent pulmonary embolism (PE) due to poor compliance with
standard anti-coagulation. A 19-year-old female, with no past medical
history, presented acutely with exertional breathlessness and pleuritic
chest pain 4 weeks after an elective termination of pregnancy.
D-dimers were raised at 2483 mg/l (0–500). CT pulmonary angiography
demonstrated large bilateral proximal pulmonary arterial emboli. A
standard thrombophillia screen was unremarkable, except for positive
anti-phospholipid (aPL) anti-bodies. IgG anti-cardiolipin antibodies
(ACA) were raised at 87 U/ml (NR: 0–12) and anti-beta2-glycoprotein-1
(anti-B2-GP-1) antibodies were 49.1 U/ml (NR: 0–12). Levels of ACA
and anti-B2-GP-1 antibodies rose to >120 U/ml and >100 U/ml
respectively on repeat testing over subsequent months. Lupus anti-
coagulant testing was not performed. Anti-nuclear antibody (ANA)
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screening was positive, 1:80 (speckled) and anti-dsDNA antibodies
titres were mildly raised (51 U/ml, NR 0–22), but complement levels
were normal and there were no clinical features of systemic lupus.
Anti-ENA screening was negative. She was treated acutely with
heparin and was then started on warfarin (target international normal-
ized ratio of 2.5–3.5).
Methods: Due to poor compliance with treatment and monitoring
(INR’s<1.5), she went on to suffer two further episodes of
pulmonary embolism over the next 6 months. On haematological
advice she was switched to dabigatran (a direct thrombin inhibitor)
150 mg b.d. (maximum dose). Four months later she suffered a fourth
PE requiring admission and heparin treatment. Echocardiography
showed moderate dilatation of the right atrium and proximal
pulmonary arteries. Pulmonary arterial systolic pressure was estimated
at 82 mmHg.
Results: The patient refused treatment with daily subcutaneous
heparin due to needle phobia. A decision to treat with two infusions
of rituximab, 1 g 2 weeks apart, was made. Two months post infusion
her ACA titre had fallen to 67 u/ml, and anti-B2-GP-I antibodies to 33
U/ml. Levels of both had fallen to normal by 8 months. A year after
rituximab treatment, she has not had any further PEs and her ACA and
anti-B2-GP-I antibodies remain suppressed.
Conclusions: There are only a handful of case reports published on
the use of rituximab in patients with primary, secondary and
catastrophic APS. A reduction in aPL antibody titres with rituximab
treatment has been reported, as has the prevention of recurrent and/or
severe thrombotic events in APS over 10–36 months of follow-up. B
cells are likely to be central to the generation the aPL-induced clinical
manifestations, so could constitute a therapeutic target in APS.
This case appears to show a clinically important response to
rituximab treatment in a patient with malign anti-phospholipid
syndrome and suggests that rituximab may have a role in the
management of APS when poor compliance or complications of
treatment render anti-coagulation ineffective.
Disclosures: The authors have declared no conflicts of interest.
10. BEHC¸ET’S DISEASE ASSOCIATED WITH IDIOPATHIC
INTRACRANIAL HYPERTENSION
Nehal Narayan1 and Christopher Marguerie1
1Rheumatology, Warwick Hospital, Warwick, UK
Background: Neurological manifestations occur in up to 20% of
patients with Behc¸et’s disease, with focal parenchymal lesions and
complications of vascular thrombosis being the most common
abnormalities. Most reports state that intracranial hypertension in
patients with Behc¸et’s disease is usually due to cerebral venous
thrombosis.
Methods: Here, we describe a case of a patient with Behc¸et’s disease
who developed intracranial hypertension, with no apparent underlying
cause, suggesting an association between Behc¸et’s and idiopathic
intracranial hypertension, a little reported phenomenon.
Results: Our patient is a 26-year-old Caucasian male. He presented to
clinic with an 8 year history of recurrent oral ulceration, with no other
past medical history. A biopsy of an ulcer some years ago showed
apthous ulceration, with no evidence of vasculitis. On examination
now, however, ulceration was severe and cyclosporin and predniso-
lone were initiated. 4 months later, cyclosporin was discontinued due
to side effects of low mood, and he was maintained on prednisolone
alone for the next 18 months. He then developed genital ulcers,
pathergy and possible erythema nodosum on the shins, and AZA was
commenced, but compliance was poor. 8 months later, he presented
with continuous left sided headache and blurred vision in his left eye.
Opthalmology noted bilateral papilloedema. MRI brain with contrast
was unremarkable. Lumbar puncture demonstrated raised opening
pressure of 42 mmHg (reference range 5–15 mmHg). Microscopy of
cerebrospinal fluid (CSF) was completely unremarkable. Both head-
ache and visual symptoms improved with acetazolamide. Biopsy of a
pustular rash on the patient’s right leg subsequently demonstrated
marked thrombosis of dermal venules with perivascular inflammation,
consistent with a diagnosis of Behc¸et’s disease.
Conclusions: Idiopathic intracranial hypertension (IIH) is defined by
clinical criteria that include symptoms and signs of raised intracranial
pressure (headache, papilloedema, visual loss), elevated intracranial
pressure with normal CSF composition, and no other cause of
intracranial hypertension evident on neuroimaging or other evalua-
tions. Secondary causes of intracranial hypertension include intracra-
nial mass lesions, lesions causing reduced CSF absorption
(subarachnoid haemorrhage, granulation adhesions post meningitis),
hydrocephalus, choroid plexus papillomas causing increased CSF
production and conditions obstructing venous outflow (including
venous sinus thrombosis). There was no evidence of any of these
causes on neuroimaging of our patient, and our patient met all other
criteria for diagnosis of IIH. Multiple associations of IIH have been
reported, including systemic conditions (such as obesity and sleep
apnoea) and medications (such as retinoids and tetracyclines). None of
these associations of IIH were present in our case. In our patient, there
appears to be an association of Behc¸et’s disease with IIH, indepen-
dent of other known variables.
Disclosures: The authors have declared no conflicts of interest.
11. SEROPOSITIVE NON-EROSIVE RHEUMATOID
ARTHRITIS PRESENTING WITH THE CUTANEOUS ROPE SIGN
(INTERSTITIAL GRANULOMATOUS DERMATITIS) AND
SUBLCINICAL SYNOVITIS RESPONSIVE TO STEROIDS AND
METHOTREXATE
Helena Robinson1, Lorrette Ffolkes1, Fiona Worsnop1, Lucy Ostlere1
and Patrick Kiely1
1Rheumatology, St George’s Healthcare NHS Trust, London, UK
Background: Interstitial granulomatous dermatitis (IGD) is a distinct
entity with a typical histological pattern. It tends to present with
erythematous papules and plaques on the trunk and proximal limbs
with approximately 10% manifesting hard cord-like lesions—the rope
sign. There is an established but rare association between IGD and
autoimmune disease particularly RA and lupus. We present a case of
IGD presenting with the rope sign revealing a diagnosis of RA
responsive to steroids and MTX. Written consent was obtained for
publication from the patient.
Methods: 36-year-old male smoker who worked as a labourer and
electrician presented to dermatology outpatients with a years’ history
of sudden onset dermal lines (the rope sign) extending bilaterally from
the iliac crests to the anterior shoulder following an episode of heavy
lifting. Skin biopsy demonstrated normal dermis, a mild perivascular
and periadenexal lymphocytic infiltrate in the superficial dermis and a
fibrotic deep dermis with infiltrating interstitial histocytes. A diagnosis
of IGD was made and he was found to be RF and CCP antibody
positive.
Rheumatology assessment revealed a 3 year history of low grade
flitting arthralgia with a recent exacerbation giving a 6 week history of
morning stiffness and intermittent pain in the metocarpophalangeal
(MCP) joints, knees and metatarsophalangeal (MTP) joints. There was
no overt clinically detectable synovitis but ultrasound demonstrated
synovial thickening in all the MCP joints and increased doppler
flow throughout consistent with active synovitis. A diagnosis of
seropositive non-erosive RA was made. He was administered
120 mg of intramuscular (IM) depomedrone and commenced on
15 mg of MTX weekly.
Results: The patient reported a rapid and sustained subjective
improvement in his symptoms of pain and stiffness that was
maintained at 4 months follow up. Repeat ultrasound at that stage
demonstrated regression of synovial thickening and less florid doppler
flow confirming the response to treatment. The rope sign remains
visible and palpable but is less prominent and is causing less
discomfort and restricted movement
Conclusions: Seropositive RA can present in unusual ways in this
case initially with IGD and subclinical synovitis showing an excellent
response to IM steroids and MTX monotherapy. Close liaison with
dermatology is essential to ensure early diagnosis of RA presenting
with unusual skin manifestations to ensure rapid effective treatment
and prevention of joint damage and associated morbidity
Disclosures: The authors have declared no conflicts of interest.
12. A CASE OF ULCERATIVE LUPUS PROFUNDUS
RESPONDING TO RITUXIMAB
Chethana Dharmapalaiah1, Nada Hassan1, Anupama Nandagudi1,
Anurag Bharadwaj1, Malgorzata Skibinska2 and Nagui Gendi1
1Rheumatology, Essex and Thurrock University Hospitals NHS
Foundation Trust, Essex and 2Dermatology, Essex and Thurrock
University Hospitals NHS Foundation Trust, Essex, UK
Background: Lupus profundus/panniculitis is a rare cutaneous
manifestation of lupus occurring in 2–5% of SLE. It presents with
subcutaneous nodules located mainly on the upper part of the body
and causing atrophic changes of the skin. Ulceration of these lesions is
a rare complication of the condition. Antimalarials, corticosteroids and
immunosuppressants are the most commonly used forms of
treatment.
Methods: We report a case with multiple cutaneous manifestations
developing in succession in a patient with SLE, including discoid lupus
and lupus profundus with severe disfiguring skin ulcerations. The case
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illustrates the difficulty in management. We reviewed patient’s case
notes plus histopathology and performed a literature search for
treatment of lupus profundus with Rituximab.
Results: A 31-year-old Nigerian lady was diagnosed with SLE in 2005
with clinical presentation of photosensitive facial rash, arthritis and
fatigue, with antibody profile of positive ANA (5 units), anti-dsDNA,
anti-Ro and La antibodies and lupus anticoagulant. She was initially
treated with low dose prednisolone, aspirin and MTX mainly for
arthritis. She was later commenced on HCQ.
In June 2007, she developed skin rash in the form of indurated
erythematous plaques on face and right elbow. A biopsy showed
hyperkeratosis, deposition of fibrinoid material within collagen and
liquefaction of basal layer, all thought to be consistent with lupus
which responded to topical and oral steroids.
In May 2010 she developed severe rash with some lesions
resembling discoid lupus, scarring alopecia and deeply indurated
plaques forming ulcers. They caused disfiguring depressions of the
skin on face and shoulders.
The ulcerated lesions remained very resistant to treatment despite
prednisolone 60 mg/day, mepacrine, hydroxychoroquine and MTX.
She was intolerant to MMF. Antibiotics, topical flamazine and
hydrocolloid dressings were required as secondary infection occurred
with swabs growing S. Aureus and Pseudomonas on separate
occasions.
Biopsies from the indurated lesions showed leucocytoclastic
vasculitis, perivascular lymphocytic infiltrate, panniculitis with fat
necrosis and hyalinization of collagen consistent with the
diagnosis of lupus profundus. Tuberculosis and fungal infections
were excluded.
She was then treated with 2 infusions of rituximab 1 g i.v. (2 weeks
apart). This halted development of new ulcers and promoted slow
healing of the lesions, thus enabling reduction of prednisolone to
10 mg/day.
Conclusions: This case illustrates efficacy and safety of rituximab in
the treatment of refractory discoid LE and ulcerated lupus profundus
developing despite corticosteroids and immunosuppressive treatment.
Disclosures: The authors have declared no conflicts of interest.
13. TOCILIZUMAB FOR THE TREATMENT OF
AUTOINFLAMMATORY DISEASE
Emma J. Davies1, Mohammed Akil1 and Rachael Kilding1
1Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust,
Sheffield, UK
Background: Autoinflammatory disorders are an uncommon, hetero-
geneous group of conditions characterized by recurrent, episodic
fevers without any associated bacterial or viral infection. Often
associated with rash, arthralgia and high inflammatory markers.
A genetic defect has been found for some autoinflammatory
diseases including the periodic fevers: Familial Mediterranean Fever
(FMF) and TNF receptor-1 associated periodic fever syndrome
(TRAPS).
We describe three patients with histories consistent with an
autoinflammatory disease, all unresponsive to traditional therapies,
who have responded well to Tocilizumab.
Methods: A retrospective review of patients’ case notes.
Results: We present three patients with a history of: recurrent fevers,
anaemia, raised inflammatory markers, rash (panniculitis), arthralgia
and reactive bone marrow. Two of these patients also experienced
recurrent cardiac events; evidenced by chest pain, increased troponin
level and ECG changes.
All three patients had a normochromic, normocytic anaemia; raised
CRP and ESR; and reactive bone marrow on bone marrow aspiration.
Exhaustive investigation including: immunological testing, infectious
screens, imaging and endoscopy were unremarkable.
These patients required frequent, often prolonged, hospital admis-
sions and responded well to high dose steroid administration during
exacerbations. Patients were unresponsive to disease modifying anti-
rheumatic medications (DMARD’s) and anti-TNF drugs. Two patients
had an initial response to Anakinra (anti-IL1) but this had to be
discontinued due to side effects.
Tocilizumab (anti-IL-6) was commenced 4, 16 and 17 months ago
respectively. In all three patients fevers have resolved and serological
indices have normalized.
Conclusions: These patients exhibit features consistent with an
autoinflammatory disease that we are not yet able to characterize
through genetic testing. Anti-IL-6 treatment appears to have abolished
the inflammatory process and may have the potential to benefit other
patients with a similar history.
Disclosures: The authors have declared no conflicts of interest.
14. ATYPICAL MYCOBACTERIAL INFECTION IN THE
IMMUNOCOMPROMISED: BEWARE OF THE SKIN LODGERS
Jagdish Ramachandran Nair1, Maeve Walsh2, Wendy Farrar3 and
Robert N. Thompson1
1Rheumatology, Aintree University Hospital, Liverpool,
2Dermatology, Broadgreen University Hospital, Liverpool and
3Dermatology, Aintree University Hospital, Liverpool, UK
Background: Patients on immunosuppressive drugs are at risk of
contracting a variety of opportunistic infections which may be difficult
to recognize as such. This includes infection with non-tuberculous
mycobacteriae (NTM). We describe two cases in which
Mycobacterium chelonei, a NTM, caused skin infections in immuno-
suppressed patients leading to management difficulties.
Methods: Case no 1: A 78-year-old Caucasian woman with severe
deforming erosive Rheumatoid arthritis (RA) with a 40-year history of
DMARD therapy including prednisolone was admitted feeling unwell
with a 3-month history of multiple ulcerating nodules on her toes and
legs. Examination showed what appeared to be vasculitic lesions with
multiple ulcerated gangrenous toes and papulo-nodular skin lesions in
both legs. The histology of skin nodules showed granulomatous
abscesses. Acid-fast bacilli were confirmed on culture as M. chelonai.
The patient died at home of other causes before therapy for NTM
could be instituted.
Case no 2: A 65-year-old Caucasian man with history of
myasthenia gravis and membrano-proliferative glomerulonephritis
treated with AZA and steroids presented with rapidly spreading
ulcerating papulo-nodular rash on the lower legs of several weeks
duration. Biopsy culture and histology confirmed M. chelonai.
Clarithromycin and moxifloxacin cleared the lesions without sequelae.
Results: Autoimmune and inflammatory diseases present with protean
manifestations. The diverse clinical presentations can cause diagnos-
tic difficulties. This is further complicated by the treatment and
consequences of immunosuppression. Rheumatoid skin diseases are
manifold; granulomatous skin nodules, vasculitis, interstitial granulo-
matous dermatitis (IGD) and palisaded neutrophilic and granulomatous
dermatitis (PNGD) can present as skin nodules which are essentially
treated with immunosuppression whilst in cutaneous TB, immunosup-
pression should be avoided.
M. chelonai, an atypical mycobacteria, classified in Runyon group
IV, is found in soil, dust and water sources worldwide. It can cause
diverse clinical symptoms including lung disease, cutaneous disease,
ocular disease and osteomyelitis. Patients who are immunosup-
pressed often show widespread rapid cutaneous dissemination.
Incidence of NTM infection has risen in recent years.
Diagnosis can be made by isolation of the mycobacteria from
tissues like skin, blood, sputum, and bone marrow. Polymerase chain
reaction (PCR) analysis is available for certain mycobacteria. Culture
and antibiotic sensitivity will guide treatment. Quantiferon tests
(Interferon gamma release assays {IGRA}) and tuberculin skin testing
are not useful in atypical mycobacterial infections and immunocom-
promised patients
Conclusions: The possibility of a mycobacterial infection should be
considered when examining an immunosuppressed person with a new
cutaneous eruption.
Disclosures: The authors have declared no conflicts of interest.
15. DRESS SYNDROME CAUSED BY NAPROXEN
Liubov Borukhson1, Charles McFadyen1, Deepwant Singh1 and
Vivek Rajagopal1
1West Suffolk Hospital, Bury St Edmunds, UK
Background: Drug reaction with eosinophilia and systemic symptoms
(DRESS) syndrome is a rare but potentially life-threatening condition
with the mortality rate estimated at 10–40%. It is characterized by the
presence of at least three of the following findings: fever, exanthema,
eosinophilia, atypical circulating lymphocytes, lymphadenopathy, and
hepatitis. There most common medications associated with this
condition are anticonvulsants (phenytoin, phenobarbital, carbamaze-
pine), antibiotics (vancomycin, minocycline, nitrofurantoin sulphona-
mides), as well as allopurinol, dapsone, imatinib therapy. DRESS
syndrome is a delayed type IV hypersensitivity reaction and generally
starts 2–8 weeks after the first exposure to the drug responsible. To
the best of knowledge of the authors, this abstract describes the first
case of naproxen-induced DRESS syndrome in an adult patient.
Methods: A 63-year-old previously fit gentleman was admitted with
florid confluent maculopapular rash mainly on his arms, back and
lower limbs, which gradually worsened over 4 days, as well as pruritus,
pyrexia (40C), visual hallucinations, shortness of breath, pleuritic chest
pain, hypoxia, abdominal pain and loose stools. His admission bloods
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shown deranged LFTs (bilirubin-13, ALP-137, ALT-108), raised
inflammatory markers (WCC 19.1, neutrophils 17.6, CRP 161, ESR
49) and eosinophilia (initially 0.7 with the peak of 8.8). Vasculitic and
myeloma screens were negative. He did not report any past medical
history, did not travel abroad recently and was only taking naproxen
for the sciatica pain during the previous 2 months. Naproxen was
immediately discontinued. He was extensively investigated for an
infectious cause of his presentation: measles, influenza viruses, HIV,
CMV, HH6 virus, respiratory syncytial virus, adenovirus, chlamydia,
mycoplasma pneumonia, coxiella burnetii, which all came back
negative. His stool culture was negative for clostridium difficile,
gram-negative enteric bacteria and cryptosporidium oocysts. Blood
film revealed reactive picture with eosinophils and lymphocytoplas-
moid cells. Urine HIAA and serum tryptase tests were performed to
rule out carcinoid tumour, mastocytosis and anaphylaxis.
Results: The amalgamation of these clinical symptoms and laboratory
findings led to diagnosis. One week after the commencement of 40 mg
of prednisolone, an improvement of patient’s liver function, inflamma-
tory markers and resolution of rash were observed. Three months later,
he remains well. He was advised to avoid any NSAIDs or COX-2
inhibitors due to severity of his recent reaction and possible cross-
hypersensitivity between different NSAIDs.
Conclusions: We encourage clinicians to consider the diagnosis of
DRESS syndrome in patients with rash and multiorgan failure in
addition to infections and CTDs. Prompt recognition and steroid
initiation appears to be effective steps in managing of this condition.
Disclosures: The authors have declared no conflicts of interest.
16. AN UNEXPECTED CAUSE OF SEVERE HYPOKALAEMIA
IN A PATIENT WITH SJO¨GREN’S SYNDROME: A CASE
REPORT
Angela Marie L. Chan1 and Li Wearn Koh1
1Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital,
Singapore, Singapore
Background: Hypokalaemia in patients with Sjo¨gren’s syndrome
is well described as a consequence of potassium wasting and
renal tubular acidosis due to chronic lymphocytic interstitial
nephritis. Here we describe a patient with Sjo¨gren’s syndrome and
autonomic dysfunction who presents with new onset rhabdomyolysis
and muscle paralysis due to severe hypokalaemia of unexpected
cause.
Methods: Our 59-year-old female patient was diagnosed with
Sjo¨gren’s syndrome and autonomic neuropathy 3 years previously,
when she presented with sicca symptoms and postural hypotension.
She was found to have positive Schirmer test, ANA 1:160, Anti-Ro and
La antibodies and a polyclonal rise in IgG, and there was autonomic
dysfunction on testing with severe postural hypotension with abnormal
sympathetic skin response and borderline parasympathetic
responses. She was on HCQ 200 mg od, prednisolone 5 mg od and
fludrocortisone 0.3 mg nocte with no dose changes for 6 months and
her last attendance at rheumatology clinic occurred 1 month prior to
admission, where her serum potassium was normal.
She was admitted acutely with a 1 week history of progressive
weakness and myalgia with no other systemic symptoms. On
admission, she was found to have a marked myopathy with power
2/5 in all muscle groups in both upper and lower limbs. Initial
investigations showed a serum potassium of 1.6 mmol/l, raised serum
bicarbonate at 42 mmol/l, normal corrected calcium 2.28 mmol/l and
normal serum sodium at 139 mmol/l, raised creatinine kinase at
29600 IU/l. She was also hypertensive with blood pressure of 170/110
on admission.
Results: The clinical picture was one of pseudohyperaldosteronism
leading to severe hypokalaemia and subsequent rhabdomyolysis. On
repeated questioning, the patient revealed that in the 3 weeks leading
up to admission, she had been taking a herbal supplement twice daily
to treat her sicca symptoms. Chemical analysis of the components of
the herbal supplement revealed the presence of liquorice. With
discontinuation of the supplement and correction of the biochemical
abnormalities, her muscle strength recovered, and to date she remains
well with no recurrence of the biochemical abnormalities on her
previous medication.
Conclusions: Liquorice is a common component of both Western and
Chinese herbal remedies and has been increasingly described as a
cause of hypertension and hypokalaemia through its active ingredient,
glycyrrhizin. Sensitivity to glycyrrhizin can be influenced by genetic
polymorphisms and baseline health status. Physicians should be
aware of such supplements as a potential cause in patients who
present with pseudohypoaldosteronism.
Disclosures: The authors have declared no conflicts of interest.
17. SUCCESSFUL TREATMENT OF SCHNITZLER’S
SYNDROME WITH ANAKINRA, COMPLICATED BY THE
DEVELOPMENT OF ANTI-NUCLEAR ANTIBODIES
Jennifer D. Christie1 and Lorraine Croot1
1Rheumatology, Barnsley Hospital NHS Trust, Barnsley, UK
Background: Schnitzler’s syndrome is a rare, autoinflammatory
condition characterized by a chronic urticarial skin rash and mono-
clonal IgM gammopathy together with 2 of intermittent fever,
arthralgia, bone abnormalities on imaging, lymphadenopathy, hepato
or splenomegaly, neutrophilia and/or a raised ESR.
Recently cases have been reported documenting successful
treatment of Schnitzler’s syndrome with the IL-1 receptor antagonist
(IL1-RA), anakinra.
Other rheumatological conditions are often treated with biologic
drugs targeting the TNF pathway. In some patients, efficacy and usage
of these drugs is limited by the development of anti-nuclear antibodies
(ANA). This has not previously been reported following treatment with
IL1-RA.
Methods: Written consent for publication was obtained from the
patient.
Results: A 54-year-old female presented to dermatology with a 6
month history of arthralgia and a widespread urticarial rash mainly
affecting her trunk and sparing sun exposed areas. Individual wheals
measured 1–3 cm, lasted for 24 to 72 h and were painful rather than
itchy. Biopsy demonstrated leucocytoplasia and extravasation of red
blood cells but no definite urticarial vasculitis.
Investigations including FBC, ANA, ENA, dsDNA, immunoglobulins,
C1q and complement were normal. ESR and CRP were raised.
She was initially managed unsuccessfully with antihistamines,
dapsone and immunosuppressants including HCQ, AZA and myco-
phenolate. Prednisolone, at doses above 15 mg od, improved her
symptoms minimally.
Further investigation detected an IgM kappa monoclone (2.2 g/l).
Urinary Bence Jones protein was negative. Bone marrow biopsy
showed reactive changes and there was no hepatosplenomegaly nor
lymphadenopathy on CT scanning.
At review 1 year later, she had developed generalized fatigue,
intermittent fever and marked arthralgia and was referred to
rheumatology. ESR was 58 mm/h (1–15) and CRP 55 mg/l (0–10).
ANA not detected. A diagnosis of Schnitzler’s syndrome was made
and anakinra 100 mg s/c od prescribed. Within 48 h, her rash and
arthralgia completely resolved. Prednisolone was withdrawn.
Dermatology Life Quality Index improved dramatically. Inflammatory
markers and neutrophil count normalized.
9 months after starting anakinra she developed significant titres of
positive ANA with a coarse speckled pattern on indirect immuno-
fluorescence using Hep-2 cells. DsDNA and ENA antibodies remain
negative. She has no clinical symptoms of an autoimmune condition.
Conclusions: Schnitzler’s syndrome shares many similarities with
other cryopyrin-associated periodic syndromes and this case adds
further evidence to the use of IL1-RA to treat these diseases. The
development of ANA is a well recognized complication of treatment
with anti-TNF but has not previously been reported with IL1-RA. The
clinical significance of the antibody formation in this case remains
unclear but will be closely monitored.
Disclosures: The authors have declared no conflicts of interest.
18. CETROLIZUMAB-INDUCED ACUTE LIVER FAILURE
Mary Gayed1, Benjamin Disney2, Saket Singhal2 and Karl Grindulis1
1Rheumatology, Sandwell and West Birmingham Hospitals,
Birmingham and 2Gastroenterology, Sandwell and West Birmingham
Hospitals, Birmingham, UK
Background: Certolizumab pegol is a pegylated tumour necrosis
factor-a (TNF-a) specific Fab fragment of a humanized monoclonal
antibody. It was first licensed by NICE in 2010.
Methods: We present a case of a 65 year old, diagnosed with RA in
1996, she was initially commenced on SSZ and prednisolone.
Sulphasalazine was later substituted for MTX due to poor efficacy.
The dose was gradually escalated as the patient’s disease became
more active to 25 mg once weekly. In June 2011, her disease remained
active. The DAS28 was 6.43 therefore HCQ was commenced, which
failed to adequately control her RA, so in January 2012 certolizumab
was commenced.
Results: Liver function tests (LFTs) were normal prior to treatment with
certolizumab. However, within 4 months of treatment the patient had
developed an asymptomatic hepatitis with an ALT of 226. The patient
became clinically icteric 6 months after treatment.
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The bilirubin peaked at 479 umol/l, ALT at 1609, INR>15 and the
albumin decreased to 18 g/dl. An USS of the abdomen and an MRCP
were normal, as was a full liver screen.
Due to concerns of acute liver failure she was transferred to the
regional liver unit for continuing observation. A liver biopsy was
consistent with drug-induced liver injury (DILI). The patient made a full
recovery after the discontinuation of certolizumab. Currently this
patient’s RA is in remission and LFTs have returned to normal. Current
treatment is prednisolone 5 mg and ursodeoxycholic acid.
Conclusions: DILI has been described with other anti-TNFa agents
(adalimumab, infliximab, etanercept). However, this is the first case
described with respect to certolizumab. The diagnosis of DILI, requires
a high degree of suspicion, pattern recognition, establishing a
temporal relationship and excluding other causes of liver injury.
Although the role of liver enzyme monitoring is unclear, an awareness
of this adverse effect is important, given the potential for a rapid and
complete response to specific treatment. The possible underlying
pathological process is thought to be due to hepatic sinusoids
involved in the clearance of immune complexes via Fc receptor-
mediated interactions that in turn could activate Kupffer cells to
release reactive oxygen species or lead to local hepatocyte damage.
It is important to monitor and report adverse events in new drugs,
as this can lead to changes in product labelling. Spontaneous reports
of cases of severe hepatotoxicity led to the placement in 2004 of a
warning on the infliximab product label. The incidence of hepatotoxi-
city was estimated to be about 1 incident per 16 500 users per year (38
cases among 576 000 treated patients over 6 years).
The British Society for Rheumatology Biologics Register is currently
collecting data on certolizumab pegol and will be able to provide future
prospective information.
Disclosures: The authors have declared no conflicts of interest.
19. GRANULOMATOSIS WITH POLYANGIITIS PRESENTING
WITH A RIGHT-SIDED RENAL MASS
Timothy D. Reynolds1
1Medical Directorate, University Hospital of Wales, Cardiff, UK
Background: Renal disease is common in granulomatosis with
polyangiitis (GPA). Around 80% of patients develop signs of
glomerulonephritis, however it is often not present at the time of
diagnosis.
Renal masses have previously been described in patients with GPA
and often provide a diagnostic dilemma. Several groups have reported
that there is an increased incidence of renal cell carcinoma in patients
with GPA. Therefore any renal mass should be taken seriously.
Methods: We present the case of a 29-year-old Caucasian lady with a
6-week history of fevers, coryzal illness, arthralgia of knees and elbows
and night sweats, together with microscopic haematuria.
Her bloods revealed a normochromic normocytic anaemia with
neutrophilia and a raised CRP, but normal renal, liver and bone profile.
She had a normal rheumatoid factor, anti-nuclear antibody and
p-ANCA but a markedly positive c-ANCA (PR3 >250).
She had 4 sets of negative blood cultures but was found to have a
positive Quantiferon TB Gold. Chest radiograph and transthoracic
echocardiogram were reported normal. CT imaging of chest, abdomen
and pelvis revealed bilateral ill-defined low attenuation lesions at both
lung bases along with a 3.4 x 5.8 cm ill-defined enhancing mass in the
lower pole of the right kidney.
This created several possible explanations:
1. Underlying vasculitic process (most likely GPA)
2. Renal tuberculosis (with false positive c-ANCA)
3. Renal cancer (with false positive c-ANCA)
Renal core biopsy revealed fibrosis and non-necrotizing, non-
caseating granulomatous inflammation. Tuberculous testing was
negative. Further biopsies of peri-lesional tissue revealed necrotizing
glomerulonephritis with fibrosis.
The combination of renal granulomatous changes, chest infiltrates
and positive c-ANCA clinched the diagnosis of granulomatosis with
polyangiitis.
She was treated with cyclophosphamide and prednisolone,
followed by AZA as maintenance therapy together with isoniazid and
pyridoxine to cover for latent tuberculosis.
Repeat imaging with ultrasound at 8 months revealed that the renal
mass had resolved. The inflammatory markers and c-ANCA had
normalized and both renal function tests and urine analysis were
unremarkable.
Results: On review of the literature we have found 16 examples of
GPA presenting with renal masses, stretching back as far as 1978.
Of these, 12 (75%) were unilateral and 4 bilateral. Twelve (75%) of the
16 were ANCA positive (although 3 reports did not specify ANCA
status) and 6 (37.5%) of the 16 had normal urine analysis. Interestingly,
of the 16 cases in the literature, 9 (56.3%) received either partial or
total nephrectomy.
Conclusions: Renal masses can occur in the context of GPA and can
be inflammatory or neoplastic in nature. This case highlights the
importance of obtaining a clear diagnosis in patients presenting with a
renal mass to avoid potentially unnecessary surgical intervention and
the timely initiation of appropriate treatment.
Disclosures: The author has declared no conflicts of interest.
20. RHEUMATOLOGISTS BEWARE: SERIOUS ADVERSE
REACTION BETWEEN INJECTED TRIAMCINOLONE AND
RITONAVIR, COMMONLY USED FOR TREATMENT OF HIV
Katie Conway1, Debbie Williams1, John Quin1, Gillian Dean1,
Duncan Churchill1 and Karen E. Walker-Bone2
1HIV/GU Medicine, Royal Sussex County Hospital, Brighton and
2Rheumatology, Brighton and Sussex Medical School, Brighton, UK
Background: HIV affects about 90,000 people in the UK. Since the
advent of combination anti-retroviral therapies (cART), the prognosis
has transformed and life expectancy is normal. It is likely that
rheumatologists will increasingly need to treat HIV-infected patients
for rheumatic symptoms.
Methods: Ritonivir is a protease inhibitor, widely used as a booster of
cART. It inhibits the cytochrome P450 3A4 reducing corticosteroid
metabolism. HIV Physicians recommend dose reduction of oral
prednisolone by 50%. A serious interaction has been recognized
between inhaled fluticasone and ritonavir so that the combination is
now contraindicated. Cases have been reported of acute hypercorti-
solism induced by triamcinolone in HIV patients, one after 40 mg
injected into a shoulder and one after caudal epidural injection of
80 mg. The common factor was ritonavir. We report a series of HIV-
infected patients taking ritonavir who received triamcinolone
injections.
Results: CASE 1: A 50-year-old HIV-infected woman taking abacavir,
lamivudine, darunavir and ritonavir for >2 years was diagnosed with
seronegative SpA. At a clinic appointment, complaining for painful
shoulders and hips, she was injected with triamcinolone 40 mg into
each shoulder and each trochanteric bursa. She presented 7 weeks
later with postural dizziness, lethargy, facial swelling and weight gain.
Random blood sugar was elevated and she had glycosuria. She was
cushingoid with proximal myopathy. Random cortisol was low and
challenge with synacthen test demonstrated adrenal insufficiency. One
year later, she requires long-term steroid replacement therapy and
insulin. She is pursuing a medico-legal claim against the NHS Trust.
CASE 2: A 58-year-old HIV-infected lady taking emtricitabine,
atazanavir, tenofovir and ritonavir was treated in primary care with
injection of 40 mg triamcinolone into her right knee for OA. 4 weeks
later she presented with weight gain and increased appetite. She was
cushingoid and random cortisol low (67 nmol/l) with attenuated
response to synacthen. Re-testing after 3 weeks demonstrated
recovery and steroid replacement therapy was not required.
CASE 3: A 42-year-old HIV-infected man taking tenofovir, emtrici-
tabine, darunavir and ritonavir was treated in the pain clinic with a
caudal epidural of 40 mg triamcinolone and presented 8 weeks later
with abdominal distension, increased appetite, acne and sweats. He
was cushingoid. Random cortisol was low and response to synacthen
stimulation was markedly insufficient. He has required long-term
steroid replacement therapy.
Conclusions: Ritonavir affects the cytochrome P450 system enhan-
cing potency of corticosteroids. We wish to draw a possible effect of
triamcinolone to the attention of rheumatologists and recommend that
triamcinolone should not be injected in patients taking ritonavir. So far,
there have not been cases of adrenal dysfunction after depomedrone
but caution is advised.
Disclosures: The authors have declared no conflicts of interest.
21. TAKO-TSUBO CARDIOMYOPATHY ASSOCIATED WITH
SYSTEMIC SCLEROSIS: A SIGN OF MYOCARDIAL
RAYNAUD’S PHENOMENON?
Iain Goff1,2, Gary Reynolds2 and Matthew Grove3
1Department of Rheumatology, Newcastle Hospitals NHS Trust,
Newcastle, 2Institute of Cellular Medicine, University of Newcastle,
Newcastle and 3Department of Rheumatology, Northumbria
Healthcare NHS Trust, North Shields, UK
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Background: A 65-year-old woman with limited SSc (RP, pulmonary
fibrosis, anti-centromere antibodies) attended for routine orthopaedic
surgery. Comorbidities included hypertension and primary biliary
cirrhosis and she regularly attended for prostaglandin infusions for
her RP. At anaesthetic induction she developed hypotension and non-
sustained ventricular tachycardia leading to the procedure being
abandoned. She experienced cardiac sounding chest pain and
developed pulmonary oedema, with ECG showing ST elevation in I,
II, aVL, V5 and V6. She was transferred to the regional cardiology
centre for emergency coronary angiography angioplasty.
Methods: Coronary angiography showed patent vessels with the
exception of a longstanding occlusion of one superficial branch of the
right coronary artery. A ventriculogram showed severely impaired left
ventricular (LV) systolic function with sparing of basal segments,
akinetic mid segments. Although there was a rise in Troponin T levels
cardiac MRI showed no evidence of myocardial ischaemia.
She was managed conservatively and 2 days after admission her
LV function was graded as moderate, whilst at review 4 weeks post-
discharge it had returned to normal.
Results: Tako-tsubo cardiomyopathy is a rare disorder characterized
by transient ballooning of the LV apex leading to acute LV dysfunction,
in the absence of acute coronary artery occlusion. The name derives
from the Japanese term for octopus pot, due to the resemblance of the
ballooning LV to the short-neck round flask shape of the pots
traditionally used for catching octopus.
The syndrome, observed predominantly in women >60 years, is
provoked by profound physical/psychological stress. It is character-
ized by ischaemic ECG changes mimicking acute myocardial infarction
with a reduction of ejection fraction but minimal release of cardiac
enzymes. Most survive, usually with rapid restoration of cardiovascular
function and full recovery of ejection fraction.
Though the cause remains unknown, it is suspected that
simultaneous vasospasm of multiple coronary arteries contributes to
the tako-tsubo syndrome. Hypersensitivity of the coronary vasculature
to the catecholamine surge of the physiological stress response is one
proposed mechanism for this co-ordinated spasm throughout the
coronary vasculature. It is also well known the myocardial Raynaud’s
phenomenon leads to silent coronary vasospasm in patients with
systemic sclerosis.
Conclusions: In our patient the hypotension experienced at general
anaesthetic (GA) induction is likely to have triggered a Raynaud’s type
coronary vasospasm leading to the tako-tsubo syndrome. Only one
previous report of tako-tsubo cardiomyopathy in association with
systemic sclerosis has been published. This case further suggests a
link between systemic sclerosis and tako-tsubo syndrome and acts as
a warning when considering a GA in patients with systemic sclerosis.
Disclosures: The authors have declared no conflicts of interest.
22. NECROTIZING BALANITIS DUE TO POLYARTERITIS
NODOSA
Priya Patel1, Mark N. Lazarus1, Frederico Roncaroli2,
Carolyn Gabriel3 and Anne R. Kinderlerer1
1Rheumatology, St Mary’s Hospital, London, 2Histology, St Mary’s
Hospital, London and 3Neurology, St Mary’s Hospital, London, UK
Background: Polyarteritis Nodosa (PAN), a rare necrotizing vasculitis
affecting small to medium-sized arteries, is extremely difficult to
diagnose.
Methods: Here, we present a case of PAN in a middle-aged man who
presented to the sexual-health clinic with sterile epidydimitis, followed
by a penile rash and a constellation of insidious symptoms before
developing acute necrosis of his glans penis.
Results: Careful clinical examination allowed for rapid histological
confirmation of the diagnosis and prompt treatment without the need
for invasive angiography.
Conclusions: This case emphasizes the importance of considering
the possibility of PAN in patients with a sterile penile rash or ulceration
as misdiagnosis can lead to a fatal outcome.
Disclosures: The authors have declared no conflicts of interest.
23. IMPROVEMENT OF COELIAC DISEASE IN A PATIENT
WITH SJO¨GREN’S SYNDROME TREATED WITH RITUXIMAB
Elena Nikiphorou1 and Frances C. Hall1
1Rheumatology, Cambridge University Hospitals Foundation Trust,
Cambridge, UK
Background: Sjo¨gren’s/lupus spectrum disorders reflect immune
dysregulation which also increases the incidence of other immune--
mediated phenomena, such as coeliac disease. B-cell depletion
therapy may be effective for these associated conditions. However,
economic restrictions require more tangible evidence of efficacy in
order for such strategies to be funded.
Methods: A 52-year-old female presented with ascending lymphangi-
tis in the arm and a blistering rash on her legs. She had fatigue,
diarrhoea and weight loss of 5 kg. She had a several year history of
dry eyes, photosensitivity, tinnitus and pleuritic chest pain. Past
medical history included parotitis and cholecystectomy for gallstones
4 years previously. Her father had sicca symptoms and died from a
lymphoma.
On examination, she weighed 65.6 kg, had a malar rash, bilateral
conjunctival injection but general examination was otherwise
unremarkable.
Investigations revealed anaemia, normal renal, liver and bone
function tests, reduced folate (203mg/l), ESR 61 mm/h and CRP 3 mg/l.
She had positive ANA, anti-Ro, anti-La, RhF, ACL and anti-TTG. She
was negative for anti-dsDNA antibodies, ANCA and cryoglobulins. She
had a polyclonal hypergammaglobulinaemia, and a hypocomplemen-
taemia with C4 0.12 g/l.
Minor salivary gland biopsy demonstrated lymphoplasmacytic
infiltration with two foci per 4 mm2. Duodenal biopsy showed partial
villous atrophy with crypt hyperplasia and chronic inflammatory
infiltrate. Biopsy of the vesicular rash revealed a thrombotic
capillaritis with neutrophilic exudate but negative immunofluorescence
assays.
Diagnoses of primary Sjo¨gren’s syndrome, with lupus spectrum
features and with coeliac disease were made. The patient commenced
a strict gluten-free diet and was commenced on prednisolone 30 mg
od HCQ and MMF.
Results: Conventional immunotherapy for 15 months resulted in
resolution of the vasculitic rash and improvement of duodenal
histology but constitutional features, including weight loss
continued. After 12 months of rituximab, she exhibited marked
improvement of gastrointestinal, constitutional, functional and serolo-
gical measures.
Conclusions: This is the first report of efficacy of B-cell depletion
therapy for a composite presentation of coeliac disease with Sjo¨gren’s
syndrome.
TABLE 1. Response to rituximab in addition to conventional therapy
Measure Pre-
treatment
Post-diet,
HCQ and MMF
Post-
rituximab
Frequency of bowel movement 9/day 7/day 4/day
Weight, kg 65.6 56.3 61.2
SF36, BILAG 37, 25 nd, 17 64, 2
Anti-TTG (0–6 U/ml), U/ml 128 9.2 5.4
RF (0–30 IU/ml), IU/ml 916 52 nd
IgG (6–13 mg/dl);
IgA (0.8–3.7 mg/dl), mg/dl
28.9; 4.03 9.9; 2.7 9.9; 2.9
Prednisolone dose, mg o.d. 30 10 7.5
SF36: short-form 36 (functional questionnaire); BILAG: score of lupus activity; TTG:
tissue transglutaminase; nd: not done.
Disclosures: The authors have declared no conflicts of interest.
24. AN UNUSUAL CASE OF BILATERAL PAROTID AND
SUBMANDIBULAR GLAND INVOLVEMENT IN ANCA
ASSOCIATED VASCULITIS, REFRACTORY TO
CYCLOPHOSPHAMIDE BUT SUCCESSFULLY TREATED WITH
RITUXIMAB
Ellen Bruce1, Leanne Gray1, Maria Krutikov1, Surabhi Wig1 and
Ian Bruce1
1Rheumatology, Manchester Royal Infirmary, Central Manchester
University Hospitals, Manchester, UK
Background: ANCA Associated Vasculitis (AAV) is a disease of
unknown aetiology characterized by necrotizing vasculitis of the small
and medium vessels. Granulomatosis with Polyangiitis (GPA) typically
involves the upper and lower respiratory tract and kidneys. We
describe a patient with a rare presentation of aggressive bilateral
parotid and submandibular gland involvement with bilateral lower
motor neurone facial nerve palsy.
Methods: A 68-year-old female patient presented with a 4-week
history of pain and swelling in the right parotid and left submandibular
gland region. Initial antibiotic treatment for presumed localized
infection was unsuccessful. Due to worsening pain and swelling, a
biopsy of the affected area was performed, which demonstrated
features in keeping with GPA. The patient reported significant weight
loss and malaise but no other clinical features such as skin, eye,
respiratory, joint or renal disease were present. Laboratory investiga-
tions demonstrated an elevated ESR at 74 mm/h and weakly positive
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ANCA (PR3 5.7 IU/ml) and oral prednisolone was therefore com-
menced. Despite this, the patient developed a right-sided lower motor
neurone facial nerve palsy and pulsed intravenous cyclophosphamide
was initiated for AAV.
Results: Despite 4 months of 3-weekly pulsed cyclophosphamide,
the patient’s disease progressed to a bilateral facial nerve palsy. This
was accompanied by further destruction of the parotid and sub-
mandibular glands with enlarging sinus tracts to the skin and
associated concerns regarding secondary infection. Magnetic
Resonance Imaging confirmed progressive glandular destruction and
air within the cavity, raising the possibility of actinomycosis infection.
The ESR remained elevated and ANCA weakly positive and a further
submandibular gland biopsy again demonstrated features consistent
with granulomatous inflammation. Infection with actinomycosis was
not present.
Following exclusion of an alternative diagnosis and in the absence
of significant infection, the patient was commenced on rituximab as
per the RAVE regime. After 1 month of treatment the sinus tracts had
almost healed, the ESR had normalized and the patient had begun to
gradually regain weight.
Conclusions: This unusual presentation of AAV involving only the
parotid and submandibular glands demonstrates how aggressive
localized disease can be. In this case the disease was refractory to
cyclophosphamide but effectively controlled with rituximab.
Disclosures: The authors have declared no conflicts of interest.
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25. EARLY RESPONSE TO ABATACEPT PLUS MTX IN
MTX-IR RA PATIENTS USING POWER DOPPLER
ULTRASONOGRAPHY: AN OPEN-LABEL STUDY
Maria A. D’Agostino1, Richard Wakefield2, Hilde Berner Hammer3,
Olivier Vittecoq4, Mauro Galeazzi5, Peter Balint6, Emilio Filippucci7,
Ingrid Moller8, Annamaria Iagnocco9, Esperanza Naredo10,
Mikkel Ostergaard11, Corine Gaillez12, Wendy Kerselaers13,
Karina Van Holder14, Manuela Le Bars12 and OMERACT US
Task Force. 1
1Service de Rhumatologie, AP-HP Ambroise Pare Hospital,
Boulogne-Billancourt, France, 2Department of Rheumatology,
University of Leeds, Leeds, UK, 3Department of Rheumatology,
Diakonhjemmet Hospital, Oslo, Norway, 4Department of
Rheumatology, University Hospital, Rouen, France, 5Institute of
Rheumatology, University Hospital, Siena, Italy, 6Rheumatology
Department, National Institute of Rheumatology and Physiotherapy,
Budapest, Hungary, 7Clinica Reumatologica, University Politecnica
delle Marche, Ancona, Italy, 8Rheumatology Institute, Instituto Poal,
Barcelona, Spain, 9Dipartimento di Clinica e Terapia Medica
Applicata, University La Sapienza, Rome, Italy, 10Department of
Rheumatology, Hospital Severo Ochoa, Madrid, Spain, 11Department
of Rheumatology, University Hospital, Copenhagen, Denmark,
12Medical Affairs, Bristol-Myers Squibb, Rueil-Malmaison, France,
13Global Biometric Sciences, Bristol-Myers Squibb, Braine-L’Alleud
and 14Global Clinical Operations and Strategy, Bristol-Myers Squibb,
Braine-L’Alleud, Belgium
Background: The global power Doppler ultrasound (PDUS) scoring
system combining synovial hypertrophy, joint effusion and PD signal
developed by the OMERACT-EULAR-US Task Force has good intra-
and inter-observer reliability in metacarpophalangeal (MCP) and non-
MCP joints, and demonstrates consistency between PDUS machines.
We present the first international, Phase IIIb study using the global
PDUS synovitis score to assess early impact of i.v. abatacept on
synovial inflammation.
Methods: This 6-month, single-arm, open-label study enrolled active
MTX-IR RA patients defined as DAS28 (CRP) >3.2 or 6 tender and
swollen joints and CRP >ULN. Patients had a total synovitis PDUS
score >1 for 2 MCPs and 1 for 1 other MCP (out of MCP 2–5
bilaterally; i.e. 8 joints) at screening and baseline (BL). The primary
objective was to evaluate early response to abatacept, defined by
improvement of synovitis assessed by global PDUS of affected MCP
joints bilaterally. Global PDUS was scored over 8 MCP joints (range
0–24 units) at BL, Days 7, 15, 29, 43 and 57, then monthly by a PDUS
reader blinded from clinical assessments. Early signs of improvement
were defined as the earliest time point when 95% CI for mean change
from BL in global PDUS score did not contain 0 for that and all later
time points. DAS28 (CRP) and safety were assessed for all patients
who received 1 dose of abatacept.
Results: 104 patients were enrolled; 89 completed the trial.
Demographic, clinical and PDUS data are shown (Table 1). Early
signs of improvement in global PDUS score were observed at Day 7.
Mean change from BL in global PDUS score and its components
increased to Day 169. By Day 57, threshold for clinically meaningful
improvement of 1.2 was not included in the 95% CI for mean change
from BL in DAS28 (CRP). There were no deaths; 6 (5.8%) patients
developed a serious adverse event (AE) (atrial fibrillation, bursitis,
dementia, endometriosis, pleural effusion and pulmonary fistula, and
hypertension), 62 (59.6%) an AE, and 20 (19.2%) an infection.
Conclusions: The study showed that the OMERACT-EULAR-US
global PDUS score detected early signs of improvement in synovitis,
demonstrating a significant response to abatacept at Day 7, which
increased to Month 6. Efficacy and safety data were consistent with a
previous abatacept trial in MTX-IR patients.
Disclosures: P.B., Bristol-Myers Squibb—Grant/Research Support,
Abbott, Pfizer, MSD, Roche, SonoSite, GE, ESAOTE, ACR, EULAR—
Speaker’s Bureau. E.F., Bristol-Myers Squibb—Consultant. C.G.,
Bristol-Myers Squibb—Shareholder, Employee. W.K., Bristol-Myers
Squibb—Employee. M.L., Bristol-Myers Squibb—Shareholder,
Employee. E.N., Merck Sharp and Dohme Corp—Grant/Research
Support. M.O., Abbott, Amgen, Bristol-Myers Squibb, Centocor,
Genmab, GlaxoSmithKline, Mundipharma, Novo, Pfizer, Roche,
Schering-Plough, UCB, Wyeth—Grant/Research Support,
Consultant, Speaker’s Bureau. K.V., Bristol-Myers Squibb—
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26. TWINS UK HERITABILITY STUDY OF CANDIDATE LOW
BACK PAIN PHENOTYPE SHOWS VERTEBRAL ENDPLATE
ABNORMALITIES TO BE HERITABLE.
Millicent A. Stone1,2, Francis Williams2, Lisa Wolber2,
Jaro Karppinen3 and Juhani Maatta3
1Pharmacy and Pharmacology, University of Bath, Bath, 2Department
of Twin Research and Genetic Epidemiology, King’s College London,
London, UK and 3Department of Medical Biochemistry and
Molecular Biology, University of Oulu, Oulu, Finland
Background: Low back pain (LBP) is a very common and disabling
problem in adults worldwide. One of the classical risk factors for LBP is
MRI-determined lumbar disc degeneration (LDD). One of the features
of LDD which has received less attention is vertebral end plate lesions
(VEP), which have been linked to LBP. The challenge in LBP research
is the lack of a universally accepted phenotype. While heritable factors
have been shown to influence other features of the LDD phenotypes,
VEP lesions have not been studied to date. The overall objective of this
study was to investigate the relative role of genetic and environmental
influences on the VEP in the lumbar spine.
Methods: We conducted a classic twin study of VEP changes of
880¼MRIs in 155 monozygotic (MZ) and 285 dizygotic (DZ) twin pairs
to determine whether genetic factors affected low back pain. T2
TABLE 1. Demographic, clinical and PDUS data
Demographics
Females (%) 83.7
Age, mean (S.D.), years 56.4 (14.1)
BL characteristics, mean (S.D.)
Disease duration, years 7.3 (9.1)
DAS28 (CRP) 5.29 (1.11)
Global PDUS score 12.6 (4.1)
Mean (95% CI) change from BL in global PDUS score (LOCF)
Day 7 –0.7 (–1.2, –0.1)
Day 169 –4.8 (–5.8, –3.9)
Mean (95% CI) change from BL in DAS28 (CRP)
Day 7 –0.55 (–0.70, –0.39)
Day 169 –2.13 (–2.39, –1.86)
Patients (%), day 169
Remission (DAS28 <2.6) 40/98 (40.8)
Low disease activity status (DAS28 3.2) 56/98 (57.1)
Clinically meaningful improvement
(DAS28 change >1.2)
72/97 (74.2)
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weighted sagittal sequences of the lumbar spine were available from a
previously published study conducted 2006–2010, to evaluate VEP
changes in the lumbar spine. Each lumbar disc was scored on a scale
of 0–3 for severity of endplate change across the disc and a summary
VEP score generated by adding the five lumbar discs scores together.
In the classical twin design of twins reared together, three
parameters: were modelled: an additive genetic (A), shared (C) and
non-shared (E) environmental components. The ACE full model was
compared with sub models AE, and CE. The chi-squared test was
used to compare the fit of the models while the Akaike’s information
criterion was used to determine the relative fit of the model and its
parsimony Models with lower AIC values indicate a better balance of fit
over parsimony of the data. The majority of the heritability estimates
was produced by the Mx-programme.
Results: As other features of LDD are similar in men and women, both
genders were included in the heritability analysis. Heritability estimates
ranged between 41% and 59% for VEP changes. Further more, the
model with the best fit was additive and environmental AE, Table 1.
Conclusions: Results indicate that there were significant genetic
influences over VEP changes visible on MRI in twins. Thus VEP may
represent a candidate LBP phenotype for future studies evaluating
response to treatment in LBP. Understanding further and identifying
the genetic influences on VEP may reveal pathways of pathogenic
importance, which is currently poorly understood. With the develop-
ment of large cohorts having MR information and genome-wide
association data, future research should focus on VEP in order to
characterize the molecular pathways beyond LBP.
Disclosures: The authors have declared no conflicts of interest.
TABLE 1. Heritability results
Phenotype Model for
comparison
Univariate
estimates
95% CIs
DF AIC P-value A C E
VEP ACE 41 (16, 54) 0 (0, 15) 59 (46, 75)
CE 1 5.44 0.006 - 22 (11, 32) 78 (67, 89)
AE 1 –2.00 1.000 41 (25, 54) - 59 (46, 75)
C 2 18.11 0.000 - - 1 (1, 1)
VEP: vertebral end plate.
27. CURRENT PRACTICE IN MUSCULOSKELETAL
ULTRASOUND IN THE NORTHERN REGION
Ben Thompson1, Ismael Atchia2, Alice Lorenzi1, Graham Raftery3
and Phil Platt1
1Musculoskeletal Unit, Newcastle Hospitals NHS Foundation Trust,
Newcastle, 2Department of Rheumatology, Northumbria Healthcare
NHS Foundation Trust, Whitley Bay and 3Department of
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Background: The clinical indications and potential of musculoskeletal
ultrasound (MSUS) are increasing within rheumatology. Anecdotally,
the number of rheumatologists using or seeking to learn the technique
is also increasing. However, acquiring, maintaining and demonstrating
skills in MSUS remains challenging, and there is uncertainty about the
most appropriate and effective means to achieve this. This survey
sought to determine the current practice in this area amongst
rheumatologists in the Northern Region (north-east England).
Methods: All 58 rheumatologists [46 Consultants, 12 Specialty
Trainees (STs)] in the Northern Deanery were sent an email invitation
to complete an on-line survey. Questions reflected participants’
current use of MSUS, their access to MSUS equipment, and training
and governance issues. Rheumatologists who did not use MSUS were
encouraged to access the survey, but completed only the initial
questions.
Results: 35 responses were received (26 Consultants, 9 STs)—a
response rate of 60%. 15/35 respondents scanned regularly (11
Consultants, 4 STs). The majority (10/15) performed fewer than 8
scans per week. 14/15 were confident scanning hands and wrists,
while 4/15 were confident scanning each of shoulders, hips and
temporal arteries. Only 9/15 had unlimited access to an ultrasound
machine. 6/15 scanned as part of combined sessions with a
musculoskeletal radiologist, while 4/15 fulfilled independent outpatient
MSUS lists.
All 15 respondents who regularly used MSUS maintained their own
system for recording and validating scans, although systems were not
uniform or universal. 5 kept a logbook; 7 saved images to discuss with
a mentor; 3 were able to upload their images to the hospital radiology
system. Free text comments indicated a desire for more guidance and
assistance with respect to governance and quality, but some
expressed difficulties in obtaining this from radiologists.
19/35 respondents had attended a training course in MSUS. 13 had
attended the local course; 13 had attended a BSR US course; 3
attended a EULAR course; 4 had attended courses at local
Universities.
Conclusions: At least 26% of rheumatologists (15/58) in the Northern
region are utilizing MSUS as part of their routine clinical workload.
There is a higher proportion of trainees (4/12—33%) than Consultants
(11/46—24%), suggesting that this figure is likely to increase further.
Despite debate in recent years, training in MSUS remains variable, and
clinicians who wish to develop their skills in this area face challenges
with respect to guidance on optimum methods, access to equipment,
and mentors with the time and skills to teach them. Similarly, MSUS
practitioners in the Northern Region are using a number of different
methods to demonstrate the validity of their scan results. Further effort
in meeting these needs—locally, nationally, and internationally—is
necessary to ensure that the benefits of MSUS are available at a high
standard to as many of our patients as possible.
Disclosures: The authors have declared no conflicts of interest.
28. THE PREDICTIVE VALUE OF MUSCULOSKELETAL
ULTRASOUND IN UNSELECTED EARLY ARTHRITIS CLINIC
PATIENTS WITH POLYARTHRALGIA
Philip N. Platt1 and Arthur Pratt1
1Rheumatology, Freeman Hospital, Newcastle, UK
Background: Musculoskeletal ultrasound (MSUS) has shown promis-
ing utility in the evaluation of early, clinically defined arthritis. We
explored its value as a screening tool for predicting inflammatory
arthritis in unselected early arthritis clinic (EAC) patients with
polyarthralgia.
Methods: 250 Newcastle EAC patients were scanned by an
experienced rheumatologist / MSUS practitioner (PNP) at their first
clinic attendance using a Toshiba Aplio machine. A pragmatic protocol
was undertaken, limited to grey-scale / power Doppler views of MCP,
PIP, wrist and MTP joints. The same practitioner, informed by MSUS
findings alone, classified each patient as having inflammatory arthritis,
OA, crystal induced disease or no abnormality.
After a minimum 12 months’ follow-up a review of medical records
determined each patient’s actual clinical diagnosis as being inflam-
matory arthritis (excluding gout/CPPD) or non-inflammatory. These
outcomes were compared with the MSUS-predicted diagnostic
category at baseline.
Results: Of 250 patients scanned, 77 were considered to show
evidence of definite inflammatory arthritis on gray-scale and/or
Doppler scanning, 33 showed changes of OA, 13 showed ultrasound
signs typical of gout or CPPD and 127 scans were considered normal.
Medical records confirmed outcomes of inflammatory arthritis in 92
patients and non-inflammatory diagnoses in 148. The sensitivity of
baseline MSUS assessment for a diagnosis of persistent inflammatory
arthritis was 80.4%; specificity 97.3%. Corresponding positive and
negative predictive values were 95.4% and 87.8% respectively.
Conclusions: A pragmatic MSUS screening protocol in the context of
an EAC is feasible, and provides useful prognostic information.
Despite its impressive PPV for persistent inflammatory arthritis, our
data suggest that routine MSUS assessments may overlook 20% of
inflammatory cases at baseline. The use of NSAIDs and corticoster-
oids at first clinic attendance was common and has been shown to
significantly modify ultrasound appearances.
Disclosures: The authors have declared no conflicts of interest.
29. 3D CORTICAL THICKNESS MAPPING OF THE HIP AS A
NEW IMAGING BIOMARKER OF OSTEOARTHRITIS
Thomas D. Turmezei1, Graham M. Treece1, Andrew H. Gee1 and
Kenneth E. Poole1
1University of Cambridge, Cambridge, UK
Background: Bone goes through three stages as OA develops: early
resorption, subsequent sclerosis, and then osteophyte formation. Peri-
articular cortical bone and subchondral bone pathology is ideally
suited to analysis with 3D cortical thickness mapping (CTM), a new
technique that uses clinical CT imaging of living patients to visualize
and quantify cortical bone thickness and joint space. Comparing 3D
cortical thickness maps from individuals with and without disease, we
use parametric analysis to identify patches on the femoral surface
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where cortical thickness differs, visualizing the magnitude and
significance of group differences to discover anatomically relevant
regions of interest (ROIs). In this clinical study, CTM was applied to
investigate whether areas of hip cortical bone thickening corre-
sponded with expert radiologist assessment of clinically-relevant
disease.
Methods: We analysed one hip from each participant in a study of 230
women aged 6617 years who had undergone pelvic CT. The hip was
graded by an expert radiologist for OA feature severity using a 3D
scoring system. Stradwin (v4.3) software was used to contour each hip
semi-automatically and create a 3D surface colour mapped with
individual cortical thickness values. Each of the 230 femur maps were
registered to an average femur surface. Statistical parametric mapping
was then performed to visualize, on a 3D femur model, the statistically
significant effects of age and weight on cortical thickness (thickness
difference per decade/per kilo either as a % or absolute difference in
mm). The primary outcome measure was the group difference in
cortical thickness per worsening osteophyte score (difference per
score either as % or absolute difference in mm), although similar
analyses were also conducted for subchondral cysts and joint space
width (JSW).
Results: There was a statistically significant and highly focal 40%
increase in cortical bone thickness for each increase in osteophyte
score from score 0 (n27), 1 (n110), 2 (n56) up to score 3 (n37). The
regions of cortical thickening were pathologically relevant, encircling
the epiphyseal line and extending to the loaded subchondral bone of
the superior femoral head. Age was associated with thinning of the
cortex, except at sites that are highly stressed during the normal gait
cycle. Increasing weight was associated with thicker cortex in these
same load bearing regions.
Conclusions: Our 3D bone mapping technique identified distinct,
focal thickening of marginal articular cortical bone and superior
subchondral bone with worsening radiological OA. CTM can also
measure the joint space in 3D. Together these results are an important
step towards a new automated imaging diagnostic and prognostic
biomarker for OA. ROI’s will now be taken to a prospective setting to
test the hypothesis that CTM-defined OA features are associated with
clinically and symptomatically relevant OA disease.
Disclosures: The authors have declared no conflicts of interest.
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30. HEALTH-RELATED QUALITY OF LIFE IN GOUT:
A SYSTEMATIC REVIEW
Priyanka N. Chandratre1, Edward Roddy1, Lorna Clarson1,
Jane Richardson1, Samantha Hider1 and Christian Mallen1
1Research Institute for Primary Care and Health Sciences,
Keele University, Keele, UK
Background: Gout is the most prevalent inflammatory arthritis
affecting 1.4% of European adults. The excruciating pain, chronic
arthropathy, comorbidities and frequent sub-optimal management of
gout may influence Health-related quality of life (HRQOL). To our
knowledge there are no existing systematic review articles on HRQOL
in gout.
The objectives were to: (i) to determine which instruments have
been used to measure HRQOL in gout (ii) the clinimetric properties of
these instruments, (iii) the distribution of HRQOL in gout and (iv) to
identify which factors associate with poor HRQOL in gout.
Methods: MEDLINE, CINAHL, EMBASE and PsycINFO were searched
from inception to October 2012. Search terms pertained to gout,
health or functional status, clinimetric properties and HRQOL. Titles
and abstracts of identified articles were independently reviewed by
two reviewers. Articles unsuitable for exclusion based on title and
abstract screening were included for full-text review by both reviewers.
Further exclusions were made based on re-application of the inclusion
and exclusion criteria. The references of all full-text papers were
examined for relevant studies. Disagreements were arbitrated through
consensus meetings. Study data extraction and quality assessment
were performed independently by the two reviewers.
Results: From 474 identified studies, 22 met the inclusion criteria (13
cross-sectional, 7 cohort and 2 qualitative). Of the 12 identified
instruments, Short Form-36 (SF36) and Health Assessment
Questionnaire Disability Index (HAQ-DI) were most frequently used
and highest rated with robust construct and concurrent validity,
despite high floor and ceiling effects. The Gout Impact Scale (GIS) had
good content validity with patient involvement during its develop-
mental stages. However subscales of the GIS showed poor internal
consistency, construct and concurrent validity (weak correlations with
physician rated severity as well as other generic instruments). No
studies defined or used a cut-off value for poor HRQOL in gout. Those
with gout had an overall poorer HRQOL compared with age and sex-
matched norms and controls. Gout had a greater impact on physical
HRQOL compared with other domains. Both gout-specific features
(attack frequency and intensity, inter-critical pain and number of joints
involved) and comorbidities were associated with poor HRQOL.
Evidence for the impact of tophi, serum uric acid and allopurinol on
HRQOL was less robust. Limitations of existing studies include cross-
sectional design, recruitment from specialist clinic settings and
frequent use of generic instruments.
Conclusions: Most studies have used the generic HAQ-DI and SF36.
Gout-specific characteristics and comorbidities contribute to poor
HRQOL. There is need for a cohort study in primary care (where most
patients with gout are treated) to determine which factors predict
change in HRQOL over time. This will enable those at risk of
deterioration to be identified and better-targeted for treatment.
Disclosures: The authors have declared no conflicts of interest.
31. THE BURDEN OF GOUT-RELATED ADMISSIONS TO A
DISTRICT GENERAL HOSPITAL
Abigail Lieberman1 and Peter J. Prouse1
1Rheumatology, Basingstoke and North Hampshire Hospital,
Basingstoke, UK
Background: In UK adults, the prevalence of gout is 1.4%. Gout is
often sub-optimally managed. The impact of this on hospital
admission and prolonging hospital stay has been overlooked.
Hospital Episode Statistics (HES) data for this District General
Hospital (DGH) record 30 admissions per year due to or complicated
by gout, with an average length of stay of 7.3 days. The total cost of
these admissions is given as £62400. Departmental records of
inpatient consultations undertaken for patients with suspected gout
suggested 30 admissions to be an underestimate. We explored the
role of gout in medical admissions in this DGH, if gout was a pre-
existing diagnosis and if it was being treated according to
established guidelines pre-admission.
Methods: All inpatient records where gout was coded according to
ICD-10 as a primary or secondary diagnosis were retrospectively
examined over a 3-month period (May 2011 to July 2011).
A proforma was used to document the cause of admission,
development of gout during admission, prior diagnosis of gout,
treatment of gout, serum urate, gout predisposing comorbidities,
and discharge plan.
Results: In a 3-month period, 79 inpatients had gout coded on their
discharge summary. 64 patient records were accessed. 36% (n¼23)
of these admissions were either directly related to gout (17%, n¼11)
or prolonged by complications of gout (18%, n¼12). This would
suggest 92 inpatient admissions for gout a year.
Over the 3 month study period bed days as a result of admission
directly due to gout was 130 days, with an average length of stay of
12.1 days. Where admissions were complicated due to an attack of
gout (n¼12), we examined the hospital records and planned
discharge date and found this to be prolonged by an average of
5 days, resulting in an additional 60 inpatient days.
HES data for 2011 estimated the inpatient cost for this DGH to be
£62400. Using the same daily inpatient costing our results show an
estimated 12 month cost for patients admitted due to gout to be
£148200 and for admissions complicated by gout to be £68400. The
resultant total of £216600 being 3.5 times greater than the HES
estimate.
94% (n¼60) had an established diagnosis of gout preceding their
admission, but only 33% (n¼20) had a serum urate level measurement
recorded in the year preceding admission, only 67% (n¼40) were on
treatment for gout prior to admission and only 2.5% (n¼1) were
treated according to existing management guidelines prior to
admission.
Conclusions: The frequency and cost of gout is underestimated in the
acute hospital setting. The true cost of acute hospital management is
likely to be 3 to 4 fold that estimated by HES data. Our data show an
annual cost of £216000 for our hospital catchment population of
320000. Our results also demonstrate that only a minority of patients
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were managed with urate lowering treatment and that 97.5% were not
treated to target. Appropriate community and hospital management
could result in major cost savings to the NHS.
Disclosures: The authors have declared no conflicts of interest.
32. RISK FACTORS FOR HYPERURICAEMIA AMONG A
LARGE COHORT OF HIV-INFECTED MEN
Prini Mahendran1, Amanda Samarawickrama1, Duncan Churchill1
and Karen E. Walker-Bone2
1HIV/GU Medicine, Royal Sussex County Hospital, Brighton and
2Rheumatology, Brighton and Sussex Medical School, Brighton, UK
Background: HIV is a global pandemic with approximately 90 000
adults infected in the UK. Combination anti-retroviral therapy (cART)
has transformed HIV prognosis but led to increasing numbers of
ageing patients with HIV. Increasingly, non-AIDS morbidities have
been described including hyperlipidaemia, insulin resistance and
diabetes mellitus, and since hyperuricaemia is associated with these
other manifestations of the metabolic syndrome, gout may become an
increasing problem in longstanding HIV-infected patients. We under-
took a survey of the prevalence of hyperuricaemia and explored its
association with traditional risk factors and HIV factors.
Methods: A random sample of HIV-infected men was invited to
participate in a longitudinal cohort study 2009–10. All participants
attended for a detailed baseline visit including a questionnaire which
enquired about demographic factors, medication, diet and exercise,
and measured anthropometry and blood pressure. Patients gave
consent for scrutiny of the HIV database for HIV parameters including
stage of HIV infection, CD4 count, viral load, duration since diagnosis,
current cART. Subjects gave a blood sample for assessment of urate.
Results: 432 participants were recruited, mean age 48 years (range
20–89 years). Most (95%) were Caucasian and most were infected by
sexual transmission, predominantly between men. 91% were currently
taking cART. 5% reported excess alcohol intake and 24% were
current smokers> 10/day.
Median urate was 0.33 mmol/l for this population (range 0.02–0.64).
In total, 371/432 had a serum urate <0.42 leaving 61 (14%) with
hyperuricaemia according to the local lab reference values. Those with
hyperuricaemia tended to be older (50 years vs 48 years) (NSIG) and
had significantly greater BMI (27.5 vs 25.1, P< 0.0001). Analysed as a
continuous variable in tertiles of urate (low<0.31, medium 0.31–0.37,
high >0.37), univariate analyses showed that urate was significantly
associated with BMI, systolic BP, diastolic BP, hyperlipidaemia and
self reported kidney disease. Urate was not associated with current
CD4 count, nadir CD4 count or stage of HIV infection. In total, 53
patients had a detectable viral load and increasing viral load was
negatively associated with urate. Protease inhibitors and Ritonavir use
currently were associated with higher serum urate but patients taking
Atripla had statistically significantly lower urate levels.
Conclusions: In this large cohort of HIV infected men, 14% had
hyperuricaemia. Urate was associated with traditional risk factors
including BMI, renal disease and blood pressure. However, patients
taking cART had an increased risk of higher urate levels and protease
inhibitors appeared to convey that increased risk. It is interesting that
protease inhibitors, already implicated as a cause of metabolic
syndrome in HIV patients, were significantly associated with urate.
Rheumatologists may see more gout in HIV infected adults taking
cART.
Disclosures: The authors have declared no conflicts of interest.
33. EFFECT OF PEGLOTICASE ON RENAL FUNCTION IN
PATIENTS WITH CHRONIC KIDNEY DISEASE
Faith D. Ottery1, Robert Yood2 and Marsha Wolfson3
1Global Medical Affairs, Savient Pharmaceuticals, Inc, Bridgewater,
NJ, 2Rheumatology, Reliant Medical Group, Worchester, MA and
3Clinical Affairs, Savient Pharmaceuticals, Bridgewater, NJ, USA
Background: Pegloticase is approved in the USA for the treatment of
refractory chronic gout (RCG). Chronic kidney disease (CKD) is
common in patients with gout; 49% of patients enrolled in replicate
phase III clinical trials of pegloticase had stage 3–4 CKD as defined by
the National Kidney Foundation. As CKD can impact the use of uric
acid-lowering therapies, we retrospectively analysed data pooled from
the phase III trials to determine the effects of pegloticase on renal
function and the effects of renal dysfunction on pegloticase safety.
Methods: 212 patients were enrolled in the phase III trials and
received at least 1 infusion of pegloticase. 103 of the 212 patients had
stage 3–4 CKD at baseline and were randomized to pegloticase 8 mg
q2weeks (n¼42), q4weeks (n¼41), or placebo (n¼ 20) for 6 months.
Renal function was assessed by estimated glomerular filtration rate
(eGFR, ml/min/1.73 m2) using the 4-variable Modification of Diet in
Renal Disease formula at screening (week 0) and weeks 7, 13, 19, and
25 post-randomization. Linear mixed effects (random intercept) model
was used to analyse eGFR. Treatment, time, treatment X time, age,
sex, and race were included as fixed effects; patient was included as a
random effect.
Results: Table 1 summarizes mean eGFR over time by randomized
treatment group and across the 3 study arms pooled. eGFR at week 0
was numerically (but not statistically) higher in the placebo group.
Results of the model suggest that change in eGFR was not
differentially affected by treatment (treatment X time interaction:
P¼0.28), independent of age, sex, or race. More than one-third of
patients in all groups had either no change or an improvement in renal
function during the 25-week randomized treatment phase, and
approximately one-half of patients in all groups had no more than a
10% decline in renal function. As was reported for the full pooled trial
population, the most common adverse events in the CKD cohort were
gout flares and infusion reactions.
Conclusions: Patients with RCG and stage 3–4 CKD had no changes in
renal function with up to 6 months of pegloticase therapy. There were no
differences in the pegloticase safety profile based on renal function.
TABLE 1. Mean (S.D.) eGFR over time for patients with RCG and stage 3–4 CKD
Time Point Pegloticase
q2weeks; n
Pegloticase
q4weeks; n
Placebo; n Overall; n
Week 0 40 (12); 42 40 (13); 41 43 (13); 20 41 (12); 103
Week 7 43 (14); 36 44 (19); 36 43 (16); 20 44 (16); 92
Week 13 41 (3); 36 40 (15); 33 46 (16); 19 42 (14); 88
Week 19 44 (15); 33 41 (15); 31 45 (15); 19 43 (15); 83
Week 25 42 (11); 31 41 (15); 30 47 (13); 18 43 (13); 79
Disclosures: F.O., Savient Pharmaceuticals, Inc—Shareholder,
Employee. M.W., Savient Pharmaceuticals, Inc.—Shareholder,
Employee. R.Y., Takeda—Grant (Clinical Research and Drug Trial).
34. AUDIT OF ARMA 2012 STANDARDS OF CARE FOR
PEOPLE WITH GOUT IN PRIMARY CARE IN EDINBURGH
AND THE LOTHIANS
Andrea Ang1, Philip Riches1, Janet Thomson1 and George Nuki1
1University of Edinburgh, Rheumatic Diseases Unit, Western General
Hospital, Edinburgh, UK
Background: The Arthritis and Musculoskeletal Alliance (ARMA) has
recently published Standards of Care for People with Gout, 5 years
after publication of EULAR and BSR guidelines. An audit of current
care in general practices in Edinburgh and the Lothians has been
undertaken using audit criteria based on the 2012 ARMA Standards.
Methods: An online questionnaire was emailed to 712 General
Practitioners. A separate postal questionnaire was sent to 282 patients
with gout from 79 practices, many of whom had participated in a gout
management audit in 2008. Serum urate (SUA) measurements were
captured from SCI store eHealth Record.
Results: Questionnaires were completed by 109 (15%) GPs and 145
(51%) patients, 36% of whom had been referred to rheumatology.
Confirmation of diagnosis by crystal identification had been under-
taken in 21% of patients but was never sought by 28% of GPs.
Patients were frequently assessed for some complications and
comorbidities (renal function 93%, tophi 73%, hypertension 81%)
but less often for others (obesity 69%, hypercholesterolaemia 57%,
diabetes mellitus 56%, ischaemic heart disease 48%, OA 44%) and
monitoring of any comorbidity with annual checks had only been
undertaken in 65%. Obesity (BMI 30) was a comorbidity in 43% of
patients but lifestyle modification advice was given in only 50–70%.
Urate lowering therapy (ULT) was prescribed in >80% of patients
(allopurinol 94%) but only 50% were offered flare prophylaxis. The
SUA was >360mmol/l in 42% and >300mmol/l in 72% with a mean
dose of allopurinol <300 mg/day in these subjects, but follow up SUA
was only measured in 28%. Treatment to a target SUA was the stated
aim by 66% of GPs (<300mmol/l 36%, <360mmol/l 30%) although only
5 worked in practices with a formal pathway of care. While most GPs
had received undergraduate and postgraduate teaching relating to the
diagnosis and management of gout, only 39% reported any training in
the last 5 years and only 10% and 37 % were aware of the EULAR and
BSR guidelines. Patient education was inadequate. While 88% of
patients reported receiving explanation of the causes and treatment of
gout only 43% were given written information, 40% were unaware that
commencement of treatment with ULTs could be associated with gout
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flares and <50% were given advice about self management of acute
attacks.
Conclusions: The ARMA Standards of Care are not being met for
many people. Despite improvement in the prescription of ULTs since
2008, target levels of SUA are still not achieved in a large proportion of
patients and there are important deficits in patient education, training
of health care professionals, diagnosis and assessment for comorbid-
ities as well as in treatment and follow up. Standards of care for people
with gout might be greatly improved by dissemination of concise
guidelines, application of care pathways and inclusion of gout in the
quality outcome framework (QOF) for GPs.
Disclosures: The authors have declared no conflicts of interest.
RHEUMATOID ARTHRITIS:
CLINICAL FEATURES
35. HIGH POSITIVE ANTIBODY STATUS IS ASSOCIATED
WITH INCREASED MORTALITY IN PATIENTS WITH EARLY
INFLAMMATORY ARTHRITIS: RESULTS FROM THE NORFOLK
ARTHRITIS REGISTER
Jennifer Humphreys1, Suzanne M. Verstappen1,
Jacqueline Chipping2, Kimme Hyrich1, Tarnya Marshall2 and
Deborah P. Symmons1
1Arthritis Research UK Epidemiology Unit, School of Translational
Medicine, University of Manchester, Manchester and 2Rheumatology
Department, Norfolk and Norwich Hospital, Norwich, UK
Background: Mortality is increased in RA and this may be particularly
marked in patients who are rheumatoid factor (RF) and/or anti-
citrullinated protein antibody (ACPA) positive. We have previously
shown that patients with early inflammatory arthritis (EIA) who fulfil the
2010 ACR/EULAR classification criteria for RA have increased
mortality compared with those who do not. Within the 2010 criteria,
RF and ACPA positive patients are assigned different weighting
depending on whether the titre is low or high, suggesting they may
have a differential prognosis. The aims of this study were to examine
whether, in a cohort of patients with EIA, patients with low and high
positive serology have increased mortality compared with (i) the
general population and (ii) patients with EIA who are seronegative.
Methods: Adults with 2 swollen joints for 4 weeks were recruited to
the Norfolk Arthritis Register (NOAR) between 1990 and 2009. Patients
included in this analysis had symptom duration <2 years and had not
received disease modifying therapy at initial assessment. At baseline
visit patients were assessed by a nurse who performed a 51 joint
examination and took blood samples for RF and ACPA estimation. All
patients registered with NOAR are flagged with the Office for National
Statistics (ONS) who provide mortality data. Deaths prior to 31st
December 2010 were included. Standardized mortality ratios (SMR,
95% CI) were calculated for all patients with 7 years follow up using
age and sex matched death rates for the Norfolk population as the
comparator. Survival analyses were performed using Cox proportional
hazards models univariately, and a multivariate model was developed
including all components of the 2010 criteria as well as baseline
smoking status, age and gender. Results are shown as hazard ratio
(HR, 95% CI).
Results: 1643 patients had complete data for analysis, 1074 (65%)
were female, median age at symptom onset 55 years. At baseline, 892
(54%) patients fulfilled the 2010 criteria. 466 deaths were reported by
ONS during 20113 person-years follow up. Patients with high positive
serology (3 times the upper limit of normal), had increased rates of
death compared with the general population (SMR 1.77, 95% CI 1.52,
2.30), but not low positive (SMR 1.17, 95% CI 0.70, 2.09) or negative
serology (SMR 1.07, 95% CI 0.89, 1.30). In the multivariate Cox
proportional models high positive serology predicted early death
compared with seronegative patients (HR 1.71, 95% CI 1.32, 2.20);
there was no association with low positive serology (HR 0.85, 95% CI
0.55, 1.71).
Conclusions: In patients presenting with EIA, those with high positive
RF or ACPA have increased risk of mortality compared with both the
general population and to seronegative EIA patients. High seroposi-
tivity may be important in predicting long term outcomes in patients
with EIA.
Disclosures: The authors have declared no conflicts of interest.
36. THE FALLING PREVALENCE OF EROSIVE DISEASE IN
RHEUMATOID ARTHRITIS: A CLINICAL EXPERIENCE
Matthew Roy1, John R. Kirwan1 and Robert W. Marshall1
1Academic Rheumatology Unit, University Hospitals of Bristol NHS
Foundation Trust, Bristol, UK
Background: Rheumatoid arthritis (RA) is a chronic progressive
inflammatory arthritis characterized by the development of joint
erosions with subsequent joint damage, deformity and potential
disability. Historically, the prevalence of erosive disease at diagnosis
reported in the literature ranges from 48–83% and data from as
recently as 2009 suggest that erosive disease at presentation still
remains significant within the UK population. Our clinical impression is
slightly different.
Since 2009, at University Hospitals of Bristol (UHB) we have had a
standardized pathway to manage newly diagnosed RA patients. All
patients must fulfil 1987 ACR classification criteria for RA following
which they are stratified into a moderate or severe arm dependent on
their baseline level of disease activity. Treatment commences with the
ARC regimen or COBRA regimen respectively. Inclusion criteria for the
two arms are the same as those in the original studies.
Methods: 115 consecutive patients enrolled onto our RA pathway
were included in our analysis. Demographics were obtained by review
of patient notes. Baseline X-rays of hands and feet were reviewed by a
musculoskeletal radiologist and by a rheumatologist. For the purposes
of this study patients were grouped according to the presence or
absence of erosions. Results were compared with data from the
original ARC and COBRA studies.
Results: Only 11% of our patients (12/115) had erosive disease at
presentation compared with 31% in the ARC study (n¼128) (P<0.05).
Disease duration (months) did differ between the two groups (ARC
study 15.7 vs 7.8 at UHB) although this is unlikely to fully account for
the significant difference in erosions. There was a statistically
significant difference in rheumatoid factor (RF) positivity (51% at
UHB vs 70% in ARC study) when baseline demographics were
compared.
4% of patients (1/24) with severe disease at UHB had erosive
disease at baseline compared with 77% of patients in the COBRA
study (n¼155). Patients in the COBRA study had a shorter median
disease duration compared with our patient population (4.0 months vs
4.8 months). There was no difference in RF positivity between the two
groups (P< 0.01).
Patients in our pathway were also significantly older than those in
both the ARC and COBRA studies [mean age (S.D.) in years 58.4
(13.6) at UHB vs 49.2 (10.1) in ARC study].
Conclusions: Our study suggests that the presence of erosive disease
in RA at presentation has significantly decreased over the last 15 years
and this change cannot be fully accounted for by earlier diagnosis. The
average age at diagnosis also appears to have risen and both may
suggest a general change in the classic phenotype of RA.
Disclosures: The authors have declared no conflicts of interest.
37. THE IMPACT OF RHEUMATOID ARTHRITIS ON QUALITY
OF LIFE ASSESSED USING THE SF-36: A SYSTEMATIC
REVIEW AND META-ANALYSIS
Faith Matcham1, Ian C. Scott2, Lauren Rayner1, Matthew Hotopf1,
Gabrielle H. Kingsley3,4, David L. Scott5 and Sophia Steer5
1Department of Psychological Medicine, Institute of Psychiatry,
King’s College London, London, 2Academic Department of
Rheumatology, King’s College London, London, 3Department of
Rheumatology, King’s College London School of Medicine, London,
4Department of Rheumatology, University Hospital Lewisham,
London and 5Department of Rheumatology, King’s College Hospital,
London, UK
Background: We have demonstrated in a previous systematic review
that RA uniquely impacts on all aspects of quality of life (QoL), with
detrimental effects observed in all 8 health domains of the Medical
Outcomes Study 36-item Short-Form Health Survey (SF-36). The
recent shift in the paradigm of RA management towards early
combination therapies may have altered the impact of RA on QoL.
We therefore performed an updated systematic review examining the
impact of RA on QoL measured using the SF-36.
Methods: Medline and Embase were searched using the terms RA or
RA and quality of life or SF-36. Observational studies were included
that reported mean and standard deviation scores for all SF-36
domains in RA patients. Domain scores across studies were combined
within a meta-analysis to provide summary scores for each domain.
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Results: A total of 35 studies were eligible for inclusion in the review,
including 23,785 patients. Meta-analyses revealed the pooled mean
QoL scores for the SF-36 domains to be: physical function 45.2 (95%
CI 37.7, 52.8); role physical 36.9 (95% CI 29.1, 44.8); bodily pain 41.5
(95% CI 35.3, 47.8); global health 47.3 (95% CI 41.3, 53.4); vitality 48.6
(95% CI 42.9, 54.3); social function 58.1 (95% CI 50.8, 65.5); role
emotional 51.5 (95% CI 43.0, 60.1); and mental health 59.6 (95% CI
54.2, 65.0). Reduced physical QoL was generally associated with
increased disease activity, physical disability, pain and fatigue;
reduced mental QoL was generally associated with increased disease
activity, pain, fatigue, and increasing age. Furthermore, mental QoL
and physical QoL were significantly associated (r¼0.60, P<0.001);
reduced mental QoL was associated with reduced physical QoL. A
sub-analysis comparing pooled mean physical and mental QoL scores
before and after the shift in RA management was performed. The
results indicated no difference in physical QoL before and after the
change in management: publication year at/pre 2009 physical QoL
41.7 (95% CI 30.9, 52.5); publication year post-2009 physical QoL 41.5
(95% CI 31.3, 51.7). However the same comparison for mental QoL
indicates a non-significant reduction in mental well-being following the
changes in RA management: publication year at/pre 2009 mental QoL
57.9 (95% CI 45.8, 68.2); publication year post-2009 mental QoL 50.4
(95% CI 39.9, 60.8).
Conclusions: RA impairs QoL, particularly the physical components of
the SF-36. QoL is associated with several disease characteristics,
including pain and fatigue. Furthermore, the recent change in RA
management whilst not impacting physical QoL, may have implica-
tions for patients’ mental well-being. Therefore optimal care of RA
patients requires a broader clinical perspective, taking into account
patients’ physical and mental health needs. A specific focus on mental
health may lead to improved outcomes for both physical and mental
well-being.
Disclosures: The authors have declared no conflicts of interest.
38. SEROLOGICAL STATUS: A ROLE IN PERSONALIZED
MEDICINE FOR RHEUMATOID ARTHRITIS
Margaret H. Ma1, Chanaka Dahanayake1, Ian C. Scott2,
Gabrielle Kingsley1, Andrew Cope1 and David L. Scott1
1Academic Department of Rheumatology, King’s College London,
London and 2Medical and Molecular Genetics, King’s College
London, London, UK
Background: Rheumatoid arthritis (RA) is a heterogeneous disease with
diverse outcomes. Serological status such as rheumatoid factor (RF) and
anti-citrullinated peptide antibody (anti-CCP) positivity are associated
with poorer outcome. Early intensive treatment regimes aiming at
achieving remission have been shown to reduce disease activity,
structural damage and long-term disability. However, it is currently
unclear whether all patients should receive the same intensive regimes.
We aimed to investigate the use of serological status as predictors for
the need for intensive therapy to induce remission.
Methods: We analysed samples from a published randomized
controlled trial (CARDERA study) which compared four treatment
regimes in patients with early active RA (disease duration <2 years):
MTX monotherapy, double therapy (MTXþ ciclosporin or predniso-
lone) and triple therapy. The trial randomized 467 patients; 68% female
and their median age was 54 years. Disease activity was assessed
using the DAS28. Remission was defined as DAS28 <2.6 at 24
months. Rheumatoid Factor isotypes (IgM and IgA) and ACPA levels
were measured using commercial ELISA kits. Statistical analysis used
Pearson’s chi-squared test.
Results: 86% was positive for RF IgM, 74% for RF IgA and 74% for
ACPA. We further sub-grouped patients into low antibody levels (<3
times upper limit of normal, ULN) and high antibody levels (>3x ULN).
81%, 64% and 68% patient had high levels of RF IgM, RF IgA and
ACPA respectively. 355 (76%) of the patients had full datasets at 24
months and analyses were restricted to this group. 75 patients (21%)
achieved remission at 24 months. In RF IgM negative patients, the
proportions achieving remission at 24 months were similar in all
treatment groups (22%–30%). In patients with high RF IgM levels,
fewer patients achieved remission with monotherapy (17%) and
double (17%) therapy compared with triple therapy (34%)
(P¼0.001). There were similar and consistent findings with RF IgA
and ACPA serological status. Significantly more patients with high
antibody levels achieved remission using triple therapy than
monotherapy.
Conclusions: Contemporary treatment of RA emphasize on the use of
intensive therapy to achieve remission. However, our study suggests
that not all patients require such an aggressive approach to therapy.
Given the heterogeneity of this disease, treatment of RA should be
personalized to the individual. This would minimize costs of treatment
as well as potentially toxic side-effects. Our study suggests that only
patients who are strongly seropositive should be considered for more
intensive therapies.
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39. RHEUMATOID FACTOR IGA AND ANTI-CYCLIC
CITRULLINATED PEPTIDE ANTIBODIES: PREDICTORS OF
RADIOGRAPHIC PROGRESSION
Chanaka Dahanayake1, Margaret H. Ma1, Ian C. Scott2,
Gabrielle H. Kingsley1, Andrew Cope1 and David L. Scott1
1Rheumatology, King’s College London, London and 2Medical and
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Background: There is a continual need to identify biomarkers to predict
poor outcomes in RA. Ongoing radiographic damage is associated with
increased disability and high disease activity and therefore it is one of the
main measures of poor outcome. The role of rheumatoid factor (RF) and
anti-cyclic citrullinated peptide antibodies (ACPA) as predictors of
radiographic progression has been studied extensively. However, few
studies have investigated the specific isotypes.
Methods: The CARDERA trial (Combination Anti-Rheumatic Drugs in
Early RA) was a randomized double blind factorial trial, studying the
benefits of various combination therapies. Patients selected had active
RA, (68% female, mean age 54 years). 467 baseline serum samples
were analysed for RF isotypes and anti-CCP2 using commercial kits,
(Euroimmun and Axis Shield respectively). Univariate and multivariate
linear regression modelling were used to assess the relationship
between RF isotypes and ACPA status and radiographic progression
(defined as increase in Larsen Score).
Results: In total, 86% of patients were RF IgM positive, 71% RF IgA
positive, 19% RF IgG positive and 71% ACPA positive. In patients who
showed no X ray progression at 12 months, 61% were RF IgM
negative, 54% RF IgA negative, 17% RF IgG negative and 53% ACPA
negative. Upon univariate linear regression analyses, RF IgM, RF IgA
and ACPA positivity were all significant predictors of radiographic
progression at 12 months (b¼ 2.019, b¼1.975 and b¼1.587,
respectively, P-values¼ 0.006 to 0.03). RF IgG positivity was not a
significant predictor (Table 1). Upon multivariate regression analysis,
with adjustment for potential confounding factors including baseline
Larsen score, ESR, Assessor Global Assessment (AGA) score, DAS28
and steroid therapy, RF IgA and ACPA positivity were still significant
independent predictors of radiographic progression (b¼ 1.667 95% CI
0.265, 3.070, P¼0.02 and b¼ 1.389 95% CI 0.001, 2.778, P¼0.05,
respectively). However, baseline RF IgM positivity was no longer a
significant independent predictor.
Conclusions: Our study found that baseline RF IgA positivity and anti-
CCP positivity were significant independent predictors of an increased
Larsen score after 12 months. Since baseline RF IgM status was not a
significant independent predictor, its use within a disease prediction
model may be limited.
TABLE 1. Increase in Larsen score at 12 months
Baseline clinical
variables
b Coefficient 95% CI upper 95% CI lower Significance
RF IgMþ 2.019 3.846 0.192 0.030
RF IgAþ 1.975 3.371 0.579 0.006
RF IgGþ 0.735 2.355 –0.885 0.373
ACPAþ 1.587 2.996 0.178 0.027
Larsen score 0.025 0.065 –0.016 0.233
ESR 0.056 0.077 0.036 <0.001
AGA 0.046 0.074 0.017 0.002
DAS28 0.783 1.266 0.300 0.002
Steroid treatment –2.041 –0.793 –3.288 0.001
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40. SHOULD THERE BE DIFFERENT DISEASE ACTIVITY
CRITERIA FOR ASSESSMENT OF PATIENTS WITH
RHEUMATOID ARTHRITIS ACCORDING TO ETHNIC
BACKGROUND?
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Background: Previous studies on RA features between different
ethnic groups have mainly focused on disability and DASs, structural
damage, genetic factors and health inequalities. However, data on RA
distribution of joint involvement according to ethnicity are scarce. We
investigated joint involvement distribution and other clinical features in
a cohort of ethnically diverse patients with RA.
Methods: We included patients with active RA who previously failed to
respond to 2 non-biologic DMARDs, including MTX and were being
considered for TNFi therapy between 2001 and 2012. Data collected
included tender joint counts (TJC), swollen joint counts (SJC),
inflammatory markers, visual analogue scale (VAS) and DAS28
score. We examined the joint involvement distribution and other
clinical manifestations by race, classified as Caucasian, Asian, Afro-
Caribbean (AC), and other/mixed race, with the Caucasian group
serving as the referent.
Results: The study sample included 401 patients with active RA. Of
these, 266 (66%) were Caucasian, 88 (22%) Asian and 28 (7%) Afro-
Caribbean, and 19 (5%) were other/mixed race. Compared with
Asians, Caucasians were older (62 vs 53 years, respectively; P< 0.001)
and heavier (76 kg vs 67 kg, respectively; P<0.001). Compared with
Caucasians, Asians had a higher ESR (42 and 36, respectively;
P¼0.04), which was confirmed after controlling for age, weight, SJC,
TJC and smoking (b 11.74; P¼0.003); and a lower CRP (26.8 vs 30;
P¼0.6). The overall DAS score was also slightly higher in Asians
compared with Caucasian (6.63 vs 6.39; P¼0.09). There were no
significant differences with regards to other DAS28 components (i.e.
VAS, TJC, SJC). Compared with Caucasians, AC had a higher ESR (47
vs 36, respectively; P¼0.04), which was confirmed after adjustment
for age, weight, SJC, TJC and smoking (b 10.9; P¼0.05), and slightly
higher CRP (32.4 vs 30; P¼0.5). There were no significant differences
with regards to age, VAS, TJC, SJC or DAS28. PIPJ involvement
(presence of swelling or both tenderness and swelling of any PIP joint)
was more common in Caucasians than in Asians (84% vs 71%,
respectively; P¼0.006), and AC patients (84% vs 64%, respectively;
P¼0.01), with right PIP involvement more commonly seen among
Caucasians (70% vs 53%; P¼0.005 and 70% vs 54%; P¼0.07).
There were no differences with regards to other joint involvement
distribution.
Conclusions: Our results show that Caucasian patients with active RA
are more likely to have PIPJ involvement than Asian and AC patients,
but with a similar distribution of other joint involvement. In contrast,
Asian and AC patients are more likely to have a higher ESR than
Caucasians, in line with previous studies. Our data provide further
evidence for ethnic variation in ESR, independent of joint involvement.
In contrast to previous studies no differences in tender and swollen
joint counts and VAS scores were observed.
Disclosures: The authors have declared no conflicts of interest.
41. CAN RADIOGRAPHIC SCORES OF HANDS AND FEET IN
THE FIRST THREE YEARS OF RA PREDICT EVENTUAL NEED
FOR ORTHOPAEDIC SURGERY OF HAND AND FOOT JOINTS?
RESULTS FROM A LONG-TERM INCEPTION COHORT
Elena Nikiphorou1, Lewis Carpenter2, Keeranur Jayakumar1,
Csilla Solymossy1, Josh Dixey3 and Adam Young1
1Rheumatology, ERAS, St Albans, 2Centre for Lifespan and Chronic
Illness Research, University of Hertfordshire, Hatfield and
3Rheumatology, New Cross Hospital, Wolverhampton, UK
Background: The need for hand and foot surgery in Rheumatoid
Arthritis (RA) is the result of failed medical treatment and a surrogate
marker for joint destruction. Prognostic markers are currently limited
but have a potential role in guiding clinicians in early management
decisions. This group has previously reported on the value of standard
clinical and laboratory measures for predicting joint surgery in RA. This
study examines a subset of this cohort with damage scores of hands
and feet (Larsen).
Methods: Standard clinical and laboratory measures, and X-rays of
hands and feet, were performed at baseline, prior to DMARD therapy
and then yearly in the Early RA Study (ERAS, n¼ 1465, 1986–1998,
median follow up 10years). Treatment of patients included disease
modifying, steroid and biologic therapies according to standard UK
practices for management of hospital based RA patients. Larsen
scoring was performed in a subset (n¼ 1186) to include wrists, MCP,
PIP and MTP joints. Source data of orthopaedic interventions included
patient report and medical records, Hospital Episode Statistics (HES)
and the National Joint Registry. Length of follow up was based on the
National Death Registry. Joint surgery of hands and feet included
synovectomies, arthroplasties and fusion.
Results: Larsen scores of hands and feet at 0, 1, 2, 3years were
available in 1146 patients, as a total score, and 3 subtotal scores of
wrists, MCP and PIP, and MTP joints. Joint surgery was performed in a
total of 553 patients (38%), of whom 159 had at least one orthopaedic
procedure of a wrist, hand or forefoot joint for RA, at a median of 10, 7
and 8.8 years respectively. Using the first 3 years of Larsen scores,
ROC analysis was performed to identify suitable cut-off points of total
and subtotal scores to predict surgery of the hands and feet. A Cox
regression model with competing risk and controlling for age at
disease onset, sex and baseline disease activity indicated that having
a Larsen score>¼10 within the first 3 years increased the risk of hand
or feet surgery by more than 2-fold (SHR¼2.58; P<0.001, 95% CI
1.63, 4.08). Results for specific joints were more positive: wrist (SHR
2.67, P< 0.001, 95% CI 1.46, 4.83), MCP/PIP (SHR¼ 2.77, P<0.003,
CI 1.43, 5.38), MTP (SHR¼ 2.98, P<0.001, CI 1.58, 5.62). The
differences in cumulative hazard between the total, and each domain
Larsen score (based on ROC) with eventual need for hand/foot surgery
will be displayed graphically.
Conclusions: Orthopaedic surgery is an important and common
outcome reflecting structural joint damage in RA, it is not often
reported and is difficult to predict. Larsen scores in first 3 years of RA
add predictive value for eventual need for hand and foot surgery.
Disclosures: The authors have declared no conflicts of interest.
42. ETHNIC AND SMOKING VARIATIONS IN EARLY
RHEUMATOID ARTHRITIS: EXPERIENCE FROM A LARGE
SECONDARY CARE CENTRE
Animesh Singh1 and Henry Penn1
1Rheumatology, Northwick Park Hospital, London, UK
Background: Rheumatoid arthritis (RA) is a chronic systemic
inflammatory autoimmune disease characterized by a symmetrical
polyarthritis. Early diagnosis and treatment of the disease results in
earlier clinical improvement and less progression of joint damage.
Racial differences in health-related attitudes of patients have been
alluded to in a variety of chronic diseases including RA. Previous
studies have also implicated cigarette smoking as an independent risk
factor in RA, particularly increasing the risk of anti-cyclic-citrullinated
peptide (CCP) antibodies in certain patient groups.
Methods: A retrospective audit of 118 patients on the Early Arthritis
database at Northwick Park Hospital between 2009 and 2012. We
elicited a variety of parameters including ethnicity, time from symptom
onset to secondary care presentation, antibody status, DAS28 score at
presentation and 1 year together with smoking history. We assayed
anti-CCP antibodies using the anti-mutated citrullinated vimentin (anti-
MCV) antibody ELISA assay (Orgentec).
Results: In total 118 patients were identified of which 109 belonged to
3 major ethnic groups: Asian (54), white (43) and black (12). There were
14 smokers, 15 ex-smokers and 89 patients who had never smoked.
Statistical analysis was by ANOVA (Sofa software).
Mean time from disease onset to presentation to a rheumatologist
was 7.04 months for Asians, 7.58 months for whites and 7.75 months
for black patients (P¼ ns). Mean DAS28 at presentation was 6.37 for
black patients vs 5.71 for Asians and 5.14 for whites. Mean DAS28 at
12 months was 4.18 for black, 3.17 for Asians and 2.65 for white
patients (P¼ 0.013).
A lower proportion of smokers were positive for anti-CCP
antibodies (9/14, 64%) as compared with ex-smokers (10/15, 67%)
and non-smokers (66/89, 74%) (P¼0.66 2). Smokers also had lower
DAS28 scores at presentation (4.6) as compared with ex-smokers (5.5)
and non-smokers (5.6) (P¼0.17) and again at 12 months (2.24 vs 2.86
vs 3.33) (P¼ 0.20).
Conclusions: Our results suggests that there is a prolonged delay in
presentation of early RA amongst all ethnic groups but particularly so
in black patients. We also found that black patients had more
aggressive disease both at presentation and at the end of year 1 of
treatment. This may reflect genetic variations, delayed interaction with
primary care or indeed differing attitudes towards disease and early
aggressive therapy.
In contrast to previous investigators we found smokers and ex-
smokers had less aggressive disease with a lower incidence of anti-
CCP antibodies compared with non-smokers. As yet we are unable to
explain these results and suggest correlation with early arthritis data
from other centres.
Further work is required to investigate genetic susceptibility to RA
across ethnicities as well as evaluating differences in attitude of both
patients and doctors towards disease symptoms and treatment.
Disclosures: The authors have declared no conflicts of interest.
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43. COMORBIDITY AND OBESITY ARE INDEPENDENTLY
ASSOCIATED WITH FAILURE TO ACHIEVE REMISSION IN
PATIENTS WITH RHEUMATOID ARTHRITIS
Nicholas Ellerby1, Derek L. Mattey1, Jonathan Packham1,
Peter Dawes1 and Samantha L. Hider1,2
1Haywood Rheumatology Centre, Haywood Hospital, Stoke on Trent
and 2Arthritis Research UK Primary Care Centre, Keele University,
Keele, UK
Background: Clinical remission is increasingly the target for treatment
in RA. The majority of studies examining remission in RA are within
clinical trials, rather than in patients treated in routine clinical practice.
The aim of this study was to examine the prevalence of and clinical
factors associated with remission in a cohort of established RA
patients on conventional (non biologic) therapy.
Methods: Data were derived from an existing longitudinal RA cohort
followed up for 3 years. Patients had an annual research assessment;
with their treatment at the rheumatologists discretion. Data collected
included; demographics (age, disease duration, gender, BMI), rheu-
matoid factor (RF), and disease activity (DAS28). Comorbidity was
measured using the age adjusted Charlson score (1). Remission was
defined as a DAS28 of <2.6. Comparison of clinical and demographic
factors according to remission status was carried out using Student’s t
or Mann–Whitney U-tests and logistic regression.
Results: 345 RA patients were included in the study with a mean (S.D.)
age of 62 (11) years and mean (S.D.) disease duration of 10.3 (9.6)
years. 237 (69%) were female). At baseline the mean (S.D.) DAS28 was
4.08 (1.34), with men having a significantly lower DAS28 score than
women (men 3.83 (1.36) vs female 4.19 (1.31), P¼0.019). The
prevalence of remission was low: 46/345 (13.3%) at baseline, 47/307
(15.3%) at 1 year, 56/299 (18.7%) at 2 years and 50/249 (20.1%) at 3
years. Patients ever achieving remission had a lower age adjusted
Charlson score at baseline compared with those never achieving
remission, (median age adjusted Charlson score 2, IQR 1—3 vs never-
remission median age adjusted Charlson score 3, IQR 2—4,
P¼0.0002). Patients achieving sustained remission over the first 2
years had the lowest age adjusted Charlson score (1.5, IQR 0.25—2).
No relationship was found between BMI and remission status at
baseline, but obese patients (BMI of> 30) were less likely to achieve
remission within 1 year of baseline than non-obese patients (3.0% vs
13.0%, OR 0.25, 95% CI 0.07, 0.95), and were less likely to sustain
remission over the year following (0% vs 7.1%, OR 0.09, 95% CI 0.02,
0.99). Logistic regression analysis revealed that obesity and the
presence of comorbidity were independently associated with a failure
to achieve remission at any point during the 3-year follow up. Greater
age, female sex and RF positivity was also significantly associated
with a greater likelihood of failure to achieve remission.
Conclusions: RA patients with obesity or comorbid disease are less
likely to achieve remission than non obese patients or those without
comorbidity. Patients with the greatest comorbidity burden are the
least likely to achieve remission. These data suggest that RA remission
can be significantly influenced by clinical factors other than those
usually considered in the rheumatoid disease process.
Disclosures: The authors have declared no conflicts of interest.
44. CLINICAL, IMAGING AND HISTOLOGICAL
CHARACTERISTICS OF PATIENTS WITH RHEUMATOID
ARTHRITIS AT DIFFERENT STAGES OF DISEASE
PROGRESSION
Nora Ng1, Frances Humby1, Michele Bombardieri1, Stephen Kelly1,
Maria Di Cicco1, Sabrina Dadoun1, Rebecca Hands1,
Vidalba Rocher1, Bruce Kidd2, Dev Pyne2 and Costantino Pitzalis1
1Centre of Experimental Medicine and Rheumatology, Queen Mary
University of London, London and 2Rheumatology Department,
Royal London Hospital, Barts Health NHS Trust, London, UK
Background: Rheumatoid arthritis (RA) is a chronic inflammatory
disease whose pathogenesis and response to therapy may differ at
different disease stages. While an immune-mediated inflammation
may drive early disease, at late stages, a stromal reaction may prevail.
Consequently tailored therapy within any phase of the disease requires
better appreciation of both clinical, imaging and histopathological
phenotypes. In this study we investigate these three features in three
distinct groups of patients during their course of disease modeled on
treatment escalation at different time points in their disease evolution.
Methods: Data were collected from 54 RA patients from three stages
of disease evolution and treatment,
(i) early RA cohort (EAC), n¼20 (onset< 1 year andDMARD naive,
(ii) DMARD inadequate responders (DMARDir), n¼ 20 (failed 2
DMARDS and fulfilling criteria to start anti-TNF) and (iii) anti-TNF
inadequate responders (TNFir), n¼14 (failed 1 anti-TNF and switch-
ing to different biologic).
Prior to commencing or changing therapy, all patients had a core
data set assessment including clinical, biochemical, imaging (including
US of 10MCPJþ2 wrists) and an US guided synovial biopsy of a
symptomatic joint.
Results: Mean disease duration of each cohort was 0.5 years (EAC),
6.9 years (DMARDir) and 15.2 years (TNFir). The number of previous
DMARD in each of the groups varied significantly—EAC (0), DMARDir
(mean 1.6) and TNFir (mean 2.1). About a third of patients in both the
DMARDir and TNFir group were receiving concomitant steroid therapy
(30% and 35.6% respectively).
DAS28 were similar between groups (P¼ 0.38) and as expected,
there were significant differences between each cohort in terms of
disability with TNFir patients having a higher HAQ score (P<0.001).
Rheumatoid factor and anti-CCP positivity were more prevalent in
the DMARDir and TNFir cohorts (P<0.001).
The TNFir and DMARDir cohort showed a significant difference in
the presence of radiographic erosions (P<0.001) compared with EAC.
US showed no significant difference in grey scale synovitis (P¼ 0.78)
but marked differences in the power Doppler signal between all groups
(P¼0.036).
Histological grading was significantly different between groups
(P<0.04), with 64% of TNFir group having a diffuse histological
pattern. Lower levels of T cells (P<0.04) and B cells (P<0.02) within
the synovium were also noted in this group. The synovitis score did not
differ significantly between groups (P¼0.17).
Conclusions: We have described a number of clinical, imaging
and histological differences in RA patients at different stages of
disease evolution. This may facilitate better patient stratification
and may inform treatment decisions if shown to be prognostic.
However, it remains unclear whether these characteristics represent
the natural disease progression or related to therapeutic intervention.
Further prospective studies are required to answer this important
question.
Disclosures: The authors have declared no conflicts of interest.
45. SHOULD WE CONTINUE TO GROUP ALL SEROPOSITIVE
RA PATIENTS TOGETHER? A VERY STRONGLY POSITIVE
ANTI-CCP IN THE PRESENCE OF A NEGATIVE/WEAKLY
POSITIVE RF: A SEROLOGICAL PERMUTATION WITH AN
ATYPICAL CLINICAL PRESENTATION?
Sophie Poore1 and David Hutchinson1
1Rheumatology Department, Royal Cornwall Hospital, Truro, UK
Background: RA has been viewed for many years as a heterogeneous
collection of rheumatic diseases. Previously rheumatoid factor (RF)
positive and negative patients were regarded as distinct clinical
subtypes. Additionally, within seropositive RA those with very strongly
positive RF levels were also thought to have a characteristic disease
process. The addition of anti-citrullinated protein antibody (anti-CCP)
testing has led to a distinction between anti-CCP positive and negative
patients. However, no studies have compared the clinical presentation
of RA patients with very strongly positive anti-CCP levels associated
with a negative or low-positive RF levels with those RA patients with a
very strongly positive RF. The objective of this study was to assess the
clinical presentation and demographics of RA patients with very
strongly-positive anti-CCP levels (170 IU) in the presence of a
negative or low-positive RF (30 IU) compared with patients with a
very strongly-positive RF (300 IU).
Methods: The study included 64, outpatient-based, RA patients with a
disease duration <5 years. A negative or low-positive RF associated
with very strongly positive anti-CCP levels (arbitrarily 10 fold higher
than the upper normal limit (UNL) 0–17, i.e. 170 IU) was present in 22
patients, this group represented the ‘cases’ and will be referred to as
the ‘discordant antibody group’. 42 ‘controls’ were selected from
patients with a very strongly-positive RF levels (arbitrarily 30 fold
higher than the UNL 0–30, i.e. 300 IU). Data were collected through
analysis of clinic letters and a serologically blinded telephone
questionnaire. Patients with a personal or family history of psoriasis
were excluded.
Results: Demographics: There was a significantly increased preva-
lence of females in the discordant antibody group (82% vs 45%)
P¼0.005
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Clinical features: Palindromic rheumatism was significantly more
likely to precede the diagnosis of RA in the discordant antibody group
[8 of 22 (36%)] compared with the strongly-positive RF group [1 of 42
(2%)] P¼ 0.0009. An asymmetrical onset was significantly more likely
in the discordant antibodies group [15 of 22 (68%) vs 14 of 42 (33%)]
P¼0.008. There was a significantly increased prevalence of large joint
involvement in the discordant antibody group [16 of 22 (72%) vs 15 of
42 (35%)] P¼0.005. Large and small joints were defined according to
2010 ACR-EULAR criteria.
Conclusions: Patients with very strongly-positive anti-CCP levels
associated with a negative or low-positive RF levels were signi-
ficantly more likely to be female and to have a palindromic type
presentation. Large joint and an asymmetrical presentation were also
significantly more prevalent in this group and further studies are
required to determine whether this group is a new and distinct subtype
of RA.
Disclosures: The authors have declared no conflicts of interest.
RHEUMATOID ARTHRITIS:
COMORBIDITIES
46. ASSOCIATION OF ANTI-TNF THERAPY AND THE RISK
OF ISCHAEMIC STROKE IN SUBJECTS WITH RHEUMATOID
ARTHRITIS: RESULTS FROM THE BSRBR-RA
Audrey Low1, Mark Lunt1, Louise Mercer1, James Galloway2,
Rebecca Davies1, Kath Watson1, British Society for Rheumatology
Biologics Register Control Centre Consortium1, Will Dixon1,
Deborah Symmons1,3 and Kimme Hyrich1 on behalf of the British
Society for Rheumatology Biologics Registers
1Arthritis Research UK Epidemiology Unit, Manchester Academic
Health Science Centre, University of Manchester, Manchester,
2Academic Department of Rheumatology, King’s College London,
London and 3NIHR, Manchester Musculoskeletal Biomedical
Research Unit, Manchester, UK
Background: Subjects with RA are at increased risk of stroke (CVA).
Anti-TNF therapy may influence this risk, potentially by reducing
inflammation. The aim of the analysis was to study the association of
anti-TNF therapy with ischaemic CVA (isCVA) in routine clinical
practice.
Methods: The BSRBR-RA is an ongoing national prospective cohort
study. Subjects with RA starting anti-TNF therapy (etanercept,
infliximab, adalimumab) and a biologic-naı¨ve comparator cohort
treated with non-biologic drugs (nbDMARDs) were recruited from
2001–2009. All were followed by clinician and patient questionnaires 6-
monthly for 3 years and annual clinician questionnaires thereafter, and
also linked to the national death register. Subjects with prior CVA were
excluded from this analysis. Incident CVAs reported from question-
naires and death certificates were validated against the World Health
Organization criteria for CVA and further classified as isCVA using CT
brain reports or if isCVA was reported as the underlying cause of
death using International Classification of Diseases 10 code I63.
Subjects were censored at incident isCVA, death, date of last clinician
follow-up or 31/10/2010, whichever came first. Risk of isCVA was
compared between the nbDMARD cohort and subjects ever exposed
to anti-TNF using Cox regression, adjusted using propensity scores
stratified by deciles (PD). All-cause mortality at 30 days and 1 year
post-isCVA was compared between nbDMARD and anti-TNF cohorts
using multivariate logistic regression (MVLR). Confounders in PD and
MVLR were age, gender, RA-related factors, comorbidities and drugs
(Table 1).
Results: 130 verified incident isCVA occurred: 21 in 3271 nbDMARD
subjects, 109 in 11642 anti-TNF subjects (175 vs 178 per 100 000
person-years respectively; Table 1). After adjustment using PD, there
was no association between ever exposure to anti-TNF and isCVA risk:
hazard ratio (HR) 0.88 (95% CI 0.46, 1.71). Exposure to anti-TNF
therapy was not associated with 30-day or 1-year mortality post-
isCVA: adjusted odds ratio (OR) 1.41 (95% CI 0.18, 11.05) and OR 1.28
(95% CI 0.22, 7.56) respectively.
Conclusions: No association between ever-exposure to anti-TNF
therapy and risk of isCVA or mortality post-isCVA was observed
when compared with nbDMARD therapy in routine UK clinical
practice.
TABLE 1. Patient characteristics
nbDMARD
(n¼ 3271)
Anti-TNF
(n¼11642)
Age, mean (S.D.), years 60 (12) 56 (12)
Female, n (%) 2420 (74) 8964 (77)
Disease duration, median (IQR), years 6 (1–15) 11 (6–19)
DAS28, mean (S.D.) 5.3 (1.1) 6.6 (1.0)
HAQ, mean (S.D.) 1.5 (0.7) 2.0 (0.6)
Years of follow-up per subject, median (IQR) 4 (2–5) 5 (4–7)
Risk of isCVA: PD-adjusteda HR (95% CI) Referent 0.88 (0.46, 1.71)
Number of deaths at 1 year post-isCVA, n (%) 4 (19) 17 (16)
1-year all-cause mortality post-isCVA: fully
adjusteda OR (95% CI)
Referent 1.28 (0.22, 7.56)
aVariables in PD and logistic regression: age, gender, disease duration, DAS28,
HAQ, steroid exposure, number of previous nbDMARDS, entry year to study,
hypertension, ischaemic heart disease, diabetes, smoking, COPD, antiplatelet,
NSAIDs/COX2 inhibitors, digoxin/warfarin use.
Disclosures: BSRBR-RA, Abbott Laboratories, Amgen, Merck, Pfizer
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47. THE RISK OF LYMPHOMA IN PATIENTS RECEIVING
ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS:
RESULTS FROM THE BSRBR-RA
Louise Mercer1, Mark Lunt1, Audrey Low1, James Galloway2,
Kath D. Watson1, William G. Dixon1, BSRBR Control Centre
Consortium1, Deborah Symmons1,3 and Kimme L. Hyrich1 on behalf
of the BSRBR
1Arthritis Research UK Epidemiology Unit, Manchester Academic
Health Science Centre, University of Manchester, Manchester,
2Academic Department of Rheumatology, King’s College London,
London and 3NIHR, Manchester Musculoskeletal BRU,
Manchester, UK
Background: The risk of lymphoma is increased in people with RA
compared with the general population and is greatest in severe RA.
Anti-TNF therapy is now widely used to treat severe RA in the UK. The
aim of this study was to determine whether anti-TNF influences the risk
of lymphoma when used in routine UK clinical practice.
Methods: The analysis was conducted in the BSRBR-RA, a national
cohort study. Patients with RA starting treatment with the TNF
inhibitors etanercept, infliximab or adalimumab and a biologic-naı¨ve
cohort exposed to non-biologic therapy (nbDMARD) were recruited
2001–2009. Subjects with a history of lymphoproliferative cancer prior
to registration were excluded. Incident cancers were identified in 3
ways; lifelong flagging with national cancer agencies; 6 monthly patient
and physician questionnaires for 3 years and annual physician
questionnaires thereafter. Only first lymphoma per subject, confirmed
by histology or cancer agency, was analysed. The first 6 months of
follow-up (fup) were excluded. Subjects were followed up until 31/01/
2011, 5 years fup, first lymphoma or death, whichever came first. The
rates of lymphoma and non-Hodgkin lymphoma (NHL) in the
nbDMARD cohort and in patients ever exposed to anti-TNF were
compared using Cox proportional hazards models adjusted using
deciles of propensity score (PD) which included baseline age, sex,
DAS, HAQ, disease duration, steroids, no. prior nbDMARD, comor-
bidity, ethnicity, smoking and registration date. Cumulative time on
anti-TNF was calculated in the anti-TNF cohort and categorized <1.5
years, 1.5–<3 years and 3–5 years. Hazard ratios (HR) for each
category of anti-TNF exposure were calculated.
Results: There were 67 incident lymphomas: 19 in 3368 nbDMARD-
treated subjects and 48 in 11 931 anti-TNF (157 vs 90 per 100 000
person-years). After adjusting using PD there was no difference in risk
of lymphoma between the cohorts; HR for anti-TNF 1.00 (95% CI 0.49,
2.05). Whilst the HR numerically increased with cumulative exposure to
anti-TNF (Table 1), this was not significant (P¼ 0.410). There were 16
(79%) NHL in the nbDMARD cohort and 42 (83%) in anti-TNF. The
most frequent subtype was diffuse large B-cell lymphoma; nbDMARD
7 (37% of NHL) and anti-TNF 18 (38%). There was no difference in risk
of NHL between the cohorts; PD adjusted HR 1.15 (95% CI 0.53, 2.48).
Conclusions: There is no evidence that anti-TNF increases the risk of
lymphoma over the background risk associated with RA, but further
fup is needed to establish if the picture changes with prolonged
treatment.
Disclosures: O.T., Abbott Laboratories, Amgen, Merck, Pfizer Ltd,
Roche, Swedish Orphan Biovitrum (SOBI), UCB Pharma Ltd—
Research Grant. All other authors have declared no conflicts of
interest.
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48. RELATIONSHIP BETWEEN ANTI-TNF THERAPY AND
RISK OF MYOCARDIAL INFARCTION IN SUBJECTS WITH
RHEUMATOID ARTHRITIS: RESULTS FROM THE BSRBR-RA
Audrey Low1, Mark Lunt1, Louise Mercer1, Ellen Bruce1, British
Society for Rheumatology Biologics Registers Control Centre
Consortium1, Will Dixon1, Kimme Hyrich1 and Deborah Symmons1,2
on behalf of the British Society for Rheumatology Biologics Registers
1Arthritis Research UK Epidemiology Unit, Manchester Academic
Health Science Centre, University of Manchester, Manchester and
2NIHR, Manchester Musculoskeletal Biomedical Research Unit,
Manchester, UK
Background: Subjects with RA are at increased risk of premature
cardiovascular disease (CVD) including myocardial infarction (MI), partly
through shared inflammatory mechanisms. Anti-TNF therapy may
influence this risk through control of inflammation and mediation of
other CV risk factors. The aim of the analysis was to study the association
of anti-TNF therapy with the risk of MI in routine UK clinical practice.
Methods: The BSRBR-RA is an ongoing national prospective
observational cohort study. Subjects with RA starting anti-TNF
(etanercept, infliximab, adalimumab) and a biologic-naı¨ve comparator
cohort of subjects exposed to nbDMARD were recruited 2001–2009.
All were followed by clinician and patient questionnaires 6-monthly for
3 years, annual clinician questionnaires thereafter and linked to the
national death register. All reported MIs from any source were
validated against the 2007 AHA/ESC MI criteria. Additional criteria
were acute thrombolysis/angioplasty for MI or MI as the underlying
cause of death on death certificates. Subjects were censored at 20/4/
2010, death, incident MI or date of last clinician follow-up, whichever
came first. Subjects with prior CVD were excluded from analysis. Risk
of MI was compared between nbDMARD and subjects ever exposed
to anti-TNF therapy using Cox regression adjusted by propensity score
deciles (PD; Table 1). The PD included age, gender, RA-related
factors, CV risk factors and drugs. Risk of MI was explored further with
different drug exposure models and also modelled over time. 30-day
and 1-year all-cause mortality post-MI was compared between
nbDMARD and anti-TNF subjects using multivariate logistic regres-
sion, adjusted for the same confounders.
Results: 235 verified incident MIs were analysed; nbDMARD: 43 in
10337 person-years (PY), anti-TNF: 192 in 55636 PY (42 vs 35 per
10 000 PY; Table 1). There was a trend for a reduced risk of MI in
subjects ever exposed to anti-TNF compared with nbDMARD: PD-
adjusted hazard ratio 0.65 (0.42–1.01). Risk estimates were similar
when limited to periods receiving anti-TNF drug only and did not vary
over time. 30-day and 1-year mortality post-MI was not associated
with ever-exposure to anti-TNF: adjusted odds ratios (OR) 0.93 (0.29,
2.95), OR 0.97 (0.33, 2.79) respectively.
Conclusions: Subjects with RA ever exposed to anti-TNF experienced
a reduced risk of MI over the medium term, further supporting the role
of TNF and inflammation in CVD.
TABLE 1. Results
nbDMARD
(n¼ 3225)
Anti-TNF
(n¼11536)
Age, mean (S.D.), years 60 (12) 56 (12)
Female, n (%) 2420 (74) 8964 (77)
Disease duration, median (IQR), years 6 (1–15) 11 (6–19)
DAS28, mean (S.D.) 5.3 (1.1) 6.6 (1.0)
HAQ, mean (S.D.) 1.5 (0.7) 2.0 (0.6)
Years of follow-up per subject, median (IQR) 4 (2–5) 5 (4–6)
Risk of MI in subjects ever exposed to anti-TNF
therapy: PD-adjusteda HR (95% CI)
Referent 0.65 (0.42, 1.01)
Risk of MI in subjects on anti-TNF therapy (þ 90
days lag window): PD-adjusteda HR (95% CI)
Referent 0.67 (0.42, 1.05)
aBaseline variables in PD: age, gender, disease duration, DAS28, HAQ, steroid
exposure, number of previous nbDMARDS, entry year to study, hypertension,
diabetes, smoking, COPD, antiplatelet use, NSAIDs/COX2 inhibitors use.
Disclosures: BSRBR-RA, Abbott Laboratories, Amgen, Merck, Pfizer
Limited, Roche, Swedish Orphan Biovitrum (SOBI), UCB Pharma
Limited—Research Grants. All other authors have declared no
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49. HAS THE CAUSE OF DEATH IN RHEUMATOID ARTHRITIS
PATIENTS CHANGED RECENTLY?
Saadia P. Malik1, Clive Kelly2, Jennifer Hamilton2, Carol Heycock2,
Vadivelu Saravanan2 and Martin Rynne2
1Rheumatology, Freeman Hospital, Newcastle and 2Rheumatology,
Queen Elizabeth Hospital, Gateshead, UK
Background: Most mortality studies in RA have found an increased
risk of death due to cardiovascular disease, sepsis, and some
malignancies. In addition, patients with RA have been reported as
dying up to 8 years earlier than age and gender matched controls
without the disease. With the advent of newer and earlier therapeutic
interventions, we were interested to see if the causes of death and life
expectancy had changed in comparison with an audit undertaken in
Gateshead between 2000 and 2004.
Methods: Gateshead rheumatology department serves a population
of approximately 250,000. Since 2000, all patients are monitored via an
electronic database. All deaths amongst our RA population between
January 2005 and December 2010 were identified from the database.
Case notes and death certificates were analysed using a standardized
pro forma. Where case notes were not available archived clinic letters
and computer records were examined. We assessed whether death
resulted from direct or indirect effects of RA or its therapy. We also
calculated median age and median disease duration at death.
Comparison was made with results from the earlier Gateshead study.
Results: The database contained 11466 patient-years from 2100
patients monitored during the study period. There were 256 deaths in
RA patients, of these, 62% were female. Median age at death was 75.4
years (range 52 to 93 years), with a median duration of RA of 11 years.
60% of patients died in hospital. The predominant cause of death was
sepsis (46%), with vascular disease and cancers (most commonly lung
cancer) accounting for just 25% each. Sepsis was most commonly
related to the respiratory tract (70 % of cases), and 21% of these
patients were taking long term oral steroids, as compared with 9% of
our RA population overall. Only 5 patients (2.4%) died from RA
interstitial lung disease and one patient died from bone marrow failure
thought to be related to disease rather than therapy. Therapy was felt
to be a contributing factor in only 4 (1.6%) of deaths- 3 patients died
from sepsis secondary to bone marrow failure on DMARDs (SSZ 1,
MTX 1 and biologics 1) and the fourth from suspected LEF induced
lung injury. In comparison with the previous study median age at death
has risen from 74.4 to 75.4 years, the commonest cause of death was
sepsis vs cardiovascular disease and rate of death per 100 patients
has fallen from 2.8 to 2.23.
Conclusions: In comparison with the general population the mean
reduction in life expectancy in RA has fallen to <3 years. Deaths
directly related to disease or therapy are rare. The proportion of
Gateshead RA patients dying from sepsis has increased which is in
contrast to the fall in cardiovascular deaths. Patients dying from sepsis
were more likely to be on steroids at time of death however further
work is needed to identify any other potentially modifiable contributing
factors which may lead to further future improvements in life
expectancy.
Disclosures: The authors have declared no conflicts of interest.
50. SUCCESS OF A SMOKING AND RHEUMATOID
ARTHRITIS AWARENESS CAMPAIGN IN FIFE, SCOTLAND
Helen E. Harris1, Fiona Tweedie1, Yiannis Skaparis2, Marie White1,
Nicola Scott1 and Kay Samson3
1Fife Rheumatic Diseases Unit, NHS Fife, Kirkcaldy, 2Department of
Medicine, University of Dundee, Dundee and 3Smoking Cessation
Team, NHS Fife, Kirkcaldy, UK
Background: Tobacco smoking increases the risk of developing RA
and is associated with a reduced response to RA drug therapy. The
TABLE 1. Results
nbDMARD, n¼ 3368 Anti-TNF, n¼ 11 931
Follow-up (person-years) 12132 53214
Age, mean (S.D.), years 60 (12) 56 (12)
Sex, % female 74 76
RA disease duration, median (IQR), years 6 (15) 11 (6–19)
DAS28 score: mean (S.D.) 5.3 (1.1) 6.6 (1.0)
Lymphoma: age and gender adjusted HR (95% CI) Referent 0.67 (0.39, 1.16)
Lymphoma: PD adjusted HR (95% CI) Referent Overall: 1.00 (0.49, 2.05) <1.5 years: 0.66 (0.25, 1.75)
1.5–3 years: 0.97 (0.40, 2.37) >3 years: 1.31 (0.45, 3.79)
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study objectives were: 1. Launch a public health awareness campaign
about the link between RA and smoking. 2. Assess the knowledge of
RA patients about the links between RA and smoking before and after
the campaign. 3. Assess the impact of the campaign on RA smokers.
4. Identify factors that motivated smoking cessation in RA ex-smokers.
Methods: 1200 seropositive RA patients in Fife were identified, half
were contacted by telephone before the campaign and half after-
wards. A group of RA smokers identified before the campaign were
followed up afterwards. The campaign materials are available at
www.nras.org.uk. The campaign was launched to the media and
mailed to all RA patients in Fife on the same day.
Results: In September 2011 the campaign launch resulted in publica-
tions in 2 newspapers and interviews on 2 radio stations creating
289,660 media impressions. 306 patients completed questionnaires
before the before the launch and 318 in the 3–12 months afterwards.
There was a marked improvement in patients’ knowledge about a link
between RA and smoking and that smoking could interfere with the
treatment (Table 1). After the campaign 33% remembered receiving an
information card and 6% had read a newspaper article. When directly
questioned 17–49% had knowledge about each of the 5 campaign
messages. 62 smokers identified before the campaign were contacted
again following the campaign and found to have modest changes in their
attitudes to smoking (Table 1). 32% of the RA smokers were aware of
campaign information and following the telephone interview 42% stated
that knowing more about the link between RA and smoking would
increase their likelihood of attempting to quit. The reasons that some RA
smokers were not planning to quit were cited as pleasure or relaxation in
24%. The 146 ex-smokers in the pre-campaign group and 151 in the
post-campaign group revealed that experiencing a smoking related
illness such as a chest infection was the commonest motivator to give up
smoking. 63% of RA ex-smokers used pharmacotherapy to quit
smoking and 85% quit after 1–3 attempts.
Conclusions: The Fife smoking and RA awareness campaign has
successfully increased patients’ knowledge of the link between RA and
smoking and the effect of smoking on RA therapy. A modest change in
RA smokers’ attitudes to smoking occurred. To increase the number of
quit attempts by RA smokers this study suggests that patients may be
motivated by learning that RA is a smoking related disease.
TABLE 1. Pre- and post-campaign knowledge and beliefs about smoking and RA
Pre- (%) Post- (%)
Knowledge of link (all) 5 27
Effect on treatment (all) 4 49
Smokers planning to stop 6.7 9
Smokers thinking about stopping 47.5 51
Smokers NOT intending to stop 45.8 40
Disclosures: H.H., Pfizer—Educational grant to fund development of
campaign and cost of telephone work and analysis, Pfizer—
Consultation Fees and Speaker Fees, Menarini, Napp, MSD—
Speaker fees. N.S., Pfizer—Educational grant to fund telephone
work. Y.S., Pfizer—Educational grant for telephone work on study.
F.T., Pfizer—Educational grant to fund study work. M.W., Pfizer—
Educational grant to support telephone work of study. All other authors
have declared no conflicts of interest.
51. FRACTURE RISK MANAGEMENT IN PATIENTS WITH
NEWLY DIAGNOSED RHEUMATOID ARTHRITIS: RESULTS
FROM A CARE PATHWAY
Cecilia Mercieca1 and Shane Clarke1
1Academic Rheumatology Unit, Bristol, UK
Background: Rheumatoid arthritis (RA) results in generalized bone
loss and increased fracture risk. The prevalence of osteoporosis in RA
is increased about twofold. High disease activity, immobility and
glucocorticoids (GC) substantially increase fracture risk in addition to
other factors such as age, BMI and gender. Fracture risk increases
rapidly after starting GC treatment. Our department recently intro-
duced a standardized care pathway for patients with newly diagnosed
RA. The protocol included a DXA scan and fracture risk assessment for
each patient. We set out to determine the risk for osteoporotic fragility
fractures in patients with newly diagnosed RA and the proportion, and
demographics, of those subsequently recommended bone protection
medication.
Methods: We reviewed data from 100 consecutive patients admitted to
the RA care pathway in 2010 or 2011. Clinical data comprising risks for
osteoporotic fragility fractures, medication and DXA scan reports were
collected from the case notes. Bone protection was recommended
where the lowest T scores (spine, total hip or femoral neck) were  –2.5,
or, in a patient with low bone mass, where the calculated fracture risk
exceeded 20% (major osteoporotic fracture) and/or 5% (hip).
Results: Mean age was 58.6 years (S.D. 14.4, range 20–85 years, 69
women). All patients had confirmed RA and had been prescribed at
least 7.5 mg prednisolone. Twenty-three patients had high RA disease
activity at presentation and were commenced on high dose corticos-
teroid (COBRA regimen). Fifty-four patients had another risk factor for
fragility fractures other than RA and GC treatment, while 16 had more
than two risk factors. The most frequent additional fracture risks were
previous fracture and smoking.
DXA scans were carried out in 92 patients. The mean time from RA
diagnosis to DXA scan was 3.2 weeks (S.D. 2.81). The mean FRAX risk
(calculated with femoral neck T scores) for a major osteoporotic
fracture was 13.9% (S.D. 9.6) and for hip fracture 3.6% (S.D. 5.5).
Following fracture risk assessment bone protection medication was
recommended in 31 patients. Treatment was recommended in 2
patients <50 years (n¼ 23), in 6 patients 50–64 years (n¼32) and in 23
patients 65 years or older (n¼ 37). Six patients were on a bispho-
sphonate prior to being diagnosed with RA. Of these 3 patients were
recommended to continue bisphosphonate treatment following DXA.
Conclusions: A small minority of patients newly diagnosed with RA,
and aged under 50 were recommended treatment to reduce fracture
risk. In contrast more than 2/3 of those over 65 were advised such
treatment. These results serve to highlight the benefits of DXA
scanning in such patients to help refine fracture risk. The scans
allow clinicians to avoid recommending unnecessary drugs. The short
time interval between commencing treatment for RA and fracture risk
assessment may be helpful to attenuate adverse effects of GCs on
bone.
Disclosures: The authors have declared no conflicts of interest.
52. ARE PATIENTS WITH INFLAMMATORY POLYARTHRITIS
EXPERIENCING THE SAME REDUCTIONS IN
CARDIOVASCULAR-SPECIFIC MORTALITY AS
THE GENERAL POPULATION?
Alexander J. Warner1, Jennifer Humphreys1, Mark Lunt2,
Tarnya Marshall3, Deborah Symmons1 and Suzanne Verstappen2
1Arthritis Research UK Epidemiology Unit, University of Manchester,
Manchester, 2Arthritis Research UK Epidemiology Unit, Manchester
Academic Health Science Centre, Manchester and 3Norfolk and
Norwich University Hospitals, Norfolk and Norwich University
Hospitals Trust, Norwich, UK
Background: It is widely acknowledged that cardiovascular (CV)
mortality is increased in patients with inflammatory polyarthritis (IP). CV
mortality rates have fallen in the UK general population over the last
few decades (1), but is the same true for IP patients? This study aimed
to examine CV mortality over time in a cohort of recent onset IP
patients compared with the general population in Norfolk, UK.
Methods: Between 1990–2004, patients >16 years with 2 swollen
joints for 4 weeks were registered to the Norfolk Arthritis Register
(NOAR), a primary-care based inception cohort. Three cohorts (limited
to symptom onset <2 years at baseline assessment) were defined by
year of baseline assessment: cohort 1 (1990–1994); cohort 2 (1995–
1999); and cohort 3 (2000–2004). At baseline the 1987 ACR and 2010
ACR/EULAR RA criteria were applied. Patients were tracked via the
Office for National Statistics (ONS) for notification of death. CV death
was defined according to ICD-10 (Chapter I). The ONS also provided
CV death rates for the Norfolk general population. CV standardized
mortality ratios (SMRs) were calculated for all cohorts over 5 years
from baseline and for subgroups fulfilling the 1987 and 2010 RA
criteria. Mortality rates per 1000 person-years (PY) for NOAR and
Norfolk general population were also calculated.
Results: In NOAR, the median age at onset rose with time, as did the
percentage with CV death within 5 years and the crude CV mortality
rate (Table 1). Five year CV SMRs were raised in all cohorts but only
statistically significant in Cohort 3. Patients fulfilling the 1987 ACR and
2010 ACR/EULAR RA criteria at baseline followed a similar trend
although were not statistically significant. The overall crude CV death
rate per 1000 PY in adults >16 years in Norfolk decreased over time:
3.3 (1990–1994); 3.0 (1990–1994) and 2.7 (2000–2004).
Conclusions: Raised SMRs for IP patients in advancing cohort years
may be due to the declining CV deaths in the general population over
the same time period. CV mortality remains increased in IP patients
despite reductions in the general population emphasizing the
importance of CV disease management in IP patients.
Disclosures: The authors have declared no conflicts of interest.
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53. RA-RELATED INTERSTITIAL LUNG DISEASE: WHICH
FACTORS PREDICT ITS DEVELOPMENT?
Esther Chan1, Clive Kelly1, Felix A. Woodhead2, Mohamed Nisar3,
S. Arthanari3, Julie Dawson4, Nav Sathi4, Yasmeen Ahmad5,
Gouri Koduri6 and Adam Young6
1Rheumatology, Queen Elizabeth Hospital, Gateshead, 2Chest
Medicine, University Hospital, Coventry, 3Rheumatology, Queens
Hospital, Burton, 4Rheumatology, Knowsley Hospital, St Helens,
5Rheumatology, BCU Hospital, North Wales and 6Rheumatology,
ERAS/ERAN City Hospital, St Albans, UK
Background: Rheumatoid arthritis (RA) is associated with clinically
relevant interstitial lung disease (ILD) in approximately 5% of patients.
The ERAS group has previously shown an association between RA-ILD
and each of increased age, raised ESR and high HAQ scores in a
group of 52 patients with the condition. We have assessed other
variables for their ability to predict the development of ILD in RA in a
large multi centre UK cohort over a 25 year period.
Methods: We collected data from six centres across the UK on
patients with both RA and ILD (proved on high resolution CT)
diagnosed between 1987 and 2012 using a standard proforma. We
studied the temporal relationship between the onset of both RA and
ILD. We analysed variables including gender, age, duration of both RA
and ILD, smoking history and serology [rheumatoid factor (RF) and
cyclic citrullinated peptide (CCP) antibody]. We compared the results
to a control group of age and gender matched RA patients with no
evidence of lung disease drawn from one centre.
Results: A total of 230 patients were identified from across the UK
with proven RA-ILD diagnosed over 25 years. In total 110 patients
(48%) were male, giving a male:female ratio of 1:1.09 and the median
(range) age at diagnosis of RA-ILD was 64 (37–83) years. Articular
disease predated ILD in 85%, lung disease predated RA in 10% while
the conditions were synchronous in 5%. The median (range) duration
of RA at the time of diagnosis of ILD was 9 (0–31) years. A total of 154
patients (67%) were past (121) or present (33) smokers with a median
(range) of 26 (5–88) pack years. Smoking was more frequent in males
(72%) than females (60%) [P¼0.02], and the median number of pack
years was greater in males (35) than females (20) [P¼0.01]. Smoking
was less prevalent among RA controls (60%) and median pack year
consumption was lower at 21 (5–60) [P¼ 0.03]. Among patients with
RA-ILD, RF was positive in 89% and 94% had anti-CCP antibodies. By
comparison, RF and anti-CCP antibodies were present in 58%
[P¼0.01] and 55% [P¼0.006] of RA controls respectively. Titres of
both antibodies were significantly higher in patients with RA-ILD.
Conclusions: This is the largest study of factors predicting the
development of RA-ILD in the UK. It demonstrates that there is an
almost equal prevalence of RA-ILD in both genders. In contrast with
earlier reports, the condition can occur at a young age and most often
within the first decade of RA. Smoking is strongly associated with the
development of RA-ILD and is greater in males, which may contribute
to the relatively higher frequency of RA-ILD in men. Seropositivity for
rheumatoid factor and CCP antibodies are also strongly associated
with the development of RA-ILD, and might suggest that B-cell
activation, possibly as a result of smoking, may trigger the develop-
ment of RA-ILD in some patients.
Disclosures: The authors have declared no conflicts of interest.
54. RA-RELATED INTERSTITIAL LUNG DISEASE: SURVIVAL
TRENDS OVER 25 YEARS
Clive Kelly1, Esther Chan1, Yasmeen Ahmad2, Felix A. Woodhead3,
Mohamed Nisar4, S. Arthanari4, Julie Dawson5, Nav Sathi5,
Gouri Koduri6 and Adam Young6
1Rheumatology, Queen Elizabeth Hospital, Gateshead,
2Rheumatology, BCU Hospital, North Wales, 3Chest Medicine,
University Hospital, Coventry, 4Rheumatology, Queens Hospital,
Burton, 5Rheumatology, Knowsley Hospital, St Helens and
6Rheumatology, ERAN/ERAS City Hospital, St Albans, UK
Background: Rheumatoid arthritis (RA) is associated with clinically
relevant interstitial lung disease (ILD) in approximately 5% of patients.
In a previous study by the ERAS the prognosis had been poor, with a
mean survival of 3 years following diagnosis of RA-ILD. However, the
advent of more aggressive treatment regimes in RA over the last
decade might have altered the outcome of patients with RA-ILD and a
reassessment is appropriate. Hence, we have assessed survival trends
in patients with RA-ILD in a large multi-centre UK cohort over a 25 year
period.
Methods: We collected data from 6 centres across the UK on patients
with both RA (EULAR 2010 criteria) and ILD (proven on high resolution
CT) using a standard proforma. The period covered patients
diagnosed between 1987 and 2012. We analysed the patients’ age,
duration of both RA and ILD, outcome and, where appropriate, cause
of death. By breaking the data into four clusters based on year of
diagnosis, we assessed the change in life expectancy associated with
RA-ILD, the percentage of patients dying from ILD and the change in
age at death over time.
Results: A total of 230 patients were identified from across the UK
with proven RA-ILD diagnosed over a 25 year period. The male:female
ratio was 1:1 and the median age at diagnosis of RA-ILD was 64 (37–
88) years. A total of 73 deaths were recorded, of which 35 (48%) were
related to ILD. Median age at death from ILD increased from 63 years
(for onset 1987–93) to 76 years (for onset 2006–12), the percentage of
patients dying from ILD fell from 67% to 30% and median survival rose
from 33 months to 48 months over the same period. Most patients
diagnosed in the last 6 years remain alive, so figures for this period are
likely to represent an underestimate of the recent improvement in
prognosis. Further details are shown in Table 1.
Conclusions: This is the largest study of RA-ILD in the UK. It is often
reported that RA-ILD has a very poor prognosis, but this study
demonstrates that the natural history of the condition has improved
over the last 25 years, with patients living longer and being less likely to
die from their lung disease. The reasons for this remain unexplained at
present, but earlier detection and more aggressive management of ILD
may be significant contributors. As the commonest cause of death in
patients with RA-ILD is ILD, this aspect of their condition should be a
priority for therapeutic endeavours.
TABLE 1. Changes in percentages of deaths occurring as a result of interstitial lung
disease, median age at death from ILD, and median survival in those dying from
ILD, as related to year of onset in clusters of 6 years
Year of onset
of RA-ILD
% of patients
dying from ILD
Median age at
death from
ILD in years
Median survival
in months with ILD
1987–1993 67 63 33
1994–1999 42* 68* 36
2000–2005 54 72* 50*
2006–2012 30** 76** 48*
*P< 0.05, **P< 0.01 from baseline.
Disclosures: The authors have declared no conflicts of interest.
55. ANALYSIS OF COMORBIDITIES REPORTED BY PEOPLE
LIVING WITH ARTHRITIS CONTACTING A NATIONAL
HELPLINE SERVICE
Jo Cumming1, Peter Stannett1 and Richard Hull2
1Information and Helplines, Arthritis Care, London and 2CMAB,
Arthritis Care, London, UK
Background: Many in the UK, diagnosed with arthritis report living
with comorbidities. It is well recognized that ischaemic heart disease
and stroke are associated with acute active arthritis and that the
TABLE 1. Baseline characteristics and 5-year outcome
Baseline Cohort 1 (1990–1994) Cohort 2 (1995–1999) Cohort 3 (2000–2004)
Number 1006 880 638
% female 65 65 65
Age, median (IQR), years 54 (42–67) 55 (44–67) 58 (47–70)
5-year outcome
Number (%) of CV deaths 36 (3.6) 34 (3.9) 26 (4.1)
Crude CV mortality (per 1000 PY) 7.5 8.2 8.7
CV SMR (95% CI) 1.13 (0.82, 1.57) 1.29 (0.92, 1.81) 1.51 (1.03, 2.22)
1987 ACR RA patients CV SMR (95% CI) 0.72 (0.41, 1.27) 1.30 (0.79, 2.16) 1.36 (0.77, 2.39)
2010 ACR/EULAR RA patients CV SMR (95% CI) 1.07 (0.71, 1.62) 1.27 (0.80, 2.01) 1.59 (0.92, 2.73)
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support/ information needs may be higher in this group. We felt further
analysis of the data collected could examine this further.
Methods: We analysed every contact by telephone, email, letter or
online forum received in the helpline which is anonymized and logged
onto a secure confidential database complying with the UK Data
Protection Act. Self reported comorbidities were analysed.
Results: The helpline received 11,526 contacts in 2011, of which 784
(8%) reported they had at least one additional health problem and 18%
more than one additional health problem. Whole group analysis (784)
showed the most frequently reported health problem was
Osteoporosis [23%]. Next, 17.8% reported mental health problems,
often depression. Heart conditions were third at 2.5% and 10%
reported hypertension. Those reporting comorbidities increased with
age with exceptions such as Crohn’s disease which varied little over
26 years and a decline (31%) in mental health problems over 64.
Where osteoporosis was reported [n¼186] 42% were aged 26–64
and 58% over 65. 140 people with arthritis reported mental health
problems; only 68% under 65 years reported this.
Individual types of arthritis have different comorbidities reported:
OA (n¼555) reported osteoporosis [21%], depression [14.9%], heart
disease [10%], diabetes [8%] and hypertension [8%].
Of those with mental health issues, the highest percentage (64%)
had OA. People reporting comorbidities and RA (n¼ 70) are likely to
also report depression [20%] followed by heart problems [15%]. 23%
of those reporting fibromyalgia (n¼ 43) said they are being treated for
mental health problems and 18% with osteoporosis.
Of the 784 with addition health problems, 100% said that they
experienced pain compared with 62% without comorbidities. 96% of
those who have OA experienced pain compared with 56% generally.
28.8% reported feeling low/depressed and experience fatigue. 91% of
those with comorbidities were sent information about types of arthritis
compared with 61% with none. On every support parameter, the
needs of those with comorbidities were higher than those without and
16% of people were referred to other support agencies.
Conclusions: 1. We have demonstrated that 8% of 11,526 contacts
had comorbidities which affected their daily life, varying with age and
type of arthritis.
2. High levels of pain reported may be associated with significant
increases in feelings of depression and fatigue and the need for one to
one counselling support.
3. Where additional health problems are reported by people with
arthritis they have generally higher support and information needs
Disclosures: The authors have declared no conflicts of interest.
56. THE EFFECTS OF INDIVIDUALIZED AEROBIC AND
STRENGTH TRAINING ON CARDIOVASCULAR OUTCOMES IN
PATIENTS WITH RHEUMATOID ARTHRITIS
George Metsios1,2, Antonios Stavropoulos Kalinoglou2, Jet
J. Veldhuijzen van Zanten2, Peter Nightingale2, Yiannis Koutedakis1
and George D. Kitas2
1Physical Activity and Health, University of Wolverhampton, Walsall
and 2Rheumatology, Dudley Group of Hospitals, Birmingham, UK
Background: Rheumatoid arthritis (RA) is characterized by an
increased prevalence of cardiovascular disease (CVD) as well as a
compromised fitness levels (maximal oxygen uptake -VO2max), which
is also a strong predictor of CVD. Exercise is known to improve
VO2max and reduce the risk for CVD in the general population.
However, the effects of individualized exercise on CVD risk factors
have never been investigated in RA.
Methods: Twenty RA patients received a 6 month individualized
aerobic and resistance interval exercise intervention three times per
week. Another 20 patients matched for age, gender, BMI, and disease
duration formed the control group which only received advice on the
benefits of physical activity using relevant leaflets from the British
Heart Foundation. VO2max, blood pressure, lipids, insulin resistance
and body composition, disease activity (DAS28), health assessment
questionnaire (HAQ), and C reactive protein (CRP) were taken at
baseline, 3 and 6 months.
Results: The attendance rate to the exercise sessions was 88%, with
the adherence to the prescribed exercise intensity 76%. Repeated
measures ANOVA revealed significant group by time interaction
effects for VO2max (P¼0.001), systolic blood pressure (P<0.001),
high density lipoprotein (P¼ 0.042), body fat percentage (P¼0.026),
as well as CRP (P¼0.042), DAS28 (P¼0.008), and HAQ (P¼0.003).
Post hoc analyses showed that these parameters all improved in the
exercise group, whereas no change was found in the control group.
Conclusions: The proposed combined aerobic and strength training
intervention resulted in a significant improvement in VO2max and
disease-related characteristics in RA patients. This is the first study to
show that an exercise programme, specifically tailored to meet
individual needs, significantly reduced individual CVD factors.
Individualized exercise seems to be a promising intervention that
may improve the increased prevalence of CVD risk factors and
therefore reduce CVD mortality in RA.
Disclosures: The authors have declared no conflicts of interest.
57. OSTEOPOROTIC FRACTURE IN RHEUMATOID
ARTHRITIS: A STUDY OF INCIDENCE, PREDICTIVE FACTORS
AND ECONOMIC BURDEN FROM TWO UK INCEPTION
COHORTS
Elena Nikiphorou1, Josh Dixey2, Peter Williams3, Patrick Kiely4,
David Walsh5,6, Lewis Carpenter7 and Adam Young1
1ERAS, Department of Rheumatology, St Albans City Hospital,
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3Rheumatology, Medway Maritime Hospital, Gillingham,
4Rheumatology, St George’s Healthcare NHS Trust, London,
5Rheumatology, Sherwood Forest Hospitals NHS Trust,
Sutton-in-Ashfield, 6Academic Rheumatology, University of
Nottingham, Nottingham and 7Centre for Lifespan and Chronic
Illness Research, University of Hertfordshire, Hatfield, UK
Background: There are few data on incidence rates, economic burden
of, and predictive markers for osteoporotic fracture in patients with RA
studied longitudinally.
Methods: The Early RA Study (ERAS) recruited 1465 DMARD naı¨ve
patients from 1986–1998 and the similarly designed early RA Network
(ERAN) 1236 from 2002–2012 in 9 and 23 UK centres respectively.
Standard clinical, radiological and laboratory measures were per-
formed yearly for a maximum 25 and 10years (median 10 and 3years).
Yearly assessments recorded co morbidities and in-patient hospital
episodes, including fracture sites, and orthopaedic interventions
(OPCS codes). Clinical databases were supplemented and validated
with national databases, the National Joint Registry (data available
from 2003–2011), Hospital Episode Statistics (data 1997–2011) and
the National Death Register (data 1986–2011). Only patients who
moved abroad or were not registered with a general practitioner would
be absent from national databases. Treatment regimens followed
guidelines of the era, mainly conventional DMARD therapies,
 steroids, and latterly biologics.
Results: 176 (6.5%) patients suffered 182 fractures: hip (76, 42%),
wrist (32, 17.5%), vertebral (22, 12%), others (52, 28.5%). 13 hip
fractures required hip replacements and 57 dynamic hip screw
surgery. There were no immediate postoperative deaths but hip and
vertebral fractures were recorded as contributory causes of death in
12 and 2 respectively. Fracture incidence rates, types of surgery and
direct costs over time will be displayed graphically. For hip fracture,
median time from baseline was 8years (IQR 5–15) and average length
of stay (LoS, the main driver for indirect costs) was median 15days in
1986–1994, improving to 8 days in 2005–2012, but still considerably
greater than national LoS figures for all hip fractures. Fracture
prediction included traditional risk factors (age, gender) and for hip
fracture, risks also included disease severity measures in 1st year: high
rheumatoid factor (OR 1.7, 95% CI 1.1, 2.9), erosions (OR 2.4, 95% CI
1.4, 4.0), steroid use (OR 2.7, 95% CI 1.1, 6.5), high HAQ (OR 1.7, 95%
CI 1.1, 2.9) and ESR (OR 1.9, 95% CI 1.1, 3.1), low haemoglobin (OR
1.99, 95% CI 1.2, 3.1), the latter an unusual finding.
Conclusions: Osteoporotic fracture complicated RA in 6.5% over
25years, mainly hip fractures, which were a moderately early
complication of RA and most required major orthopaedic interventions
and health costs. Risk factors for hip fracture included disease severity
measures, prompting more active therapies needed for RA and bone
protection.
Disclosures: The authors have declared no conflicts of interest.
58. NATURAL HISTORY, DISEASE CHARACTERISTICS AND
AUTOANTIBODY POSITIVITY IN PATIENTS WITH
BRONCHIECTASIS AND RA: IS THE LUNG AN INITIATING SITE
OF AUTOIMMUNITY IN RHEUMATOID ARTHRITIS?
Elizabeth Perry1,2, Clive Kelly1, Anthony de-Soyza3,
Thomas Moullaali1, Paul Eggleton2 and David Hutchinson4
1Rheumatology Department, Queen Elizabeth Hospital, Gateshead,
2Peninsula Medical School, University of Exeter, Exeter, 3William
Leech Centre, The Freeman Hospital, Newcastle and 4Rheumatology
Department, Royal Cornwall Hospital, Truro, UK
Background: Rheumatoid arthritis (RA) patients have a 10-fold
increased prevalence of symptomatic bronchiectasis (BR) compared
with the general population and HRCT studies report radiological BR in
25–29%. To date the association remains unexplained. Previous
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studies question if BR precedes RA and whether BR has a role in the
pathogenesis of RA. However, many of these studies are small in
numbers (<25 cases), conflicting in results and performed without
HRCT evidence of BR.
Methods: Screening outpatient clinics at 3 NHS Trusts we identified
34 patients with symptomatic BR and RA. All had HRCT proven BR
without other lung disease, a history of 2 respiratory infections/year
and met the 2010 ACR/EULAR RA criteria. We interviewed each
patient detailing disease natural history and characteristics. We
compared these findings between patients whose RA symptoms
preceded BR (RABR) and whose BR symptoms preceded RA (BRRA).
We then compared the autoantibody profile in terms of rheumatoid
factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA, 2nd
generation assay) of all 34 patients with BR and RA to a control group
of 23 patients with RA without lung disease. Mann–Whitney and
Fisher’s Exact test were used for analysis.
Results: In total 23/34 patients (68%) BR preceded RA by a mean
duration of 25years. Disease characteristics were similar between the
BRRA and RABR groups (Table 1). Duration of BR was significantly
shorter in the RABR group averaging 8.1years compared with 41years
in the BRRA group (P<0.0001). Autoantibody positivity in the 34
patients with BR and RA was significantly higher than the control group
of 23 RA patients, 33 (97%) were positive for RF compared with 14
(61%) of controls (P¼0.0007) and 32 (94%) were positive for ACPA
compared with 11 (48%) of controls (P¼0.0001). There was no
significant difference in smoking pack-year history between the
groups.
Conclusions: Our data suggest BR typically precedes RA. Disease
characteristics are similar irrespective of the primary symptom,
although RABR patients have a shorter duration of symptomatic BR.
Exceptionally high RA autoantibody positivity is present in patients
with BR and RA. Further investigation is required, there is increasing
evidence to suggest that BR might initiate RA by the production of
autoantibodies in susceptible individuals.
TABLE 1. Characteristics of patients with BRRA and RABR
BRRA
(n¼ 23)
RABR
(n¼ 11)
P-value
Age, mean (S.D.), years 69.2 (8.2) 68.4 (6.5) N/A
Years with BR, median (IQR) 52 (21) 8 (6) <0.0001
Years with RA, median (IQR) 13 (21) 22 (20) 0.037
DAS28-CRP, median (IQR)a 3.8 (1.0) 4.0 (0.5) 0.31
Erosive disease, n (%)b 10 (71) 4 (67) 0.61
MRC dyspnoea score, median (IQR) 2 (2) 2 (2) 0.95
Chest infections in past 12 months, median (IQR) 3 (3) 3 (4) 0.18
FEV1% predicted, median (IQR)c 65.5 (52.5) 54 (42) 0.34
aBRRA: n¼ 20; RABR: n¼ 10; bBRRA: n¼ 14; RABR: n¼ 6; cBRRA: n¼ 16; RABR:
n¼ 7.
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59. ENDOTHELIAL FUNCTION IN PATIENTS WITH
RHEUMATOID ARTHRITIS: THE EFFECTS OF EXERCISE
AND ANTI-TNF TREATMENT
Jet J. Veldhuijzen van Zanten1,2, George Metsios2,3,
Antonios Stavropoulos-Kalinoglou2,4, Aamer Sandoo2 and
George D. Kitas2
1Sport and Exercise Sciences, University of Birmingham,
Birmingham, 2Rheumatology Department, Dudley Group of Hospitals
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Background: Patients with RA have an increased risk for cardiovas-
cular disease (CVD). The underlying pathways remain to be deter-
mined, but endothelial function has been implicated. Regular physical
activity can reduce the risk for CVD in the general population. In RA
patients, successful treatment with anti-TNF alpha has also been
associated with a reduced risk for CVD. The aim of the current study is
to compare the effects of a 3 month exercise intervention with 3
months of anti-TNF treatment on endothelial function in RA.
Methods: Twenty RA patients (14 female, age 5510 years) under-
went a 3 month individualized aerobic and resistance exercise
intervention. Twenty-three patients (15 female, age 54 15 years)
received anti-TNF treatment for 3 months. Measures of disease activity
(DAS28 and CRP), functional ability (HAQ) and endothelial function
(flow mediated dilatation and GTN-induced dilation) were taken at pre-
intervention baseline and after 3 months.
Results: At baseline, patients in the anti-TNF group had higher DAS28
scores and poorer functional ability compared with the patients in the
exercise group (see Table 1). Other characteristics were not
significantly different between the groups. Group by time ANOVAs
revealed that both exercise and anti-TNF treatment resulted in
improvements in DAS28, functional ability and CRP. A significant
interaction effect indicated a greater improvement in DAS28 and
functional ability in response to anti-TNF treatment compared with
exercise. There was an overall time effect as well as a group by time
interaction effect for macrovascular endothelial function. Post hoc
analyses revealed that endothelial function improved in patients in the
exercise group, whereas no change was found in response to anti-TNF
treatment.
Conclusions: Both exercise and anti-TNF treatment displayed
beneficial effects in patients with RA. Anti-TNF alpha treatment was
more successful in improving disease activity and functional ability,
whereas exercise induced a substantial improvement in endothelial
function, which was not evident in patients receiving anti-TNF
treatment. This suggests that successful anti-TNF treatment improves
cardiovascular risk by reducing disease activity, whereas exercise
improves cardiovascular risk by enhancing the function of the
vasculature. Therefore, once patients have responded successfully
to anti-TNF treatment, increasing levels of physical activity may reduce
the risk for CVD even further.
TABLE 1. Mean (S.D.) measures at baseline and at 3 months
Measures Exercise
intervention
Anti-TNF
intervention
Baseline 3 months Baseline 3 months
DAS28 3.3 (1.2) 2.9 (0.9) 4.2 (0.9) 2.8 (1.3)
HAQ 1.4 (0.8) 1.1 (0.6) 2.3 (0.3) 1.6 (0.7)
CRP, mg/l 7.9 (6.5) 3.7 (1.6) 13.1 (17.4) 7.2 (6.9)
Endothelial-dependent
vascular function (%)
7.4 (5.0) 18.4 (6.9) 9.8 (6.7) 12.3 (8.0)
Endothelial-independent
vascular function (%)
17.9 (6.1) 26.3 (7.2) 22.6 (7.5) 23.8 (7.2)
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60. INCIDENCE OF DIABETES AND EFFECT OF
ETANERCEPT AND ADALIMUMAB ON HBA1C OVER 1 YEAR:
DATA FROM A RANDOMIZED TRIAL IN PATIENTS WITH
RHEUMATOID ARTHRITIS
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Mark Pugh5 and Paresh Jobanputra1,2
1Rheumatology Research Group, University of Birmingham,
Birmingham, 2Department of Rheumatology, Queen Elizabeth
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Rheumatology, City Hospital, Sandwell and West Birmingham
Hospitals NHS Trust, Birmingham, 4Department of Rheumatology,
Solihull Hospital, Heart of England NHS Foundation Trust,
Birmingham and 5Department of Rheumatology, St Mary’s Hospital,
Newport, Isle of Wight, UK
Background: Inflammation such as that which occurs in RA is
associated with insulin resistance and risk of diabetes mellitus (DM).
Some DMARDs including TNF inhibitors (TNFi) may improve insulin
resistance and DM risk. However, it is unknown whether TNFi improve
HbA1c in patients with RA with or without DM. Data on HbA1c were
collected in a randomized trial comparing drug continuation rates for
etanercept and adalimumab [1]. We estimated the incidence of DM
from these data and studied the impact of therapy on HbA1c.
Methods: Participants with active RA, who had previously failed to
respond to 2 non-biologic DMARDs including MTX, were randomized
to etanercept or adalimumab and followed 3-monthly over 1 year. Data
collected included comorbidities, clinical and laboratory parameters,
and medications at each visit. The primary endpoint was newly
recorded diabetes defined as HbA1c >48 mmol/mol at any time point.
Predictors of HbA1c and HbA1c change were determined with
univariate and multivariate analyses.
Results: Of the 125 patients with active RA randomized to etanercept
or adalimumab, 6 (4.8%) were known diabetics and 88% were RF/
ACPA positive. Of the 119 without DM, 7 (5.9%) were diagnosed with
DM (HbA1c >48 mmol/mol) at baseline. 73 participants (73% female)
completed 1 year of TNFi therapy: mean age 54 years (S.D.12), mean
BMI 27.8, mean HbA1c 38 mmol/mol. Of these, 4 (5%) patients had
DM at baseline. A majority of patients were on MTX (67%) and 33% on
prednisolone. Baseline characteristics were similar for patients’
allocated to adalimumab (52%) or etanercept (48%), except more
patients on etanercept were on prednisolone (49% vs 18%; P¼0.006);
and more patients on adalimumab were on hydroxycloroquine (24% vs
3%; P¼ 0.01).
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After excluding those with known DM at baseline, among those
completing 1 year of TNFi (n¼ 69), 3 (4.4%) patients had an HbA1c
>48 mmol/mol at baseline, 1 (1.5%) at 3 months, 1 (1.5%) at 6 months,
and 2 (2.9%) at 12 months of follow-up. 2 (3%) cases had an HbA1c
>48 mmol/mol at 2 follow-up visits. The incidence of DM was 29 new
cases per 1000-person years (95% CI 3.51, 105).
Those on adalimumab tended to have higher levels of HbA1c than
those on etanercept but the differences between groups at each time
point were non-significant. However, there was a significant rise in
HbA1c levels after 1 year of adalimumab therapy (37.27 mmol/mol and
38.80 mmol/mol; P¼ 0.01). Etanercept therapy did not influence
HbA1c levels over time.
Conclusions: Incidence of diabetes in patients entering a randomized
trial of etanercept and adalimumab was considerably higher than other
recent data. Treatment with a TNFi did not improve HbA1c levels with
either agent in diabetics and non-diabetics. After excluding those with
diabetes, those on adalimumab had higher mean HbA1c levels after 1
year of therapy.
Disclosures: The authors have declared no conflicts of interest.
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61. INTRA-ARTICULAR INJECTION OF MESENCHYMAL
STEM CELLS LEADS TO REDUCED INFLAMMATION IN
ANTIGEN-INDUCED ARTHRITIS
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Background: Mesenchymal stem cells (MSCs) are a strong candidate
cell type for tissue engineering and cell therapy to repair damaged
structures in various arthritic conditions. MSCs have been given
intravenously or intraperitonealy in animal models of RA and lead to
different therapeutic effects, varying from significant improvement to
no effect so overall the results remains inconclusive. The reason for
this may be the route of administration. IA administration of MSCs may
be more beneficial than the intravenous/intraperitoneal route, applying
them directly to the affected tissues.
Methods: Murine mesenchymal stem cells (mMSCs) were isolated
from bone marrow of Balb/c mice and expanded in culture. Cells were
tested for their ability to form colonies and to differentiate into
chondrocytes, osteocytes and adipocytes, in addition to the MSCs
immunophenotype. Twenty-one days after the initial immunization
murine antigen-induced arthritis was induced in 7-8-week-old male
C57Bl/6 mice by IA injection of 10 mg/ml mBSA in the right knee joint.
For a control, the same volume of PBS was injected into the left knee
joint. 20 h after arthritis induction, 10 ml of serum free IMDM, containing
500 000 MSCs labelled with red fluorescent cell tracer CM-DiI were
injected intra-articularly into the right knee joint. Control animals were
injected with only serum-free IMDM. Joint diameters were measured at
days 1, 2, 3, 5, 7, 14, 21 and 28. At the end of the experiments, animals
were killed and joints were collected for histology.
Results: Knee joint diameter (swelling) was measured as a clinical
indication of joint inflammation and this parameter, was statistically
significantly less in MSC treated mice compared with control treated
animals 72 h after arthritis induction (P<0.05). This difference
continued for 7 days post IA mBSA administration (P< 0.05). Three
and 7 days after arthritis induction CM-DiI-labelled MSCs were clearly
visualized in the subintimal layer of synovium which was in the region
of the patella and between femoral and tibial surfaces. At 28 days post
induction, no MSCs could be detected in the synovium. Histologically,
the inflammation and cartilage destruction appeared less severe in
MSC treated mice compared with control animals although further
quantification is needed in this regard.
Conclusions: An IA injection of MSCs into the knee joints of mice with
antigen-induced arthritis causes reduced inflammation in terms of joint
swelling which is a clinical measure of disease severity. The injected
MSCs stayed in the knee joint and migrated into the synovium.
Funding: This work was supported by the Engineering and Physical
Sciences Research Council [grant number ECP023/0811] and Institute
of Orthopaedics Ltd, Oswestry.
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62. MACROPHAGES IN HYPOXIC RHEUMATOID JOINTS
PREFERENTIALLY EXPRESS HYPOXIA-INDUCIBLE
TRANSCRIPTION FACTOR-2
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Background: Macrophages accumulate in hypoxic disease sites
including RA joints where they possess broad pro-inflammatory,
destructive and remodeling potential leading to inflammation and joint
destruction. Macrophages respond to hypoxia by up regulating the
hypoxia inducible transcription factors- HIF-1 and -2 normally
degraded in the presence of oxygen. This study will attempt to
understand the relative contribution of HIF-2 expressing macrophages
in RA and the genes/mechanisms involved in its activation.
Methods: We obtained arthroscopy sections from RA patients for
which tissue oxygen levels had been measured. This consisted of a
random sample of mild (40 mmHg), moderate (15 mmHg) and
severe (3 mmHg) joint hypoxia. We also used samples from a second
cohort of patients scored with mild or severe disease (based upon
extent of synovitis and vascularity), a sub group of which were also
receiving anti-TNF therapy. Sections were immunostained with anti-
HIF 1 and 2 and co-localized with the pan-macrophage marker CD68
as well as other macrophage markers (Flt-1, CD147, CD206 and Tie2).
Results: In patients with mildly hypoxic joints, macrophages (CD68þ)
predominately expressed HIF-1 (20%) and CD147 and were found in
small clusters localized to the lining layer, whilst macrophages in
patients with severely hypoxic joints were in greater numbers (73%),
throughout the biopsy. These macrophages predominately expressed
HIF-2þ (>75%), Flt-1, Tie2 and CD206. A similar pattern was observed
in patients with severe disease where sections expressed more HIF-
2þFlt-1þ macrophages compared with those with mild scores (15
cells per field of view compared with 5 for mild P<0.01). There was no
significant difference in HIF-1 expression. Interestingly, this HIF-2þ
macrophage subpopulation was absent in patients who had been
successfully treated with anti-TNF.
Conclusions: In patients with both severely hypoxic joints and severe
RA macrophage numbers were significantly greater than in patients
with mild hypoxia and mild disease. Moreover, macrophages in tissue
from these patients predominantly expressed HIF-2, which activates
genes associated with both inflammation and angiogenesis. These
cells also expressed M2-like macrophage markers including Flt-1, Tie2
and CD206, important in tissue remodeling and angiogenesis. We are
currently investigating the gene expression profile of these subpopula-
tions using laser capture micro-dissection and gene arrays.
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63. THE EFFECTS OF ANTI-TUMOR NECROSIS FACTOR
AGENTS ON THE EXPANSION OF T HELPER-TYPE 17 CELLS
DRIVEN BY LIPOPOLYSACCHARIDE-STIMULATED
MONOCYTES
G. Fossati1, L. Healy1 and A. Nesbitt1
1UCB, Slough, UK
Background: T helper-type 17 (Th17) cells are proinflammatory CD4þ
cells that have been implicated in RA pathogenesis. Lipopolysacchar-
ide (LPS)-stimulated monocytes can promote differentiation of CD4þ
cells into Th17 cells and produce IL-17 in vitro. We study the effect of
4 anti-TNF agents (adalimumab, etanercept, infliximab, and certolizu-
mab pegol) on the expansion of CD4þCD45ROþmemory T cells into
Th17 cells driven by LPS-stimulated monocytes.
Methods: Monocytes and CD4þCD45ROþmemory T cells were
purified from peripheral blood mononuclear cells isolated from healthy
volunteers (positive and negative selection). Co-cultures of purified
monocytes and memory T cells (1:1) were incubated for 7 days with
CD3/CD28 Human T-Activator Dynabeads in the absence or presence
of 1 mg/ml LPS; 4 anti-TNF agents at 10mg/ml. After 7 days the CD4þ
T cells were stained for intracellular Interferon  (IFN) and IL-17A and
analysed by flow cytometry. IL-17A and IL-17F secretion into the
supernatant was determined by ELISA.
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Results: CD4þ T cells positive for IL-17A were increased from 5.7% in
the control co-cultures without LPS to 20.5% with LPS (mean of 2
experiments). The frequency of IFN-positive CD4þ T cells showed a
smaller increase from 4.4% to 10.6% when LPS was added. IL-17A
and IFN- were expressed largely by different cells, suggesting the
expansion of both Th17 and Th1 T-helper subsets. The frequency of
IL-17A-producing CD4þ T cells in co-cultures of monocytes and
memory T cells plus LPS in the presence of the 4 anti-TNF agents were
roughly 2.5 -fold lower than the LPS-positive control cultures without
anti-TNF agents (mean of 4 experiments). Cells exposed to the 4 anti-
TNF agents showed a similar level of CD4þ cells producing IL-17A and
IFN. The level of IL-17A secreted into the supernatant decreased
from 580 pg/ml in the LPS positive control to 180 pg/ml in co-cultures
generated in the presence of the 4 anti-TNF agents. IL-17F decreased
from approximately 8 ng/ml to 2 ng/ml in the LPS control and the anti-
TNF exposed cultures, respectively (mean of 4 experiments). There
were no significant differences in the concentration of IL-17A or IL-17F
from co-cultures exposed to the 4 different anti-TNF agents.
Conclusions: The increased frequency of IL-17þ T cells and secretion
of IL-17A and IL-17F suggest that LPS-activated monocytes support
the expansion of Th17 cells present within the memory pool. Exposure
to anti-TNF agents inhibited Th17 expansion and IL-17A production.
This suggesting a potential mode of action for anti-TNF agents: to
reduce Th17 expansion and, as a consequence, IL-17A and IL-17F
concentration. It is unclear whether soluble TNF or membrane TNF is
responsible for this activity.
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64. RELATIONSHIP OF BAFF-BINDING RECEPTORS WITH
SERUM BAFF LEVELS IN PATIENTS WITH RHEUMATOID
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Background: Removal of circulating B cells to <0.1% CD19þ cells
using B-cell depletion therapy (BCDT) based on rituximab can
significantly reduce symptoms in patients with RA. B-cell return,
usually after 6–10 months, mirrors ontogeny with naı¨ve B cells
regenerating from bone marrow. Clinical relapse can occur either
close to (3 months) B-cell return or in approximately 1/3 of patients,
many months later. The cytokine, B-cell-activating-factor (BAFF)
coordinates survival and differentiation of B cells into immunoglobulin
secreting cells (ISC) by binding to 3 different receptors; BAFFR,
transmembrane activator and calcium signal modulating cyclophilic
ligand interactor (TACI) and B-cell maturation antigen (BCMA). Serum
BAFF levels rise after BCDT but the relationship with BAFF-receptor
expression has not been investigated.
Methods: We included 10 Healthy Controls (HC) and 20 RA patients at
relapse (DAS28>5.1):10 with relapse 3 months after B-cell return
(Concordant Relapse:C-R) and 10 relapsing >3 months. % B cells in
each sub-population expressing BAFFR, TACI and BCMA were
defined using combinations of CD19, CD38 and IgD. Serum BAFF
levels were determined using commercial ELISA. Statistics for non-
parametrically distributed data were applied.
Results: 1) BAFF levels rose post-BCDT. Median levels remained
significantly raised (> 2.4 ng/ml¼upper limit of normal range-ULNR) at
relapse in 1/2 of patients in each group. 2) Comparing B-cell
phenotypes, % post-germinal Centre (GC) B cells and plasmablasts
were significantly higher in patients with C-R compared with patients
with later relapse (P¼0.007 and P¼ 0.02 respectively). 3) At relapse,
significantly lower %BAFFRþ B cells were found in all sub-populations
compared with HC, and negatively associated with BAFF levels above
ULNR (P< 0.01). 4) When BAFF levels were within normal limits,
%BAFF-Rþ B cells were significantly lower in naive and post-GC
populations in patients with C-R compared with later relapse
(P¼0.05). 5) %TACIþB cells were significantly reduced in post-GC
B cells compared with HC irrespective of BAFF levels. %BCMAþB
cells were similar to HC in all sub-populations throughout.
Conclusions: Binding of soluble BAFF to BAFFR delivers a survival
signal to (particularly) naive B cells, but is also thought to give a
negative signal through TACI on post-GC B cells. Loss of BAFFR
expression is also necessary in order for post-GC B cells to
differentiate to ISC. The relatively higher percentage of post-GC cells
and plasmablasts in patients with C-R indicates rapid differentiation
into ISC. Raised BAFF levels at relapse were associated with lower
%BAFFRþ and of %TACIþB cells. Resumption of disease following
BCDT after a period of clinical remission reflects differentiation or
expansion of auto-reactive B-cells. Raised BAFF levels may therefore
be altering BAFF-binding receptor expression with consequences for
survival and selection of autoreactive B cells.
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Background: The human endogenous retrovirus HERV-K10 has been
implicated in the aetiology and pathogenesis of RA. In particular the
Gag region of this retrovirus, crucial to the development of viral
particles, appears to be important with regard to immunological
reactivity. Our aim was to identify a key antigenic region within the Gag
region of HERV-K10 using bioinformatics, to assess IgG serological
reactivity to the immunodominant epitope in RA patients, and to
analyse the potential molecular mimicry with a key autoantigen in RA,
IgG1Fc.
Methods: To develop an ELISA system, we used bioinformatic
algorithms to predict an antigenic peptide segment within the HERV-
K10 Gag matrix. The derived biotinylated peptide (MAG1) was coated
onto ELISA plate. Serums from RA and controls were tested. HRP anti-
human IgG conjugate was employed to detect peptide bound
antibodies. All blood samples were collected with full ethical approval
and patients consent. We also investigated the possibility of molecular
mimicry between HERV-K10 Gag and IgG1Fc. Statistical analysis was
performed on serological data where necessary to provide a normal
distribution for parametric tests including ANOVA and Student’s t-test.
Correlation of patient information was assessed using a two-tailed
Pearson’s test.
Results: We determined a peptide sequence on the matrix segment of
HERV-K10 (MAG1) and optimized an ELISA system. On screening
patients’ serum, we found significant anti-IgG reactivity to MAG1 in RA
patients as compared with patients with IBD, patients with OA and
healthy individuals. Further bioinformatic analysis of HERV-K10 Gag
and the key autoantigen IgG1Fc, highlighted 6 regions with amino acid
sequence homology. Molecular modelling revealed that all peptide
mimics were solvent accessible and readily exposed to the immune
system. Intriguingly, these regions were also identified as key epitopes
of rheumatoid factor antibodies.
Conclusions: On screening patients’ serum, we found significant anti-
IgG reactivity to MAG1 in RA patients as compared with disease
controls and healthy individuals. The serological activity to MAG1 in
disease controls and healthy subjects was perhaps indicative of the
ubiquitous presence of this virus in the general population.
Consequently our data provide a level of base-line activity that may
be useful to future studies. Molecular mimicry between HERVs and
autoantigens has been considered a mechanism in the aetiology and
pathogenesis of RA. In this respect, we assessed potential homology
between HERV-K10 Gag and IgG1Fc proteins using bioinformatic
analysis. The serological investigations of potential cross-reactive
HERV-K10 antibodies against RA potential autoantigens may provide
conclusive evidence of this virus’s role in RA. Further bioinformatic
analysis on other RA autoantigens may also shed light on possible
epitope spreading.
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66. INVESTIGATION OF THE ROLE OF HISTONE
DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL
FIBROBLASTS
Sarah Hawtree1, Munitta Muthana1, Sarah Aynsley1,
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1Infection and Immunity, University of Sheffield, Sheffield and
2Academic Unit of Bone Metabolism, Northern General Hospital,
Sheffield, UK
Background: Rheumatoid arthritis (RA) is a chronic, autoimmune,
inflammatory disease. In RA, fibroblast-like synoviocytes (FLS)
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undergo a transformation leading to an autoaggressive phenotype that
augments tissue destruction in the joint. Currently it is not known how
the phenotype of the FLS is stably maintained, however epigenetic
changes have been implicated. Histone deacetylases (HDACs) are key
enzymes that contribute to the epigenetic signature by affecting the
acetylation of histones. Our aim is to determine the role of HDACs in
regulating the autoaggressive phenotype of RA FLS.
Methods: Real time-qPCR was used to measure HDAC1-11 mRNA
expression in RA and OA FLS. OA FLS were used as a control as
normal FLS were unavailable. HDAC1 mRNA expression was also
investigated in RA FLS incubated with TNF (50 ng/ml), LPS (100 ng/ml),
hypoxia (0.1%) and dexamethasone (1 x 106 M). To determine the
cellular localization of HDACs, joint biopsies from patients (n¼7/
group) treated or untreated with anti-TNF were co-stained with anti-
fibroblast and anti-HDAC1. In addition, HDAC1 was knocked down in
FLS using siRNA transfection and the resulting phenotype investigated
using BrdU-labelling (proliferation), flow cytometry (cell viability) and
matrigel invasion assays.
Results: All 11 HDACs showed higher mRNA expression in RA than
OA. In particular, HDAC1 showed the greatest difference, with mRNA
expression 3.9 fold higher in RA compared with OA FLS. Expression of
HDAC1 was also not altered by incubation with a range of stimuli.
HDAC1 was strongly expressed by FLS in RA but not OA, however the
number of HDAC1þ cells was significantly (P¼0.05) reduced in RA
patients receiving anti-TNF therapy. A 70% knockdown of HDAC1 did
not affect cell viability or proliferation, however this led to a significant
(P¼0.005) reduction in FLS invasion into matrigel compared with FLS
transfected with a non-targeting control siRNA.
Conclusions: HDAC1 is expressed more in RA than OA FLS but is
unaffected by stimulation with pro/anti-inflammatory mediators.
HDAC1 expression significantly increases the invasiveness of FLS
but does not affect their proliferation or viability. RA patients on anti-
TNF therapy show a significant reduction in HDAC1 compared with
untreated patients. Further work will determine the effects of HDAC
knockdown in FLS and how this influences gene expression.
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Background: B-cell activating factors of TNF family (BAFF) is
associated with the survival and maturation of B cells. BAFF is
widely expressed in the RA synovium which is characterized by the
presence of synovial niches of autoreactive B cells and sustain in situ
autoantibody production. Importantly, B-cell niches remain functional
in the RA-SCID model in the absence of recirculating cells, suggesting
that autocrine mechanisms support ongoing B-cell activation in the RA
synovium. BAFF exerts its functional role both as a membrane bound
protein and in soluble form. Here we investigated whether resident
stromal cells in the RA synovium, synovial fibroblasts (RASF), are
capable of producing either forms of BAFF and thus contribute to local
B-cell activation.
Methods: mRNA BAFF in RASF stimulated with TLR2, TLR3 and TLR4
ligands was assessed by quantitative Taqman PCR. RA dermal fibroblasts
(RADF) and OA SF (OASF) were used as controls. The cytoplasmic,
membrane bound and/or soluble forms of BAFF were investigated by
1) Western blot using total and membrane-enriched protein extracts, 2)
flow cytometry, 3) ELISA and 4) immunocy to chemistry.
Results: In vitro stimulation of TLR3, and to a significantly lesser
extent TLR4, but not TLR2 on RASF led to strong induction of BAFF
mRNA. In response to TLR3, soluble BAFF was time-dependently
released in the supernatant of RASF (600 pg/ml) and, to a lesser
extent, OASF and RADF. RASF constitutively expressed both
cytoplasmic and membrane bound BAFF as demonstrated by WB,
FACS and immunocytochemistry which was upregulated upon TLR3
stimulation and was significantly increased as compared with RADF.
Conclusions: Here we provide conclusive evidence that SF in the RA
synovium are a pivotal source of the B-cell survival factor BAFF at both
mRNA and protein level. In addition to their significant constitutive
expression, RASF can further up-regulate cytoplasmic, membrane-
bound and soluble BAFF in response to TLR3 stimulation. Overall, our
data strongly support a fundamental role for RASF in sustaining
functional B-cell activation and antibody production in the inflamed RA
synovium.
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68. SYNOVIAL FIBROBLASTS FROM PATIENTS WITH
RHEUMATOID ARTHRITIS DIFFERENTIATE INTO DISTINCT
FIBROBLAST SUBSETS IN THE PRESENCE OF CARTILAGE
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Andrew Filer1, Elena Neumann2 and Christopher Buckley1
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Germany
Background: Synovial fibroblasts (SF) are key cellular mediators of
joint inflammation and destruction in RA. RASF have the potential to
migrate to distant cartilage sites where they attach, invade and
degrade articular cartilage. Using novel markers of SF subsets to
identify lining and sub-lining layer SF we investigated the ability of
RASF to undergo self-assembly, transmigration and cartilage degra-
dation in vivo.
Methods: Healthy human cartilage was co-implanted subcutaneously
into SCID mice together with RASF. At the contralateral flank, cartilage
was implanted without cells. After 60 days, implants and blood were
removed and analysed. For the detection of human cells, immunohis-
tocytochemistry was performed with species-specific antibodies. For
in vitro studies SF were isolated from patients with established RA and
normal healthy controls under defined culture conditions and the
expression of phenotypic markers analysed.
Results: RASF at the ipsilateral implant differentiated into distinct
fibroblast subsets in the presence of cartilage. Cells proximal to
cartilage expressed markers of a lining layer phenotype (GP38, FAP,
VCAM-1 and Cadherin-11). These cells attached to, invaded and
degraded cartilage. Cells more distal to cartilage expressed sub-lining
layer phenotype markers including CD248. These cells were never
observed in the lining layer and never invaded cartilage. The
development of this stromal architecture was very similar to that
observed in vivo in the inflamed synovial membrane. This stromal
pattern of distinct lining layer and sub-lining layer differentiation was
completely recapitulated in the contralateral implant that contained
only cartilage. In addition, we demonstrate that SF in vitro can be
directed towards either a lining layer (GP38, FAP, VCAM-1 and
Cadherin-11) or sub-lining layer phenotype (CD248 and CD90)
following cytokine treatment. The lining layer, but not sub-lining cell
phenotype is associated with increased cartilage degradation in vitro.
Conclusions: Our observations demonstrate that although RASF have
an activated cell phenotype ex-vivo they also display a degree of
plasticity with the capacity to differentiate into distinct fibroblast
subsets associated with lining and sub-lining layer cell markers both
in vitro and in vivo. Differentiation into distinct subsets of fibroblasts
occurs locally at the site of engraftment following vascular transmigra-
tion and totally recapitulate the lining and sub-lining anatomy observed
at the site of origin. This plastic cell phenotype is dependent on local
factors including proximity to damaged cartilage. The formation of
such a pathogenic stromal architecture is required for cartilage
destruction by RASF. We propose that cellular therapies targeting
RASF specific subsets are a potentially important but unexplored
therapeutic approach to reduce inflammation and joint damage in
patients with RA.
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69. ORAL GLUCOCORTICOIDS AND THE RISK OF INCIDENT
TYPE II DIABETES MELLITUS IN PATIENTS WITH
RHEUMATOID ARTHRITIS
Mohammad Movahedi1, Mark Lunt1, David W. Ray2 and
William G. Dixon1
1Arthritis Research UK Epidemiology Unit, Manchester Academic
Health Science Centre, University of Manchester, Manchester and
2Institute of Human Development, Manchester Academic Health
Science Centre, University of Manchester, Manchester, UK
Background: Glucocorticoid (GC) therapy is used by the majority of
patients with RA. GCs are effective but have side effects including
diabetes mellitus (DM). The aim of this retrospective cohort study was
to quantify the risk of incident type II DM in patients with RA treated
with oral GCs, and its relationship with dose.
Methods: Adult patients with RA were identified from a large UK
primary care research database (CPRD) using a validated algorithm
during the study period 01/92–12/09. Patients with prevalent DM at the
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time of their first code for RA were excluded. Oral GC exposure was
derived from GP prescriptions. GC exposure from first code for RA
was considered using several models including a time-varying binary
indicator of ever or current use, current daily dose, average daily dose
and cumulative dose. Incident DM was defined as a READ code for
DM, at least two anti-diabetic prescriptions or abnormal blood results
(blood sugar, HbA1C or glucose tolerance test). Follow-up was
censored at onset of DM, transfer out of practice, death or study
end date, whichever was soonest. Gender, age, BMI, smoking, family
history of DM, hypertension, prior cumulative dose of oral GC, current
DMARDs and ever NSAID use were potential confounders. Incidence
rates for DM were calculated for different patterns of GC exposure.
Crude and adjusted hazard ratios (HR), compared with non-use, were
estimated using Cox regression.
Results: 23 736 adult RA patients were included. 70% were female
with a median age of 59 (IQR 49–71). Median follow-up time was 74
months (IQR 30–108). 2462 patients were diagnosed with type II DM
during follow-up: incidence 14.0 events/1000 person years (PY) in
unexposed patients and 21.9 events/1000 PY in time following GC
exposure. The crude HR was 1.53 (95% CI 1.41, 1.66) in ever GC users
compared with non-use. After adjusting for all covariates, the HR
reduced to 1.33 (95% CI 1.20, 1.48). This equates to one additional
case of DM per year for every 212 patients currently receiving GCs.
Each 5 mg increase of current oral GC was associated with a 14%
increased risk of DM (HR 1.14, 95% CI 1.11, 1.17). Patients currently
taking between 10 and 30 mg/day had an adjusted HR of 2.03 (95% CI
1.65, 2.50) compared with non-use, equating to one additional case of
DM for every 61 patients treated. A 5 mg increase in average daily
dose was associated with a 36% increased risk (HR 1.36 95% CI 1.26,
1.48), suggesting prolonged exposure increased risk.
Conclusions: Oral GC therapy is a significant and clinically important
risk factor for incident Type II DM in patients with RA, the risk
increasing with dose and duration of treatment. Screening for DM
might be warranted in patients taking oral GC therapy, particularly at
high doses or for prolonged time. Further work is planned to
investigate current practice around screening for DM in patients
receiving GC therapy, and examining the outcomes of DM in patients
taking GC therapy.
Disclosures: The authors have declared no conflicts of interest.
70. LONG-TERM EFFECTIVENESS AND SAFETY OF
ADALIMUMAB IN PATIENTS WITH MODERATE VS SEVERE
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Background: Patients with moderate RA despite DMARDs may gain
benefit from anti-TNF therapy; however, severe disease activity is
often required for reimbursement to initiate anti-TNFs. This analysis
compared treatment responses and adverse events (AEs) between
patients with moderate vs severe RA.
Methods: ReAct enrolled patients with active RA (DAS28[ESR]> 3.2)
despite DMARD treatment for open-label adalimumab (ADA) therapy
for 12 weeks; patients were eligible to enrol in ReAlise within 12
months of completing ReAct. This post hoc analysis stratified patients
by baseline (BL) disease activity, defining moderate activity as DAS28
>3.2 to <5.1, and severe activity as DAS28 5.1. Analyses on
observed data (without imputation) calculated treatment responses
(ACR criteria), the percentage of patients with DAS28 and SDAI low
disease activity (LDA) and remission, and functional ability (Disability
Index of the HAQ, HAQ-DI).
Results: Of 6610 patients enrolled in ReAct, 3435 (52%) elected to
continue in ReAlise; of these, 1805 (53%) completed the study. At BL
of ReAct, 1267 (19%) had moderate and 5343 (81%) had severe
disease activity. Patients with severe activity had slightly increased
mean age and disease duration; as expected, these patients had
higher levels of disease activity (e.g., swollen/tender joint counts, ESR/
CRP levels, and HAQ-DI). In both groups, treatment responses were
maintained through 5 years. After 5 years of ADA, ACR20/50/70
responses were greater among patients with severe disease,
while more moderate disease patients achieved LDA and remission
(Table 1). Correspondingly, absolute values of DAS28 and HAQ-DI
were lower among patients with moderate disease, yet the mean
percent change in DAS28 and HAQ-DI were comparable or greater
among those with severe disease (Table 1). AEs were comparable
between patients with moderate and severe disease: AE leading to
discontinuation (8.2 vs 8.7 E/100PY), serious AEs (13.3 vs 15.3
E/100PY), serious infections (3.2 vs 3.0 E/100PY).
Conclusions: Through 5 years of ADA treatment, more patients with
moderate disease achieved LDA and remission. Patients with severe
disease had greater clinical response rates and a similar degree of
improvement, while fewer achieved treatment targets of LDA and
remission. Given the impact of achieving these targets on preventing
damage and preserving function, these findings support the use of
anti-TNF in patients with moderate RA. There were no noticeable
differences in the safety profile for ADA between patients with
moderate and severe disease activity.
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71. HIGH RETENTION ON METHOTREXATE AT 1 YEAR
FOLLOWING TIGHT CONTROL OF RHEUMATOID ARTHRITIS
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Fouz Rahmeh1, Paul W. Thompson1 and Sarah L. Westlake1
1Rheumatology Department, Poole Hospital NHS Foundation Trust,
Poole, UK
Background: Methotrexate (MTX) is the gold standard DMARD in the
UK for RA and is the cornerstone of most combination therapies. Good
response to MTX and on-going drug retention usually predicts a better
prognosis and lower disease activity. However, side effects and
intolerance, though mostly not serious, frequently prevent full escala-
tion of MTX dose and both of these, along with clinical inefficacy, often
lead to drug withdrawal. Historically retention rates on low dose MTX
(typically <12.5 mg per week) at 1 year are better than with other
DMARDs, but usually no better than 70–75%, with the main reason for
termination being lack of efficacy.
Methods: We wished to assess MTX retention rates in our new Treat-
to-Target monthly review clinic for patients with RA of under 2 years’
duration (started 2010). This was set up at no extra staffing cost as
pre-existing clinic slots were freed up by moving patients with stable
disease to annual review with access to urgent assessment if needed.
Patients were managed to a strict treatment protocol based partly
upon NICE clinical guideline 79 and agreed by all clinicians with MTX
being the principal anchor drug. We have previously reported 56%
remission/ low disease activity at 1 year. In this study we retro-
spectively analysed all data on MTX use, including dose escalation,
management of adverse events and retention rates at 6 months and 1
year.
Results: 108 patients with newly diagnosed RA, based on the
American College of Rheumatology classification criteria 2010, were
included. Mean age 60 years, male: female 1:1.3. 70% of patients were
seropositive for Rheumatoid factor or anti-CCP. At the time of the
study all patients had been on treatment for at least 6 months and
81 patients for more than 1 year. 90% patients were started on MTX at
diagnosis and of these 94% and 92% remained on it at 6 months and
1 year, respectively. Around 80% were started at a dose of 15 mg per
week and the remainder on a lower dose. At 6 months the weekly MTX
dose for 95% of these patients was 15 mg or more with 60% receiving
TABLE 1. Clinical and functional outcomes at 5 years of ADA treatment (observed analyses)
% (n) Mean, % change (n)
ACR20/50/70 DAS28< 3.2 DAS28< 2.6 SDAI 3.3 DAS28 HAQ-DI
Moderate disease activity (DAS28<5.1 at BL) 78/58/42 (306/304/305) 75 (318) 58 (318) 42 (n¼ 315) 2.5, –43 (319) 0.65, –43 (348)
Severe disease activity (DAS28 5.1 at BL) 87/70/47 (1233/1225/1223) 62 (n171) 41 (1171) 34 (1099) 3.0, –53 (1171) 0.83, –49 (1248)
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between 20 and 25 mg. A similar trend was also seen at 1 year.
Four patients had been switched to subcutaneous MTX by 6 months
due to lack of efficacy and another 2 because of intolerance.
Moreover, the Folic acid dose was increased from 5 mg weekly to
5 mg on 6 days a week in 39% cases by 6 months to reduce MTX
related side effects. 23% patients had made at least 1 helpline call
relating to MTX use and 44% patients had 1 or more discussions about
MTX tolerability at their appointments.
Conclusions: Protocol driven tight control of RA at our Rheumatology
department through monthly review, commencing moderate doses of
MTX at baseline, not only allowed rapid escalation of MTX dose aiming
for remission but also led to higher retention rates than historically
seen at 1 year.
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72. LATITUDE BUT NOT SEASON OF INITIATION
PREDICTS CLINICAL RESPONSE TO TNF THERAPY IN
PATIENTS WITH RHEUMATOID ARTHRITIS: THE BSR
BIOLOGICS REGISTER-RA
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Background: While the management of RA has been revolutionized by
the advent of TNF inhibitors, less than a quarter achieve an excellent
response as defined by the ACR 70 in clinical trials. There is a growing
body of evidence that vitamin D deficiency directly influences the
inflammatory responses in addition to deleterious effects on muscle
and bone health in patients with RA. We explored whether vitamin D
status was associated with the clinical response to TNF inhibition
using season of therapy initiation as a surrogate marker of vitamin D
status using the BSR Biologics register.
Methods: We identified patients with a clinical diagnosis of RA starting
infliximab, etanercept or adalimumab for the first time with both
baseline and 6 month DAS. We used>¼ 1.2 improvement in DAS or a
DAS<3.2 at 6 months to define good response. We used season of
initiation as the primary exposure and latitude, derived from the
participant’s postcode, as a secondary exposure. We adjusted for
age, gender, BMI, smoking, reported ethnicity and type of biologic
given.
Results: 11,188 patients with clinical diagnosis of RA starting TNF
inhibitors for first time were studied. Their mean age was 56 years and
76% were female. Season of initiation did not predict DAS, DAS
change, adverse events or discontinuation at 6 months. However,
when we examined the effect of latitude, as a continuous measure
there was a significant linear association between more northern
latitude and poorer DAS response (adjusted OR 0.95; 95% CI 0.91,
0.98; Pl¼0.002). Further, the effect of latitude on DAS response varied
with season (interaction P¼0.072). The difference between living in
the northern quartile (> 53.58) vs other quartiles was most marked in
those initiated in the winter season (71.1% response vs 76.9%
response, P¼ 0.007).
Conclusions: While there was no direct effect of season on TNF
response at 6 months, there was a small but significant poorer
response for those residing in the North especially in winter suggesting
a possible effect of severe vitamin D deficiency. Given the prevalence
of vitamin D deficiency in the UK and the low cost for replacement
compared with the cost of TNF therapy, further clinical studies are
warranted.
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73. IMPACT OF RHEUMATOID ARTHRITIS DISEASE
EDUCATION ON ADHERENCE TO THERAPY AND FOLLOW-
UPS: A PROSPECTIVE CONTROLLED STUDY FROM INDIA
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Background: Some patients with chronic diseases such as RA are
known to lost to follow ups and have poor compliance with their
therapy. A reason could be lack of awareness regarding the disease
and the benefits of compliance. The primary objective of this
prospective 24 weeks controlled study was to assess the impact of
RA disease and management related education on adherence to
recommended follow ups and compliance with medications.
Methods: At two centres 122 consecutive adult patients with RA were
randomized into two groups; group A, n¼ 64 received dedicated
10 min education and counseling using audio-visual aids regarding RA
at the first consultation which was followed by another reinforcement
session at the first follow up visit at 4 weeks, group B, n¼58 was given
only standard information regarding RA during the first consultation.
Both groups received printed articles in Malayalam (local language)
and English regarding autoimmune diseases including RA. Non
compliance to follow ups and drugs were recorded.
Results: There was no significant difference in the age, proportion of
female patients, disease duration, baseline disability and disease
activity between the two groups. Majority of patients in both groups
had secondary education or more. The compliance both with follow
ups (cumulative 88% vs 72%, P¼0.038) and medications (at 12 and
24 weeks 100% vs 90%, P¼0.026 and 98% and 82%, P¼0.011,
respectively) was significantly higher in the group A. Disease activity
was lower in group A.
Conclusions: This study highlights the importance of dedicated
education and counseling on adherence to follow ups and medication.
A larger study may confirm the benefits of such approach on the
clinical outcomes in RA.
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74. PREDICTORS OF SIGNIFICANT DISEASE ACTIVITY
SCORE-28 (USING C-REACTIVE PROTEIN) REMISSION
ACHIEVED WITH INTRAVENOUS GOLIMUMAB IN PATIENTS
WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE
METHOTREXATE THERAPY: RESULTS OF THE PHASE III,
MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED
TRIAL
Clifton O. Bingham1, Michael E. Weinblatt2, Alan Mendelsohn3,
Lilianne Kim4, Michael Mack4, Jiandong Lu4, Daniel Baker3 and
Rene Westhovens5
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Background: Intravenous (i.v.) golimumab (GLM) is efficacious in
treating patients with active RA despite MTX. We evaluated rates of
DAS28-CRP remission and ACR/EULAR remission in these patients.
Methods: 592 patients with active RA (6/66 swollen joints, 6/68
tender joints, CRP1.0 mg/dl, RF and/or anti-CCP antibody-positive)
despite 3months of MTX (15–25 mg/week) participated in this
multicentre, randomized, double-blind, placebo (PBO)-controlled
phase III study. Patients were randomized (2:1) to i.v. GLM 2 mg/kg
or PBO at weeks0,4 and q8w; all patients continued stable MTX doses.
Clinical remission was defined by DAS28-CRP <2.6 and recently
developed ACR/EULAR remission using SDAI3.3. DAS28-CRP
analyses used last-observation-carried-forward.
Results: Statistically significantly higher DAS28-CRP remission rates
were observed with GLMþMTX vs PBOþMTX at week14 (15.4% vs
4.6%, respectively; P<0.001) and week 24 (17.7% vs 5.1%,
respectively; P< 0.001). Similar trends were seen with remission
defined by SDAI score 3.3 (Week14: 4.8% vs1.0%, respectively;
P<0.05 and week 24: 7.3% vs 2.0%, respectively; P<0.01).
Moderate (approx.10%–15%) increases in week 24 DAS28-CRP
remission rates were observed among subgroups of patients defined
by HAQ score <1.625 (24%) vs 1.625 (12%), baseline physical
Functional Class I (27%) vs Class II and III (17% each), swollen joint
count <12 (23%) vs 12 (14%), tender joint count <24 (25%) vs 24
(11%), and CRP <1.5 mg/dl (29%) vs 1.5 mg/dl (15%).
Conclusions: In patients with active RA despite MTX, i.v. GLM 2 mg/
kgþMTX yielded significantly higher DAS28-CRP remission rates and
ACR /EULAR remission rates vs PBO at weeks 14 and 24.
Achievement of DAS28-CRP remission appeared to be enhanced in
patients with lower levels of baseline physical function impairment and
lower joint counts. Confirmation of these hypothesis-generating data is
needed.
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TABLE 1. Number (%) of patients achieving DAS28-CRP <2.6 at week 24 by
baseline characteristicsa
No. randomized GLM patients 495
Age, years: <65/65 61/336 (18) / 9/59 (15)
Sex: female/male 58/326 (18) / 12/69 (17)
Body weight (median: 70 kg): <70 kg/70 kg 34/198 (17) / 36/197 (18)
Disease duration (median: 4.7 years):
<4.7 years/4.7 years
35/196 (18) / 35/199 (18)
Functional class: I/II/III 9/33 (27) / 48/284 (17) / 13/78 (17)
RF: negative/positive 6/30 (20) / 64/365 (18)
Anti-CCP: negative/positive 6/32 (19) / 64/362 (18)
CRP (mg/dl): 1.5/>1.5 20/69 (29) / 50/326 (15)
Swollen joint count (median 12): <12/12 40/174 (23) / 30/221 (14)
Tender joint count (median 24): <24/24 48/195 (25) / 22/200 (11)
HAQ score (median 1.625) <1.625/1.625 46/193 (24) / 24/202 (12)
Oral corticosteroids at baseline: yes/no 38/251 (16) / 32/144 (22)
DMARDs at baseline: yes/no 38/206 (18) / 32/189 (17)
NSAIDs at baseline: yes/no 57/323 (18) / 13/72 (18)
MTX at baseline (mg/week): <15/15 46/268 (17) / 24/127 (19)
aCutpoints for subgroups were determined by median value.
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75. RHEUMATOID ARTHRITIS RESPONSIBILITY DEAL
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Background: Rheumatoid arthritis (RA) is a complex disease to
manage. To improve clinical outcomes, patients and those making
decisions that affect their care and services—healthcare professionals,
healthcare managers and policymakers—need to work together and
take greater personal responsibility in their individual roles. To find out
which responsibilities people believe are important, the National
Rheumatoid Arthritis Society (NRAS) held a consultation and invited
comments from everyone with an interest and connection to the
disease. We then summarized the information into a series of pledges
that people could endorse.
Methods: NRAS drafted a series of open-ended questions asking
consultees which personal responsibilities patients, healthcare profes-
sionals, NHS service managers and policymakers should commit to
taking to improve clinical outcomes for RA. The questions were then
piloted, adjusted and distributed electronically to 4,679 individuals—
including all NRAS members with an email address, other supporters
of the charity, and rheumatology community stakeholders. Responses
were then grouped into thematic headings from which the pledges
were derived. NRAS then conducted a literature review to examine the
medical evidence and public policy frameworks that inform the
treatment of RA across the UK and used this information to provide
background context and accompanying justifications to the pledges.
Results: In total 691 consultation responses were returned. The
largest numbers of responses received were from patients or those
caring for people with RA (97%) with a high level of female
respondents (85%). The largest age categories for consultees were
55–64 (34%) closely followed by 45–54 (27%) and 65 and over (19%).
The majority of respondents were from England (87%), with smaller
numbers from Scotland (8%), Wales (4%) and Northern Ireland (1%).
Themes identified for patients in the consultation are the need to
improve knowledge of their disease, undertake greater self-manage-
ment and work openly with healthcare teams. For healthcare
professionals, consultees want them to continue to improve their
knowledge about RA, optimize the RA patient journey through
healthcare services, and listen more to patients. In respect of NHS
service managers, consultees wish them to focus on improving the
capacity and ability of healthcare professionals to deliver evidence
based, high quality care and look at new ways to meet the needs of
patients. Finally, for policymakers, consultees want them to increase
their understanding of RA, raise the profile of the disease amongst
other policymakers, and develop policies that raise the standards of
care and quality of life.
Conclusions: The consultees identified better communication skills
and education about RA (including self-management and continuing
professional development) as important ways that patients, healthcare
professionals and policymakers can take greater personal responsi-
bility to improve clinical outcomes.
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76. VALIDATION OF REMISSION OF RHEUMATOID
ARTHRITIS BY TRADITIONAL DISEASE ACTIVITY SCORE AND
PROVISIONAL CRITERIA BY AMERICAN COLLEGE OF
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Background: Remission by Boolean-based definition (all scores on
the tender joint and swollen joint count, CRP (mg/dl), and patient
global assessment 1) and by Simplified Disease Activity Index-based
definition (SDAI, <3.3) were proposed by ACR/EULAR. Using patient
reported outcomes as anchors, this analysis validated these remission
criteria against traditional DAS28-CRP remission (<2.6) in 3 RA
populations.
Methods: The efficacy of golimumab (GLM) was assessed in MTX-
naı¨ve RA patients (GO-BEFORE;N¼ 637), RA patients with inadequate
response to MTX (GO-FORWARD;N¼ 444), and RA patients pre-
viously treated with biologic anti-TNFa agent (s) with baseline MTX use
(GO-AFTER;N¼305). Pooled data from patients who received placebo
(PBO) þMTX or GLM (50 or 100 mg) þMTX q4w. Patient reported
outcomes were measured with the following: HAQ, SF36 PCS and
SF36 MCS, Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F), and a Visual Analogue Scale (VAS, 0–10) of impact of RA on
daily productivity. Descriptive statistics were provided for patient
reported outcomes among patients in remission as defined by the 3
remission definitions.
Results: Greater proportions of patients treated with GLMþMTX vs
patients treated with PBOþMTX achieved remission in the 3 studies
by each remission definition. In the pooled analysis, the remission rate
at week 24 was the highest (20.2%) by DAS28, compared with
remission by SDAI (10.6%, p<0.001) and remission by Boolean-
based definition (8.6%. P<0.001). Of patients with remission by
DAS28-CRP, 67.8%, 38.4%, and 62.2% achieved normal physical
function (HAQ 0.5) and normal SF-36 PCS and MCS (50),
respectively; these parameters were numerically lower than for
patients with remission by SDAI (81.3%, 62.8%, 72.1%, respectively)
or by Boolean-based definition (82.0%, 63.5%, 74.3%, respectively).
Patients in remission by DAS28-CRP had higher HAQ scores
(0.430.49) compared with patients in remission by SDAI
(0.260.41) or Boolean-based criteria (0.28 0.44). Similar results
were observed in measures of FACIT-F and productivity VAS scores.
Among MTX-naive patients in GO-BEFORE who achieved remission
by DAS28, 71.3% achieved normal physical function compared with
86.9% of those in remission by SDAI and 86.5% of patients in
remission by Boolean-based definition. Among anti-TNFa-experienced
patients in GO-AFTER, 62.1% of those in remission by DAS28-CRP
achieved normal physical function compared with 65.0% of those in
remission by SDAI and 66.7% of patients in remission by Boolean-
based definition.
Conclusions: While disease remission has been adapted as a target in
the management of RA, more stringent remission criteria proposed by
ACR/EULAR can provide optimal patient-reported outcomes.
Disclosures: M.D., Janssen Research and Development, LLC.—
Employment/Stocks. P.E., Janssen Research and Development,
LLC.—Investigator for Janssen Trials. R.F., Janssen Research and
Development, LLC—Investigator for Janssen Trials. M.G., Janssen
Research and Development, LLC.—Investigator for Janssen Trials.
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77. INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS
TREATED WITH RITUXIMAB ARE ASSOCIATED WITH
MULTIPLE RISK FACTORS INCLUDING LOW IGM LEVELS
Jennifer C. Hart1, Mark N. Lazarus1 and Anne R. Kinderlerer1
1Department of Rheumatology, St Mary’s Hospital, London, UK
Background: Studies show that the infection rate following rituximab
therapy (RTX) in patients with RA is similar to other drugs. However,
repeated cycles of RTX can lead to low immunoglobulin G (IgG) levels,
which is a known risk factor for infection. Age and cardiorespiratory
disease are also risk factors for infection following RTX in RA. The BSR
guidelines advise monitoring Ig levels and withholding RTX if there is
an underlying condition that might predispose to serious infection,
although only specifically refer to IgG levels below 6 g/l. We audited the
infection rate in our cohort of patients treated with RTX, the frequency
of Ig monitoring and examined whether any of the observed infections
could have been prevented.
Methods: Data from 23 patients with RA who had received RTX
between January 2010 and June 2012 were obtained from the hospital
records. The age, date of RTX infusions, Ig levels pre and post-RTX,
comorbidities and development of infection requiring admission were
recorded for each patient.
Results: All patients were female, with a mean age of 55.9 years
(range 20 to 84). Ig levels were tested in 11/23 patients (47.8%) pre-
RTX and in 20/23 (87.0%) post-RTX.
Six severe infections were observed in 5 patients, with a rate of
17.5 infections per 100 patient years. The infections were pneumonia
(3), cellulitis and infected skin ulcer (1), septic arthritis (1) and
candidaemia (1). The mean time to first infections after RTX was 6.2
months. The mean age was higher in the patients with infections
(P<0.01). Chronic heart and/or lung disease was present in 4/5
patients that got infections.
The mean IgG and IgM levels were lower in the patients with
infections (both P<0.01) but only 1/5 patients with infections had an
IgG level below 6 g/l at the time of infection. IgM levels were below
0.5 g/l in 4/5 patients at the time of infection. Pre-RTX IgG levels were
only available for 2/5 patients with infections, both of whom had levels
above 11 g/l. IgA levels were normal for all patients with infections and
the mean levels did not differ from the patients that did not get
infections.
Conclusions: The infection rate in our cohort of patients was much
higher than has been reported in other studies. The mean IgG level
was lower in the group that got infections, confirming that they are
important in protecting against infection but it was below 6 g/l in only
one of the patients, suggesting that better monitoring of IgG pre-RTX
would have resulted in only a small improvement in the infection rate.
Our data support studies that have shown that infections are
increased in older patients, when there is heart or lung disease and low
IgG levels, but we also found that infections were associated with low
IgM levels.
We believe that the BSR guidelines should advise caution with
using RTX in elderly patients, when there is known heart or lung
disease or when IgG or IgM levels are low.
Disclosures: M.L., Abbott—Honoraria. All other authors have
declared no conflicts of interest.
78. TOCILIZUMAB IN METHOTREXATE-INTOLERANT OR
CONTRAINDICATED PATIENTS—A COST-UTILITY MODEL
FOR THE UNITED KINGDOM
Dave Harland1, Carl Gibbons1, Hok Pang2, Catherine Huertas2,
Alex Diamantopoulos3 and Fred Dejonckheere4
1Health Economics and Strategic Pricing, Roche Products Limited,
Welwyn Garden City, 2Medical Affairs, Roche Products Limited,
Welwyn Garden City, 3Health Economics, Symmetron Limited,
London, UK and 4Global Pricing and Market Access, F. Hoffmann-La
Roche, Basel, Switzerland
Background: Tocilizumab (TCZ) is licensed for the treatment of adult
RA that has responded inadequately to one or more DMARDs
(DMARD-IR patients). Whilst typically given with MTX, TCZ is also
licensed for monotherapy treatment in patients who are intolerant of or
contraindicated to MTX. The objective was to evaluate the cost-
effectiveness of monotherapy TCZ in DMARD-IR patients intolerant of
or contraindicated to MTX in the UK (UK).
Methods: An economic model was developed to reflect the healthcare
system and treatment pathway in the UK. In the model, disease
severity is represented by the health assessment questionnaire (HAQ)
score; a surrogate health outcome which can be translated to utility
scores and ultimately quality adjusted life years (QALYs). The model
captures the progression of the HAQ score for each individual patient
in an individual simulation process. ACR response rates are used as a
measurement of response to treatment as these are readily available
from TCZ trials as well as from RCTs of the other therapies included in
this model.
Benefits were expressed as QALYs. Costs were calculated from a
National Health Service and Personal Social Services perspective and
included treatment costs as well as patient-condition-related costs.
The analysis calculated incremental costs and benefits associated with
the addition of TCZ in first line to the standard care pathway involving
certolizumab pegol, etanercept and adalimumab. Efficacy data for
comparator biologic monotherapies were available from monotherapy
trials of adalimumab (van de Putte et al 2004), certolizumab pegol
(Fleischmann et al 2009), and etanercept (Moreland et al 1999). TCZ
efficacy was informed by results from the ADACTA study (Gabay et al
2012), a new head-to-head superiority trial of TCZ and adalimumab
monotherapy in RA. The economic model used inputs derived through
a mixed treatment comparison that indirectly compared TCZ mono-
therapy with the standard of care biologic monotherapy treatments
used in the UK (Roche data on file).
Results: Base case results estimated incremental costs of approxi-
mately £20,230 and incremental QALYs of 0.88. The incremental cost-
effectiveness ratio (ICER) was £22,950 per QALY gained. The model
was most sensitive to patient weight (which drives drug cost) and the
parameters used in the HAQ-to-utility estimation equation. A prob-
abilistic sensitivity analysis produced a very similar ICER of £23,200
per QALY gained.
Conclusions: The results of this analysis suggest that TCZ mono-
therapy represents an efficacious and cost-effective addition to the
current standard of care in the UK, for treating RA patients who are
intolerant of or contraindicated to MTX.
Disclosures: F.D., F. Hoffmann La Roche—Employee. A.D., Roche
Products Limited—Consultancy Fees. C.G., Roche Products
Limited—Employee. D.H., Roche Products Limited—Employee. C.H.,
Roche Products Limited—Employee. H.P., Roche Products Limited—
Employee.
79. OUTCOMES OF PREGNANCY IN SUBJECTS EXPOSED
TO CERTOLIZUMAB PEGOL
M. Clowse1, D. Wolf2, C. Stach3, G. Kosutic4, S. Williams4,
I. Terpstra5 and U. Mahadevan6
1Medicine, Duke University Medical Centre, Durham, NC,
2Atlanta Gastroenterology Association, Atlanta, GA, USA,
3UCB Pharma, Monheim, Germany, 4UCB Pharma, Raleigh, NC,
USA, 5UCB Pharma, Brussels, Belgium and 6UCSF Medical Centre,
San Francisco, CA, USA
Background: Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-
TNF approved in the EU for the treatment of RA, and in the US RA and
Crohn’s disease. Pre-clinical and clinical data suggest a lack of active
neonatal Fc receptor-dependent placental transfer of CZP. There are
few reports of pregnancy outcomes following exposure to CZP to
date. This work provides additional information regarding the primary
pregnancy outcomes in women exposed to CZP.
Methods: The global CZP safety database was searched for all
medically confirmed cases of pregnancy through March 6, 2012. The
proportion of live births, spontaneous miscarriages, and elective
terminations for women directly exposed to CZP before or during
confirmed pregnancy were compared with those expected for the
general US population of pregnant women.
Results: Of 294 reported pregnancy events, 152 had known out-
comes, 89 had unknown outcomes and 53 were ongoing. Of the 152
events with known outcomes, 139 were cases in which the mother had
direct exposure to CZP, with 57 from the clinical trial programme and
82 from post-marketing reports. The remaining 13 were cases with the
father exposed to CZP resulting in 10 live births, 2 miscarriages and 1
elective termination. Of the 139 direct exposure cases with known
outcomes, the underlying conditions were CD (N¼107), RA (N¼17)
and healthy subjects (N¼2) with 13 cases classified as other or having
missing data. 91 of 139 cases were from the US. 103 of 139
pregnancies resulted in live births (see Table 1) and the median
gestational age was 38.3 weeks (data available for 40 births). 21
pregnancies ended in spontaneous miscarriage. 15 pregnancies
resulted in elective termination. These results are similar to those
reported in the general population in the US (see Table 1). In 103 live
births there were 2 reported cases of congenital disorder (Rate in the
US general population is 3%); 1 baby had mild, unilateral hydrone-
phrosis on antenatal ultrasound and was described as healthy upon
birth. The other baby had vesicoureteric reflux.
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Conclusions: Currently available data from 139 pregnant women
exposed to CZP report outcomes consistent with the US National Vital
Statistics data. Additional data are required to validate acceptable
safety and tolerability of CZP in pregnancy.
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80. MAINTENANCE OF REMISSION IN RA PATIENTS WITH
LOW TO MODERATE DISEASE ACTIVITY FOLLOWING
WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT:
WEEK 52 RESULTS FROM THE CERTAIN STUDY
Josef Smolen1, Paul Emery2, G. Ferraccioli3, W. Samborski4,
F. Berenbaum5, O. Davies6, W. Koetse6, B. Bennett7 and
H. Burkhardt8
1Medicine, Medical University of Vienna and Hietzing Hospital,
Vienna, Austria, 2Division of Rheumatic and Musculoskeletal Disease,
University of Leeds, Leeds, UK, 3Institute of Rheumatology, School
of Medicine, Catholic University of the Sacred Heart, Rome, Italy,
4University of Medical Sciences, Poznan, Poland, 5Pierre and Marie
Curie University, AP-HP St-Antoine Hospital, Paris, France, 6UCB
Pharma, Raleigh, NC, 7BABennett Consulting, Marietta, GA, USA
and 8Johan Wolfgang Goethe University, Frankfurt am Main,
Frankfurt, Germany
Background: Certolizumab pegol (CZP) increased rates of remission
and low disease activity (LDA) as an addition to non-biologic DMARDS
in RA patients with long-standing, low/moderate disease activity (DA).
Objective: Evaluate maintenance of remission to week 52 in
patients with low/moderate DA following treatment (tx) withdrawal
after 24 weeks of CZP or placebo (PBO).
Methods: CERTAIN, a double-blind (DB), randomized, Phase IIIb
study, enrolled patients with low to moderate DA (CDAI >6 and 16)
(NCT00674362). Following 24 week DB phase (CZP 400 mg/PBO at
Weeks 0, 2, 4, then CZP 200 mg/PBO Q2W) patients in CDAI remission
(2.8) at both week 20þ24 stopped randomized tx but remained on
conventional DMARDs; remitters who flared between week 24 and
week 52 were retreated with CZP. Patients not in remission who
withdrew at week 24 entered an OLE. Primary endpoint was CDAI
remission at both week 20þ24. Secondary endpoints included
maintenance of CDAI remission when randomized tx was stopped.
Results: Baseline (BL) characteristics (means) were similar for CZP
(n¼ 96) vs PBO (n¼98) patients. A greater proportion of CZP patients
than PBO were in LDA or remission at week 12 and week 24. Over
three times as many CZP patients had CDAI remission at both Weeks
20 and 24 vs PBO (18.8% vs 6.1%, P<0.05). Lower HAQ and pain
scores at BL were associated with improved CDAI DA status at week
24 for CZP and PBO. At week 24 18 prior CZP [1 pt withdrew before
the first efficacy measurement] and 6 prior PBO stopped therapy.
CDAI remission was retained up to week 52 in 3/17 prior CZP vs 2/6
prior PBO with 7/17 vs 2/6 in CDAI remission/LDA at week 52. SDAI
remission was observed in 4/17 prior CZP vs 2/6 prior PBO and DAS28
(ESR) remission in 4/17 vs 1/6. Median time to loss of CDAI remission
(all patients) was 42.5 days.
Conclusions: In RA patients with long-standing low/moderate DA,
addition of CZP to non-biologic DMARDs increased rates of remission
and LDA and inhibited progression to high DA. On stopping CZP
therapy most patients were unable to maintain remission, which may
have implications for stopping TNF inhibitor therapy in this pt
population.
Disclosures: B.B., UCB Pharma—Former Employee. F.B., UCB
Pharma—Consultancy Fees. H.B., UCB Pharma—Consultancy Fees.
O.D., UCB Pharma—Employee. P.E., UCB Pharma—Consultancy
Fees, Research/Grant Support. W.K., UCB Pharma—Employee,
Shareholder. W.S., UCB Pharma—Consultancy Fees. J.S., UCB
Pharma—Consultancy Fees, Research/Grant Support. All other
authors have declared no conflicts of interest.
81. TIMING AND MAGNITUDE OF INITIAL RESPONSE TO
CERTOLIZUMAB PEGOL IN A BROAD POPULATION OF
PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS PREDICTS
LIKELIHOOD OF LDA AT WEEK 28
Michael E. Weinblatt1, Roy Fleischmann2, O. Davies3, K. Luijtens3
and Desiree van der Heijde4
1Brigham and Women’s Hospital, Boston, MA, 2University of Texas
SW Medical Centre, Dallas, TX, USA, 3UCB Pharma, Brussels,
Belgium and 4Department of Rheumatology, Leiden University
Medical Centre, Leiden, Netherlands
Background: Most patients with active RA have a rapid response to
certolizumab pegol (CZP), and lack of improvement in DAS28 by week
12 predicts future failure to achieve low disease activity (LDA). We
investigated whether the timing/magnitude of week 12 DAS28 (ESR)
nonresponse (NR) and swollen joint count (SJC) NR to CZP can predict
the likelihood of achieving LDA at week 28 in a broad RA population,
including patients with prior anti-TNF, from the REALISTIC study.
Methods: Following the 12week double blind phase (CZP 400 mg/
PBO at weeks 0,2,4, then CZP 200 mg/PBO at weeks 6,8,10 plus
current treatment), patients received open-label CZP 200 mg Q2W for
16 weeks. The proportion of patients who achieved LDA
(DAS28 3.2) at week 28 was assessed according to the level of
DAS28 NR (i.e. DAS28 change from baseline [CFB] <0.3, 0.6, 0.9, 1.2,
1.5 and 1.8 units) and SJC NR (quartiles for %CFB at week 12: <29%,
<60%, <85%). Missing data were imputed using last observation
carried forward.
Results: CZP-treated patients (N¼851) had a mean baseline DAS28
of 6.4 and SJC of 11.8. Overall, 81.1% of patients had 1.2 CFB
DAS28 response and 89.3% had 29% CFB in SJC by week 12. LDA
was achieved by 27.4% of the original CZP ITT population at week 28.
Failure to achieve LDA at week 28 was dependent on the magnitude
and timing of DAS28 and SJC change up to week 12. Patients with
DAS28 changes <0.3 up to week 6 and <1.5 up to week 12, had
<10% chance of having LDA at week 28 (Table 1). Patients without a
DAS change of 1.2 by week 12 had <4% chance of achieving LDA at
week 28. Patients without a SJC change of 29% by week 12 had a 5%
chance of achieving LDA at week 28. For any given threshold in DAS/
SJC, the failure to respond up to a later timepoint was associated with
a lower chance of LDA at week 28. At BL 37.6% of CZP patients had
received prior anti-TNF therapy; 79.6% of these patients had 1.2
CFB DAS28 response at week 12, similar to the proportion of naive
patients (82.1%). Failure to achieve a DAS28 change of 1.2 by week
12 was associated with <5% chance of achieving LDA at week 28 for
both groups.
Conclusions: The majority of patients responded to CZP treatment by
week 12 in this broad pt population. Likelihood of LDA at 28 weeks
could be predicted early in the course of treatment with CZP based on
the timing and magnitude of initial DAS28/SJC change in patients both
naive and exposed to prior anti-TNF.
TABLE 1. Proportion of CZP patients achieving LDA at week 28 by DAS28 and SJC
change up to week 12
Week 2,
% (n/N)
Week 6,
% (n/N)
Week 12,
% (n/N)
DAS28 (ESR) change from BL <0.3 16.6 (27/136) 9.2 (6/65) 0a (0/42)
<0.6 17.9 (48/268) 12.2 (14/115) 1.4a (1/70)
<0.9 18.9 (66/349) 10.9 (19/174) 1.9a (2/103)
<1.2 20.9 (92/440) 13.8 (35/254) 3.9a (6/154)
<1.5 21.5 (113/526) 14.8 (51/344) 6.3 (14/224)
<1.8 22.4 (132/588) 17.1 (75/439) 10.5 (34/323)
SJC % change from
BL (week 12 quartiles)
<29 20.6 (68/330) 13.8 (19/138) 5.0a (4/80)
<60 23.7 (130/548) 17.7 (62/351) 11.9 (29/244)
<85 27.1 (184/680) 23.0 (130/564) 18.9 (89/471)
a5% probability of LDA at week 28.
TABLE 1. Results
Population Number of
pregnancy events (n)
Live births Miscarriages Elective
termination
Direct exposure to CZP from global safety database 139 103/139 (74.1%) 21/139 (15.1%) 15/139 (10.8%)
US General Population (National Vital Statistics Data—1900–2004)a 6 390 000 64.3% 16.6% 19.1%
aData taken from Ventura S.J. et al. Natl Vital Stat Rep 2008;56:1–25, 28.
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82. SAFETY UPDATE ON CERTOLIZUMAB PEGOL IN
PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH
LONG-TERM EXPOSURE
X. Mariette1, Ronald F. van Vollenhoven2, V. Bykerk3,
M. de Longueville4, C. Arendt4, K. Luijtens4 and J. Cush5
1Paris-Sud University, Paris, France, 2Karolinska Institute,
Stockholm, Sweden, 3Hospital for Special Surgery, New York, NY,
USA, 4UCB Pharma, Brussels, Belgium and 5Baylor Research
Institute, Dallas, TX, USA
Background: The safety of certolizumab pegol (CZP) in RA has been
evaluated in 10 randomized controlled trials (RCTs) and 7 open-label
extensions (OLEs). An update of long-term safety data of CZP in RA
(cut-off date of 30 Nov 2011) is provided.
Methods: Pooled data from CZP RA clinical trials were analysed.
Pooling was done across all doses (400 mg not currently licensed in
Europe). Adverse events (AEs) were defined as occurring after the first
dose and within 84 days of last dose. Serious adverse events (SAEs)
were defined conservatively by the regulatory definition with the
addition of opportunistic infections (OIs), malignancies and medical
events important to the investigator. Serious infectious events (SIEs)
were defined according to the regulatory definition with addition of the
need for i.v. antibiotics. Search terms for OIs were defined by 6
external experts and validated by the steering committee (JC/VB/RVV/
XM). External experts manually reviewed all cases of death, SIEs
(including OIs) and malignancies. Deaths were categorized as primarily
associated with cardiovascular (CV), infectious, malignant or other
causes; malignancies were classified as non-melanoma skin cancer
(NMSC), solid tumours or lymphoma. Incidence rates (IR) and event
rates (ER) per 100 pt-years (PY) are reported.
Results: 4049 RA patients had received CZP in all studies, totaling
9277PY. Mean exposure to CZP was 2.1 years (min 0.04, max 7.6);
median exposure was 0.7Y. SIEs were the most common SAEs. In
total, 43 tuberculosis (TB) infections occurred in 43 patients, of which
39 occurred in Central/Eastern Europe (CEE). 58 deaths occurred in
CZP patients (IR 0.63) as a result of 19 CV events, 13 infections,
13 malignancies and 18 other causes. 65 CZP patients in all studies
developed malignancies (ER 0.78), with 60 patients developing solid
tumours (IR 0.70) and 5 developing lymphoma (IR 0.05).
Conclusions: No new safety signals associated with CZP have
emerged in this updated long-term safety analysis. Due to the shorter
duration of PBO treatment compared with CZP, comparisons between
the CZP and PBO groups should be interpreted cautiously. TB
incidence may be explained by high recruitment in CEE prior to 2007.
The rates of malignancies and SIEs are in line with CZP data reported
in the product label and anti-TNF registry data.
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83. MANAGEMENT OF RHEUMATOID ARTHRITIS IN WALES:
AN ALL-WALES AUDIT
Afsha Khan1, Zoe Maclaren2 and Sayam Dubash3
1Rheumatology, Princess of Wales Hospital, Bridgend,
2Rheumatology Department, Wrexham Maelor Hospital, Wrexham
and 3Rheumatology Department, Hinchingbrooke Hospital,
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Background: We undertook an All Wales audit in 2012 to assess
whether we were following NICE guidelines (CG79) especially in
prescription of DMARDS and monitoring of disease. We also
compared the audit with a previous audit done in 2009 to assess
improvement in service provided in Wales and to identify our
shortcomings.
Methods: Data were collected from each rheumatology centre in
Wales. The NICE criteria assessed in our audit included (i) percentage
of people with newly diagnosed active RA who were offered
combination DMARDs therapy as first line treatment; (ii) percentage
of people with recent-onset active RA who have had their CRP
measured monthly until treatment has controlled the disease to a level
agreed with the person; (iii) percentage of people with recent-onset
active RA who have had key components of disease activity measured
monthly until treatment has controlled the disease to a level agreed
with the person.
Results: Data were collected for 169 patients retrospectively.
(i) 44% were prescribed combination DMARD therapy on diagnosis.
(ii) 41% initiated therapy within 3 months of diagnosis.
(iii) 54% had CRP done monthly, 6% didn’t have CRP checked despite
being reviewed monthly, 25% had CRP checked on each clinic visit
(visits weren’t monthly), 15% had them checked infrequently or not
at all.
(iv) 27% had DAS assessments done monthly, 14% didn’t have DAS28
calculated despite, 31% had DAS checked each visit (visits weren’t
monthly), 28% had DAS28 checked infrequently or not at all.
(v) 43% were reviewed monthly.
Conclusions: Centres in Wales with established RA clinics seemed to
adhere to NICE guidelines. In this national audit we identified
shortcomings in some centres across Wales. The reasons for not
prescribing DMARDS within 3 months mainly included delay in patient
attendance to GP, delay in referral to Rheumatology department and
delay in diagnosis. In terms of monitoring the disease it was noted that
clinic slots and resources (lack of staff, extra clinics) were the main
concern, however clinicians attitude towards DAS28 was also evident
from the audit. Documentation and recording of DAS28 was identified
as a weakness even though remarks on improvement in symptoms
were documented.
In comparison with the audit done in 2009 there seemed to be
marked improvement in DMARD initiation within 3 months 19% vs
44% respectively. In both audits difficulties were noticed in monitoring
disease activity due to reasons mentioned above. Establishment of
early RA clinics may help achieve these targets and many units are in
the process of establishing them.
Disclosures: The authors have declared no conflicts of interest.
TABLE 1. Results
RCTs All studies (RCTs and OLEs)
PBO, n¼ 1137 All CZP doses, n¼ 2965 All CZP doses, n¼ 4049
Total exposure (PY) 373 1302 9277
Mean exposure, days 110 152 782
Median exposure, days 111 112 267
IRb ERb n pts % pts IRb ERb n pts % pts IRb ERb n pts % pts
AEs 362.3 589.1 713 62.7 335.9 568.3 2048 69.1 188.8 328.9 3561 87.9
Leading to death 0.3 – 1 0.1 0.8 – 11 0.4 0.6 – 58 1.4
SAEs 17.0 21.7 61 5.4 21.0 29.5 260 8.8 14.0 21.3 1063 26.3
SIEs 1.4 1.3 5 0.4 5.6 6.1 72 2.4 3.6 4.3 323 8.0
All malignancies excluding NMSC 0.8 1.3 3 0.3 0.7 0.8 9 0.3 0.7 0.7 65 1.5
OIsa 0 0 0 0 1.0 1.1 13 0.4 0.7 0.7 62 1.5
aTreatment-emergent AEs of oesophageal candidiasis were included as OIs. bPer 100 PY.
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84. A RETROSPECTIVE STUDY OF THE EFFECTS OF
SWITCHING FROM ORAL TO SUBCUTANEOUS
METHOTREXATE ON DISEASE ACTIVITY IN PATIENTS WITH
RHEUMATOID ARTHRITIS
Venkat C. Chalam1, Tom Sheeran1, Tom Price1, Sangeetha Baskar1,
Diarmuid Mulherin1, Cauline Molloy1, Fiona Keay1,
Caroline Heritage1 and Barbara Douglas1
1Cannock Rheumatology Centre, Cannock, UK
Background: Oral MTX is the gold standard first-line therapy for RA
patients. The place in therapy for subcutaneous (SC) MTX is less clear,
even though it has proven to be effective in patients who fail to
respond to or tolerate oral MTX and allows them to continue on MTX
for longer, thus delaying the need for biologic therapy [1]. Perhaps one
reason for this is the lack of outcome data using DAS28, which is
widely used in clinical practice and in NICE [2] and BSR [3] guidelines
to determine eligibility for biologic therapy (5.1 and >3.2, respec-
tively). The aim of this audit was to evaluate the response to treatment,
as measured by DAS28, in RA patients following a switch from oral to
SC MTX and to assess the impact on clinical management.
Methods: A retrospective medical record review of all RA patients who
had switched from oral to SC MTX and had DAS28 at baseline and at 3
and/or 6 months was undertaken.
Results: 27 patients (63% female; average age 61.6 years; average
dose SC MTX 15.6 mg/week; 78% on other DMARDS) had DAS28
values at 3 months (n¼ 22) and/or 6 months (n¼18). For those with 3
month data, DAS28 fell 0.8 points, from 5.06 at baseline to 4.2, with
36% having DAS28 improvement of 1.2. After 3 months, the
proportion of patients with DAS28 5.1 and >3.2 fell from 55% at
baseline to 50% and from 95% at baseline to 73%, respectively. For
those with 6 month data, DAS28 fell 1.9 points, from 5.5 at baseline to
3.6, with over 60% having DAS28 improvement of 1.2. After 6
months, the proportion of patients with DAS28 5.1 and >3.2 fell from
67% at baseline to 11% and from 100% at baseline to 44%,
respectively.
Conclusions: This study shows that SC MTX was effective in lowering
DAS28. After 6 months’ SC MTX, 89% and 56% of patients were
below the NICE and BSR threshold for biologic therapy, respectively.
Since SC MTX can improve clinical outcomes, this treatment strategy
should be a considered before use of biologic therapy in RA patients
who do not respond to or tolerate oral MTX.
Disclosures: The authors have declared no conflicts of interest.
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85. CHANGES IN PATIENT-REPORTED OUTCOMES IN
RESPONSE TO SUBCUTANEOUS ABATACEPT OR
ADALIMUMAB IN RHEUMATOID ARTHRITIS: RESULTS FROM
THE AMPLE (ABATACEPT VS ADALIMUMAB COMPARISON IN
BIOLOGIC-NAIVE RA SUBJECTS WITH BACKGROUND
METHOTREXATE) TRIAL
Roy Fleischmann1, Michael E. Weinblatt2, Michael H. Schiff3,
Dinesh Khanna4, Daniel E. Furst5 and Michael A. Maldonado6
1Department of Internal Medicine, University of Texas Southwestern
Medical Centre, Dallas, TX, 2Rheumatology and Immunology,
Brigham and Women’s Hospital, Boston, MA, 3Rheumatology
Division, University of Colorado, Denver, CO, 4Department of Internal
Medicine, University of Michigan, Ann Arbor, MI, 5Division of
Rheumatology, University of California at Los Angeles, Los Angeles,
CA and 6Medical Affairs, Bristol-Myers Squibb, Princeton, NJ, USA
Background: Rheumatoid arthritis (RA) is associated with pain,
fatigue, disability and functional loss, which can significantly impact
a patient’s (pt’s) health-related quality of life (HRQoL). Pt-reported
outcomes (PROs) are critical since patients and caregivers do not
always perceive treatment effects equally. To highlight the pt’s
perspective, we report multiple PROs from the first head-to-head
study, AMPLE (Abatacept Vs Adalimumab Comparison in Biologic-
Naı¨ve RA Subjects with Background Methotrexate) comparing sub-
cutaneous abatacept (ABA) and adalimumab (ADA) on background
MTX.
Methods: AMPLE is an ongoing, Phase IIIb, randomized, investigator-
blinded study of 24 months’ duration with a 12-month efficacy primary
endpoint. Biologic-naı¨ve patients with active RA and inadequate
response to MTX were randomized to either 125 mg ABA weekly or
40 mg ADA bi-weekly in combination with MTX. PROs assessed were
pt pain, pt global assessment (PtGA) and fatigue, all assessed by
100 mm visual analogue scale, with a higher score indicating worse
outcome (minimal clinically important difference [MCID] reduc-
tion¼ 10 mm). Physical function was evaluated with the health
assessment questionnaire-disability index (HAQ-DI; MCID
reduction¼ 0.3). HRQoL was assessed using the Short-Form 36 (SF-
36) (including Physical and Mental Component Summary [PCS and
MCS] subscores; MCID improvement¼5). The Routine Assessment of
Patient Index Data (RAPID3), an index of three pt-reported core
dataset measures (physical function, pain and pt global estimate of
status), was also assessed (MCID reduction¼2.0).
Results: A total of 646 patients were randomized and treated with ABA
(n¼ 318) or ADA (n¼ 328) on background MTX. Pt characteristics were
balanced. A similar proportion of patients achieved a HAQ-DI
response from baseline to year 1 (60.4% patients in the ABA arm vs
57.0% patients in the ADA arm). Improvements in pt pain
(mean% S.E.) were 46.5 4.2% vs 35.64.1% at 6 months, and
53 6.1% vs 39.26.0% at 1 year for ABA and ADA, respectively.
Improvements in PtGA were 40.27.3% vs 27.67.2% and
46.13.5% vs 41.2 3.4% for ABA and ADA at 6 months and 1
year, respectively. Fatigue decreased from baseline by –22.4 1.5%
vs –19.91.5% at 6 months, and –23.2 1.5% vs –21.41.5% at 1
year for ABA and ADA, respectively. Improvements in all domains of
the SF-36, including PCS and MCS, observed at 6 months were
maintained at 1 year. For RAPID3, the ABA- and ADA-treated groups
demonstrated improvements (mean S.E.) of –2.7 0.1 vs –2.50.1 at
6 months and –2.9 0.1 vs –2.7 0.1 at 1 year.
Conclusions: In this first head-to-head comparison, subcutaneous
abatacept demonstrated significant improvements with similar kinetics
of response in PROs and HRQoL measures over 1 year, which were
comparable to ADA.
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Research Support, Consultant Fees, UCB—Research support,
Consultant fees, Speaker bureau (CME only), Biogen Idec,
Centocor—Consultant Fees. D.K., BMS—Research Support,
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86. IMPACT OF A MULTI-BIOMARKER DISEASE
ACTIVITY TEST ON RHEUMATOID ARTHRITIS DECISION
AND THERAPY USE
Wanying Li1, Eric H. Sasso1, Daniel Emerling2, Guy Cavet1 and
Kerri Ford1
1Medical, Crescendo Bioscience Inc, South San Francisco, CA, and
2Research, Biosimplify, El Cerrito, CA, USA
Background: This study assessed how use of an objective multi-
biomarker disease activity (MBDA) test for RA affects treatment
decisions made by health care providers (HCPs) in clinical practice.
Methods: At routine office visits, 101 patients with RA were assessed
by their HCPs (N¼6), and they provided samples for MBDA testing.
HCPs completed surveys before and after viewing the MBDA test
result, recording dosage and frequency for all planned RA medications
and physician global assessment of disease activity. Frequency and
types of change in treatment plan that resulted from viewing the MBDA
test result were determined. The main outcome measure was the
percentage of cases in which the HCP changed the planned treatment
after viewing the MBDA test result.
Results: Prior to HCP review of the MBDA test, disease modifying
anti-rheumatic drug (DMARD) use by the 101 patients included MTX in
62% of patients; HCQ 29%; TNF-inhibitor 42%; non-TNF-inhibitor
biologic agent 19%; and other drugs at lower frequencies. Review of
MBDA test results changed HCP treatment decisions in 38 cases
(38%), of which 18 involved starting, discontinuing or switching a
biologic or non-biologic DMARD. Other changes involved drug
POSTER VIEWING I Tuesday 23 April 2013, 10.30–11.30 i87
dosage, frequency or route of administration. The total frequency of
use of the major classes of drug therapy changed by <5%. Treatment
plans changed 63% of the time when the MBDA test result was
perceived as being not consistent or somewhat consistent with the
HCP assessment of disease activity. Study limitations include sample
size and a lack of control group or longitudinal follow-up.
Conclusions: The addition of the MBDA test to clinical assessment
led to meaningful changes in the treatment plans of 38% of RA
patients being cared for by HCPs in office practice. Even though
treatment was potentially improved, the overall quantity of drug use
was minimally affected.
Disclosures: G.C., Crescendo Bioscience, Inc.—Employee. D.E.,
Crescendo Bioscience, Inc.—Consultant. K.F., Crescendo
Bioscience, Inc.—Former Employee. W.L., Crescendo Bioscience,
Inc.—Employee. E.S., Crescendo Bioscience, Inc.—Employee.
87. STUCK IN THE MIDDLE WITH DAS: UNDERTREATMENT
OF MODERATE RHEUMATOID ARTHRITIS
Bronwen Mackenzie-Green1, David Collins1, Elizabeth Price1 and
Lyn Williamson1
1Rheumatology, Great Western Hospital, Swindon, UK
Background: In the UK access to biologic agents for the management
of RA is restricted to patients with a DAS28 score of 5.1 or greater.
Scores of 3.2 or less are accepted as representing good disease
control or remission. Patients whose score falls between 3.2 and 5.1
have no access to biologic therapy despite inadequately controlled
disease and may be vulnerable to worse outcomes. We sought to
ascertain the burden of disease activity in our clinics using DAS28 as a
surrogate marker and to assess outcome for patients with higher
scores.
Methods: For 4 weeks all RA patients attending outpatient clinics had
DAS28CRP calculated and treatment decisions reviewed. Patients
were grouped into 5 groups; Group 1 DAS<2.9, Group 2 DAS 2.6–
3.09; Group 3 DAS 3.1–4.19, Group 4 DAS 4.2–5.09; Group 5 DAS
>5.1. Patients in group 4 and 5 had their DAS scores reassessed at up
to 6 months.
Results: 333 patients were reviewed and DAS calculated on 312.
Groups 1 and 2 (good control): 166 patients (53.2%) of whom
(4.2%) had their DMARD therapy increased at the index consultation,
and 21 (21.7%) had their DMARD dose reduced.
Group 3: 70 patients (22.4%) of whom 30 (42.8%) had DMARD
therapy increased and 2 (2.8%) decreased.
Group 4: 39 patients (12.5%) of whom 19 (48.7%) had DMARD
therapy increased and none decreased.
Group 5: 37 patients (11.9%) of whom 32 (86.4%) had DMARD
therapy increased or were started on a biologic agent and none
decreased.
Follow up data were available in 20 group 4 patients and 21 group 5
patients with a mean follow up of 147 days. In group 4 the mean
change of DAS was –0.16 (range þ1.42..–2.90), (ns). In group 5 the
mean change in DAS was –1.17 (range þ0.94...–4.18), (P<0.05).
7 patients in group 5 had moved onto biologic therapy between
assessments and none of the group 4 patients had.
Using the EULAR DAS response criteria in group 4, 3 patients had a
good response, 4 moderate response and 13 no response. Of these 6
had deteriorated as judged by an increase in DAS of >0.6. In group 5;
3 had a good response, 9 a moderate response and 9 no response
with 3 deteriorating. The 6 best responses were seen in patients who
had initiated biologic therapy.
Conclusions: This small real life study showed that 53% of our
patients sampled have reasonable disease control and that treatment
escalation decisions correlate well with disease activity. Paradoxically
however, patients in group 4 with moderately active disease who (in
the UK) are not biologic eligible, are clearly disadvantaged with less
change in DAS on follow up and greater numbers showing a
deterioration compared with the more severe group. Further follow
up is required, but it is worrying that despite the drive for earlier
aggressive treatment, this group with be lost in the therapeutic
pathway and in the fullness of time will have worse a outcome than
those with a more severe disease.
Disclosures: The authors have declared no conflicts of interest.
88. SHOULD MSK ULTRASOUND ASSESSMENT BE DONE
ROUTINELY PRE-BIOLOGICS IN INFLAMMATORY ARTHRITIS
MANAGEMENT?
Janardhana Golla1 and Vipul Vagadia1
1University Hospital of North Tees, Stockton on Tees, UK
Background: Musculoskeletal ultrasound (MUS) has proven to be more
sensitive method of detecting synovitis than clinical examination. It may
provide a useful role in routine assessment for established IA
(inflammatory arthritis) patients for appropriate selection of biologics.
We have retrospectively compared and analysed MUS, as pre-biologics
assessment in IA patients and its impact on further management.
Methods: We analysed images and reports of MUS examinations of
40 patients, between Sept’11 and March’12 for IA patients diagnosis
based on ACR criteria. US (Ultrasound) done by MSK radiologist using
OMERACT synovitis criteria by both Gray scale and Power Doppler.
Studies of the hands and/or wrists were selected for patients who
failed two DMARDS and had US requested pre-biologics. Patients
who had more than 6 tender joints and had 2 or less swollen joints
were included in analysis.33 were female.12/40 (30%) RhF positive
and 6/40 (15%) ACPAb positive. Mean age 46 years and disease
duration was 2.7 years. Synovitis was categorized as high, inter-
mediate or low probability as per OMERACT scoring. Categorization of
US synovitis was made without knowledge of the patient’s subsequent
management or diagnosis. Data were gathered for each patient
including clinical diagnosis, age, duration of disease, information of
previous DMARDs, further change in treatment including biologics,
RhF and ACPAb status, DAS28.
Results: All patients were biologics naive. 32/40 on MTX, 24/40 on
SSZ, 14/40 LEF, 10/40 HCQ. Mean DAS28 was 4.72 (3.75 –5.92).17/40
showed low probability of synovitis (Grade 0–1) and 3/17 had DAS28
>5.1 who were started on biologics.14/17 DMARD treatment remain
unchanged.9/40 showed high probability synovitis (Grade 3/4) and 3/9
had DAS <5.1 so, treatment unchanged and rest 6/9 had biologics.14/
40 had intermediate probability of synovitis (Grade 2) and 3/14 had
biologics as had DAS28>5.1 while 11/14 had triple DMARD/steroids.
Ideally, 9/40 (22%) patients should have different treatment outcome
based on US finding.
Conclusions: Our observations suggest that routine use of US in
established IA patients during pre-biologics assessment can have
significant impact on outcome and management. Clinical high DAS28
score may show low probability of US synovitis and may prevent
inappropriate biologics usage. On the contrary, moderate to high US
probability of synovitis may be associated with low to moderate
DAS28. Targeting people with moderate to low DAS28 by US earlier
may alter future management for IA. The data further suggest that
patients with negative RhF and ACPAb might benefit most from MUS
in the diagnostic process. Routine pre-biologics US assessment for IA
should be clinical practice but may need further wide scale clinical
studies and evidence.
TABLE 1. Results
US in
established IA,
n¼ 40
Synovitis high
probability,
n¼ 9
Intermediate
probability,
n¼ 14
Low probability,
n¼ 17
Mean
DAS28 4.72
RF (n) 8/9 4/14 0
Anti-CCP (n) 5/9 1/14 0
Disclosures: The authors have declared no conflicts of interest.
89. REGISTRY, AUDIT AND OBSERVATIONAL STUDY OF
GREATER GLASGOW AND CLYDE RHEUMATIC PATIENTS
RECEIVING BIOLOGIC THERAPY: BASELINE FEATURES AND
ADVERSE EVENT PROFILE IN PATIENTS WITH RHEUMATOID
ARTHRITIS
Elaine Morrison1, Ann Tierney2, Hilary Wilson3 and John Hunter4
1Rheumatology, Southern General Hospital, Glasgow, 2Centre for
Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow,
3Rheumatology, Stobhill Hospital, Glasgow and 4Rheumatology,
Gartnavel General Hospital, Glasgow, UK
Background: Our aims were (i) to establish a registry and collaborative
audit of all Greater Glasgow and Clyde (GGandC) patients already
receiving or starting biologic therapy in routine clinical practice; (ii) to
provide detailed local data to the participating clinicians; (iii) to share
data, including adverse events, between units; and (iv) to ensure good
clinical governance in our biologic prescribing.
Methods: In 2007 we established a multi-disciplinary clinical group to
contribute to the project. Six units participated (Southern General
Hospital, Gartnavel General Hospital, Stobhill Hospital, Glasgow Royal
Infirmary, Victoria Infirmary and Inverclyde Royal Hospital). Biologics
are prescribed in accordance with the British Society for
Rheumatology (BSR) guidelines. All GGandC rheumatic patients
receiving biologics are included but only data from those with RA
are being presented here. Patient demographic data are collected at
baseline. DAS28 and HAQ are calculated at baseline, 3 months,
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6 months and thereafter 6 monthly. Past medical history, weight and
smoking status are recorded.
Results: Of 1118 rheumatic patients registered, the majority (n¼ 701,
F¼563, M¼ 138) have RA. For patients with RA, the median age
(n¼ 701) is 57 years (range¼19–86 years) and median disease
duration (n¼474) is 11 years (range¼ 1–56 years). Median baseline
DAS28 (n¼ 474) was 6.2 (range 3.89–9). Most patients with RA receive
biologics in years 1–10 after disease onset. Median number of
previous DMARDs (n¼ 576) is 3 (range 1–9). Reported adverse event
profile is similar to previous studies. Most patients discontinue therapy
due to lack of effect rather than an adverse event. Social deprivation
index shows that 33% of all the rheumatic patients on our registry are
Carstairs 6 and 7 (most socially deprived).
Conclusions: The majority of our patients with RA receiving a biologic
have a high baseline DAS28 and long disease duration. There is good
concordance of prescribing with BSR guidelines. There is a high
prevalence of social deprivation in our patient group. Despite this, the
reported adverse event profile is similar to that in the literature.
Disclosures: The authors have declared no conflicts of interest.
90. SYSTEMATIC REVIEW COMPARING COMBINATION
DMARD THERAPY WITH ANTI-TNF PLUS METHOTREXATE IN
DRUG-RESISTANT RHEUMATOID ARTHRITIS
Margaret H. Ma1 and David L. Scott1
1Academic Department of Rheumatology, King’s College London,
London, UK
Background: We have previously shown that combination DMARD
therapy is comparable to anti-TNF therapy in combination with MTX in
early RA. In this systematic review, we aim to compare these 2
intensive regimes in RA patients with any disease duration who have
been refractory to DMARD monotherapy.
Methods: A systematic literature search of Cochrane Library,
EMBASE and Ovid Medline identified 19 relevant RCTs. The following
outcome measures were assessed: ACR 20, ACR 50, ACR 70, patient
withdrawal for adverse events, patient withdrawal for inefficacy and
mean change in HAQ. Review Manager 5.1 was used for meta-
analysis.
Results: There were no direct head to head studies comparing
DMARD combination therapy with anti-TNF and MTX. Consequently
indirect comparisons were made between RCTs of DMARD combina-
tions and anti-TNF with MTX when compared with DMARD mono-
therapy. Both combination DMARDs and anti-TNF/MTX gave more
ACR20, 50 and 70 responders. In combination DMARD studies, there
were more withdrawals for inefficacy and toxicity when compared with
DMARD monotherapy. In anti-TNF with MTX RCTs, there were less
patient withdrawals due to efficacy and no difference in patient
withdrawal due to toxicity when compared with MTX monotherapy.
Both anti-TNF and combination DMARDs both gave greater improve-
ments in HAQ compared with DMARD monotherapy, however, the
improvement may be more pronounced in anti-TNF with MTX studies
(Table 1).
Conclusions: Unlike in early RA studies, this systematic review
showed that anti-TNF with MTX seems to have more efficacious and
less toxic than combination DMARD therapy in patients resistant to
DMARD monotherapy. This implies that anti-TNF with MTX should be
the preferable treatment regime in patients who have failed 1 DMARD.
A direct head-to-head study is required to confirm these findings.
TABLE 1. Combination DMARDs or anti-TNF/MTX vs DMARD monotherapy
Outcomes Studies OR (95% CI)
ACR20
Combo DMARDs 6 2.75 (1.79, 4.22)
anti-TNF/MTX 9 5.14 (3.12, 8.348)
ACR50
Combo DMARDs 6 5.07 (3.10, 8.29)
anti-TNF/MTX 9 8.02 (4.47, 14.38)
ACR70
Combo DMARDs 5 4.85 (2.34, 10.05)
anti-TNF/MTX 9 5.58 (3.09, 10.09)
Withdrawal due to inefficacy
Combo DMARDs 9 1.51 (1.02, 2.25)
anti-TNF/MTX 7 0.13 (0.10, 0.17)
Withdrawal due to toxicity
Combo DMARDs 9 1.59 (1.08, 2.36)
anti-TNF/MTX 7 0.94 (0.62, 1.41)
WMD (95% CI)
HAQ
Combo DMARDs 3 –0.19 (–0.27, –0.10)
anti-TNF/MTX 1 –0.35 (–0.56, –0.14)
Disclosures: The authors have declared no conflicts of interest.
91. TOCILIZUMAB IS EFFECTIVE FOR THE TREATMENT OF
ANTI-TNF- AND RITUXIMAB-REFRACTORY RHEUMATOID
ARTHRITIS
Venkat Reddy1,2, Samantha Moore2 and Michael Ehrenstein1,2
1Rheumatology, University College London, London and
2Rheumatology, University College Hospital, London, UK
Background: A significant proportion of patients with RA continue to
have active disease and accrue joint damage despite the use of
DMARDs and biologics including anti-TNF agents and B-cell depletion
therapy with rituximab. We have evaluated whether this group of
patients respond to treatment with tocilizumab as data on sequential
use of tocilizumab after rituximab are deficient.
Methods: Nineteen patients with seropositive (rheumatoid factor and/
or anti-cyclic citrullinated peptide antibody) and 6 with seronegative
RA (based on American College of Rheumatology diagnostic criteria)
were included. The mean age of patients was 54 years and the mean
disease duration was 9 years. All had an active disease with a mean
DAS28-ESR score (DAS-ESR, DAS28) of 6.1, which was refractory to
at least two conventional DMARDs; two anti-TNF agents and rituximab
used sequentially. All patients received tocilizumab, (3–48 months after
rituximab), intravenously (8 mg/kg every 4 weeks). Clinical, laboratory
and functional parameters were monitored every 3 months for the
duration of follow up of 12 months. Statistical analysis was performed
using paired ‘t’ test.
Results: At 12 months, 23 patients (92%) had sustained response
(DAS28 improved by>1.2) and 10 (40%) were good responders
(European League Against Rheumatism response criteria) with DAS28
3.2. None of the patients required an increase in the dose of
background DMARDs. Two patients had discontinued treatment due
to adverse events (recurrent mouth ulcers and diverticulitis).
At 3 and 12 months, the mean S.D. of: DAS28 reduced from
6.11.3 to 3.71.4 (P¼ 0.001) and 2.50.8 (P< 0.0001); tender joint
count decreased from 13.810.1 to 5.67.6 (P¼0.011) and 1.4 2.3
(P¼0.003); and swollen joint count decreased from 5.73.7 to
3.22.7 (P¼ 0.2) and 0.80.8 (P¼ 0.009), respectively. A significant
improvement in patient reported outcomes visual analogue -global
(P¼0.02) and -pain (P¼ 0.02) scores was noted only by 9 months. An
improvement in functional activity was noted in SF-36 (P¼0.01), but
not FACIT-52 or HAQ scores at 12 months. Also, at 3 and 12 months,
the mean S.D. of: ESR decreased from 4133 to 8 11 (P¼0.0002)
and 89 (P¼0.001); and CRP from 2323 to 2 3 (P¼ 0.001), 28
(P¼0.001), respectively. There was no significant increase in the level
of cholesterol or alanine aminotransferase. The neutrophil and platelet
count reduced significantly, but remained within the normal range and
did not result in adverse events.
Conclusions: Sequential use of tocilizumab appears to be well
tolerated, safe and effective for anti-TNF- and rituximab-refractory
RA. Whereas very rapid control of CRP was achieved within 1 month,
clinical outcome measures continued to improve beyond 3 months.
Monitoring of cholesterol, full blood count and liver function tests is
warranted.
Disclosures: The authors have declared no conflicts of interest.
92. EFFICACY AND LONG-TERM SAFETY OF RITUXIMAB IN
RHEUMATOID ARTHRITIS: 8 YEAR FOLLOW-UP OF THE
FIRST 52 PATIENTS TREATED IN THE BELFAST TRUST
RHEUMATOLOGY UNIT
Claire Benson1, Maria Wray1, Andrew Cairns1, Gary Wright1,
Adrian Pendleton1, Michelle McHenry1, Allister Taggart1 and
Aubrey Bell1
1Department of Rheumatology, Belfast HSCT, Belfast, UK
Background: B-cell targeted therapy using rituximab, an anti-CD20
monoclonal antibody, is an effective treatment for RA. Trials suggest
that rituximab is well tolerated over time.
Methods: We present an observational case analysis of longevity,
efficacy and safety data on the first 52 patients with active RA treated
in our unit with rituximab.
Results: Our cohort of patients (40 female and 12 male) received their
first dose of rituximab between September 2004 and May 2008 (273
patient-years). Patients were clinically assessed and adverse events
documented at least every 6 months. 12 patients had received no
previous anti-TNFa agents. The remaining 40 patients had received an
average of 1.9 previous anti-TNFa agents. 3 of these patients had also
received anakinra.
As of October 2012, 44% (n¼ 23) of patients were receiving
ongoing treatment with rituximab (average number of cycles per
patient¼ 6.4). 21% of patients (n¼11) had stopped due to primary
failure of rituximab, 8 of whom subsequently responded to other
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biologic drugs: tocilizumab (n¼4), abatacept (n¼2) and etanercept
(n¼ 2). 13% had stopped due to secondary failure of rituximab (n¼7)
(average number cycles per patient¼4.1), 5 of whom subsequently
responded to other biologic drugs: tocilizumab (n¼4) and adalimumab
(n¼ 1). 12% (n¼6) had gone into clinical remission and required no
further biologic treatment after 1 cycle (n¼3) and after 2 cycles (n¼ 3).
The remainder of patients had their rituximab treatment stopped due
to sepsis (n¼ 3), heart failure (n¼ 1) and at patient’s request (n¼1).
Of the 13.4% of patients who were sero-negative (n¼ 7), 5 had
primary failure of rituximab and the other 2 remain on treatment at 6
years.
Overall 34.6% (n¼ 18) of patients developed a persistently (>6
months) low IgM and 10% (n¼5) developed a persistently low IgG. A
further 17% (n¼9) developed a transiently low IgG or IgM. One patient
developed a persistent panhypogammaglobulinaemia and was taken
off all biologic drugs. Of the 5 patients with persistently low IgG, 2
patients died of sepsis, 1 patient had primary failure of rituximab, 1
patient had secondary failure of rituximab (after 3 cycles) and only 1
remained on treatment (6 cycles).
There was no significant difference in infection rates in patients who
developed a low IgM. There were no cases of tuberculosis or
opportunistic infections.
Conclusions: Our experience confirms that rituximab is an effective
long term treatment for RA, particularly in seropositive disease. It
remains generally well tolerated over time. Data from our unit showed
a significantly higher frequency of persistently low IgM (34.6%) and low
IgG (10%) compared with a recent large pooled observational case
analysis (Van Vollenhoven et al) (22.45 and 3.5% respectively).
Disclosures: The authors have declared no conflicts of interest.
93. DEVLOPMENT OF PATIENT-REPORTED EXPERIENCE
MEASURES FOR RHEUMATOID ARTHRITIS: RESULTS OF A
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Background: Improving patient experience is a priority for the NHS: (i)
the Care Quality Commission (CQC) and National Institute for Health
and Clinical Excellence (NICE) published a Quality Standard that
focused on improving pt experience; (ii) the NHS Patient Experience
Framework (NPEF), published by the DoH, outlines the issues most
important to patient experience of the NHS. It highlights the need to
measure and improve the pt experience. Patient experience is not
currently routinely measured in RA. Commissioning for Quality in
Rheumatoid Arthritis (CQRA) has previously developed quality com-
missioning metrics for RA. We demonstrated that implementation of
the metrics can facilitate improvement of quality of care. CQRA has
now developed a set of Patient Reported Experience Measures
(PREMs) based on the NPEF.
Methods: CQRA carried out a scoping project to gain patients’ views
and establish patient priorities on their journey through the healthcare
system. Scoping covered eight areas corresponding to the evidence-
based list in the NPEF. A focus group was selected as the preferred
scoping method: 8–10 participants were selected and a maximum
variation sample was used. Participants were National Rheumatoid
Arthritis Society (NRAS) members aged 18 years, with active RA. A
pilot study interview was conducted with one participant and analysis
undertaken by recording and transcribing the focus group and
interview. Using NVivo qualitative analysis software, data were
coded and emerging themes grouped together. Similarities and
differences between respondents were then identified.
Results: The scoping project identified a number of key themes to be
addressed in the design of a rheumatology services PREMs
questionnaire. Overarching themes were: respect for patient-centred
values, preferences, and expressed needs; coordination and integra-
tion of care; information, communication, and education; physical
comfort; emotional support; involvement of family and friends;
transition and continuity of care; and access to care. A PREMs
questionnaire was developed through CQRA workshops using outputs
from the scoping project together with the NICE clinical guideline on
RA management, mapped against the NPEF. The questionnaire has
been piloted in NRAS members, refined and re-piloted in four RA units.
We will present full results of these pilot studies and the final PREMs
questionnaire.
Conclusions: Following the development of RA quality commissioning
metrics, CQRA has developed and piloted a PREMs questionnaire.
Implementation of the PREMs and metrics will enable commissioners
and providers to improve the quality of services delivered to RA
patients and to improve patient experience of care under an integrated
team for a long term condition.
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Background: Randomized controlled trials (RCTs) of abatacept (ABA)
in patients with RA have demonstrated sustained, long-term efficacy,
high pt retention and consistent safety. We evaluate 1-year retention,
efficacy and safety of ABA in routine RA clinical practice (according to
label at enrolment) in Europe and Canada.
Methods: AbataCepT In rOutiNe clinical practice (ACTION) is an
ongoing, non-interventional, prospective cohort of ABA-treated RA
patients with inadequate response to MTX or anti-TNF therapy,
initiated Mar 2008. At data cut-off in Feb 2012, all patients had
reached 1-year follow-up. Retention rate (Kaplan–Meier estimate) and
EULAR response are reported over 12 months for patients on
treatment with data available, according to whether patients received
ABA as a first biologic, or after failure of 1 or 2 anti-TNFs. Safety is
reported for all patients enrolled, up to data cut-off.
Results: 1138 patients were enrolled and 1120 were evaluable. 1000
(89.3%) had previously failed biologic treatment, 982/1000 (98.2%)
had failed 1 anti-TNF. 120 (10.7%) had not received biologic
treatment prior to ABA. Baseline characteristics are shown (Table 1).
Retention rates, reasons for discontinuation and EULAR responders at
Mth 12 are presented for ABA when used as the first biologic, first
switch agent, and after 2 anti-TNFs. Earlier usage of ABA resulted in
higher retention (Table 1). 106 serious adverse events were reported in
60/1138 (5.3%) patients (21 discontinuations). 11 deaths were
reported, 3 were due to serious infections unrelated to ABA (sepsis
[4 months after last ABA infusion; pt was receiving tocilizumab];
Pneumocystis jiroveci [4 months after last ABA infusion, pt had deep
vein thrombosis]; and urosepsis). 23 patients experienced serious
infections; 9 malignancies; 5 serious cardiac disorders; and 3 serious
vascular disorders. No TB occurred, 2 opportunistic infections were
reported (cytomegalovirus and P. jiroveci).
Conclusions: This large-scale, international, observational, real-life
study showed that abatacept as the first biologic in MTX-inadequate
responders, or after first or later switching from anti-TNFs, was
associated with good pt retention over 12 months, particularly when
used earlier in the course of treatment. Abatacept was clinically
effective and well tolerated. These data are consistent with previous
RCTs and national registry data for biologics.
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Background: Partnerships with patients are understood as essential
for the development of evidence-based care in the UK and across the
globe and may offer one solution to the slow translation of clinical
science into meaningful treatment. Service user partnerships in
research exist in mental health but there have been few advances in
other disciplines. Our objective was to develop a patient-generated
expectancy measure for new treatments in Rheumatoid Arthritis, using
a participatory method.
Methods: Stage1: three repeated focus groups and two expert panels
with RA patients conducted by a Patient Researcher. Stage2:
feasibility study of draft scale with 22 consecutive outpatient attendees
over 1 week and Stage3: psychometric testing with 140 patients over
4 months.
Results: Patients identified 21 dimensions of new treatment expecta-
tions, grouped into (i) physical (ii) psycho-social and (iii) expectations
relating to impact of treatment. This resulted in a scale assessed in a
feasibility study and psychometric assessment. 140 patients were
recruited into stage 3. 64 returned the questionnaires so far with
following personal characteristics: mean age 58 years (S.D.: 13.71), age
range 25–95 years, 73% female, 74% Caucasian and 43% reported
disabled. Table 1 shows mean of scores of the 3 identified domains at
each time point. There were no mean difference in the physical domain
between times 1 and 2 (paired t-test, P¼ 0.1948) however, there were
significant mean differences between the two time points in the
psycho-social and impact of new treatment dimensions, P¼0.0332,
0.0096, respectively. The kappa statistics for the individual items
ranged from 0.22 to 0.55, indicating moderate agreement, the internal
consistency of the items was high, with an overall Cronbach’s alpha of
0.88. All 21 items of the new score were entered into an exploratory
factor analysis. Three dominant factors were identified that contributed
to expectations in RA, the four-factor solution explained a total of 58%
of the variance.
Conclusions: Participatory research methods are useful in involving
patients actively in research and to produce collaboratively a feasible,
valid and acceptable measure in RA. Our results illustrated that
patients’ expectations were high in relation to the impact of treatment,
compared with the physical and psycho-social expectations. The
scale will be included in a longitudinal observational study, with newly
diagnosed patients, to assess sensitivity to change for expectations
when in receipt of new treatment over time.
TABLE 1. Mean scores of the three domains at each time point and kappa statistics
Time 1 Time 2 Percentage
observed
agreement
Percentage
expected
agreement
ka
Items Mean (S.D.) Mean (S.D.)
Physical domain 24.09 (8.21) 22.41 (11.73) 76 66 0.30
Psycho-social domain 18.09 (8.73) 15.41 (9.59) 73 64 0.25
Impact of new
treatment domain
29.83 (9.67) 25.67 (13.81) 78 66 0.35
aWeighted kappa, all six scales were included.
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COMPARABLE ONSET OF TREATMENT RESPONSE AND
MAGNITUDE OF EFFICACY IMPROVEMENT OVER 6 MONTHS
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Background: The aim of this analysis was to compare clinical and
functional responses with subcutaneous (SC) abatacept administered
with or without an intravenous (i.v.) loading dose, in patients with active
RA and inadequate response to MTX.
Methods: Patients from the intent-to-treat populations of the
ACQUIRE and AMPLE studies randomized to SC abatacept plus
MTX were included in this analysis. All patients received fixed-dose SC
abatacept 125 mg/week; in ACQUIRE, patients also received an i.v.
loading dose (10 mg/kg based on weight range) on Day 1; no i.v.
loading dose was administered in AMPLE. For this post-hoc analysis,
assessments included ACR 20 and Health Assessment Questionnaire-
Disability Index (HAQ-DI) response (improvement of 0.3) over
6 months, with patients who discontinued considered non-responders.
Mean changes from baseline over 6 months in DAS28-CRP were
assessed in patients with DAS28 >5.1 at baseline (last observation
carried forward), to account for differences in baseline disease activity
between the two studies.
Results: A total of 736 patients from ACQUIRE (i.v. loading dose) and
318 patients from AMPLE (no i.v. loading dose) were included. All
patients were biologic naı¨ve at baseline, with mean disease duration of
7.6 and 1.8 years, DAS28 (CRP) 6.2 and 5.5, and HAQ-DI 1.72 and
1.5 in ACQUIRE and AMPLE, respectively. Efficacy was compared at
Days 15, 29, 57, 85, 113, 141 and 169. For patients treated with SC
abatacept with an i.v. loading dose, ACR 20 response rates were 24.6,
44.5, 58.0, 66.6, 69.3, 72.4 and 74.8%, respectively. For patients
treated without an i.v. loading dose, ACR 20 response rates were
similar: 27.4, 42.5, 58.5, 60.1, 66.0, 70.1 and 66.0%, respectively.
TABLE 1. Baseline characteristics
ABA first biologic,
n¼ 120
ABA first switch (1 previous anti-TNF),
n¼ 481
ABA after 2 previous anti-TNFs,
n¼ 501
Baseline characteristics
Age, mean (S.D.), years 59.0 (13.8), n¼ 120 56.2 (12.4), n¼ 481 56.0 (12.4), n¼501
RA duration, mean (S.D.), years 7.0 (7.8), n¼ 118 9.8 (8.0), n¼ 465 13.1 (9.4), n¼ 484
1 CV risk or comorbidity, n (%) 86 (71.7), n¼ 120 336 (69.9), n¼ 481 365 (72.9), n¼ 501
Mth 12 outcomes
Retention, Kaplan–Meier estimate, % (95% CI) 83.6 (74.9, 89.5) 73.2 (68.8, 77.2) 64.1 (59.5, 68.4)
Discontinuation for lack of efficacy, n (%) 11 (9.2), n¼ 120 75 (15.6), n¼ 481 101 (20.2), n¼ 501
Discontinuation for intolerance, n (%) 3 (2.5), n¼120 11 (2.3), n¼ 481 15 (3.0), n¼501
Good EULAR response, % 34.5, n¼ 29 34.5, n¼ 194 27.3, n¼ 165
Moderate EULAR response, % 37.9, n¼ 29 41.8, n¼ 194 45.5, n¼ 165
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HAQ-DI response rates were also similar: 31.7, 45.1, 53.5, 59.5, 63.2,
64.4 and 68.3%, respectively, with the i.v. loading dose, and 31.8,
42.8, 54.4, 58.5, 60.1, 61.9 and 61.0%, respectively, without. For the
overall populations, mean (S.D.) changes from baseline to Day 169 in
DAS28 were –2.57 (1.30) and –2.09 (1.38) in ACQUIRE and AMPLE,
respectively. For patients with baseline DAS28 >5.1, mean changes in
DAS28 over time were also comparable for both studies.
Conclusions: Time to onset and magnitude of ACR 20 and HAQ-DI
responses and DAS28 improvements were similar for patients treated
with SC abatacept with or without i.v. loading who have RA and an
inadequate response to MTX. Previous pharmacokinetic data show
that in the absence of i.v. loading, target therapeutic concentrations
are achieved in the majority of patients by Week 2 of SC abatacept
treatment. The findings from this post-hoc analysis suggest that SC
abatacept can be given effectively without an i.v. abatacept loading
dose.
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Background: The AMBITION study was the first trial to demonstrate
clinical superiority of tocilizumab (TCZ) monotherapy over MTX
monotherapy. In patients MTX-naive or MTX-free for 6 months,
treatment with TCZ 8 mg/kg monotherapy resulted in statistically
greater ACR 20/50/70 responses than MTX at 24 weeks. This post-hoc
exploratory analysis evaluates the long-term efficacy of patients who
remained on TCZ monotherapy in an ongoing long-term extension
(LTE) of AMBITION.
Methods: Patients randomized to TCZ 8 mg/kg in AMBITION (n¼286)
who entered the LTE were included. During the LTE, MTX/other
DMARDs could be added in patients not achieving a 50% reduction in
the number of tender and swollen joints from baseline (core study).
Efficacy assessments and DMARD status were evaluated up to 240
weeks.
Results: Of 243 patients on TCZ monotherapy who entered the LTE,
57.2% (n¼139) remained on monotherapy [102 (73%) reached 240
weeks], 9.9% (n¼ 24) added a DMARD before LTE entry, and 32.9%
(n¼ 80) added a DMARD after LTE entry [18.5% (n¼ 45) 3 weeks
post-entry and 14.4% (n¼35) >3 weeks post-entry]. DMARDs
included MTX (93%) HCQ (3%) LEF (2%) and parenteral gold (2%).
Mean SJC, TJC and DAS28 (data not shown) decreased sharply during
the first 24 weeks and levels continued to decrease or were maintained
thereafter (Table 1). Similar trends in improved disease state were
observed (40.1% and 16.7% of patients achieved DAS28 <2.6 and
clinical disease activity index (CDAI) remission by week 24 respec-
tively); rates increased or were maintained thereafter; absolute
numbers achieving these endpoints increased to weeks 192 and
120. Absolute numbers of patients achieving DAS28 3.2 and CDAI
low disease activity increased to weeks 120 and 96 (data not shown),
respectively.
Conclusions: TCZ monotherapy provided durable efficacy in a large
proportion of patients continuing treatment in the AMBITION LTE.
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Background: Nitric oxide (NO) plays a central role in inflammatory joint
diseases and has been shown to correlate with inflammatory disease
activity in these rheumatic diseases. Hence, it is a potential therapeutic
target. In recent years, IL-6 antagonist, tocilizumab has emerged as an
important therapeutic agent in treatment of RA. However, there is no
study to evaluate the impact of tocilizumab on NO. So we aim to
investigate the serum nitrite levels in patients with RA before and after
12 weeks treatment with IL-6 antagonist, tocilizumab, and to correlate
with inflammatory disease activity measures and endothelial dysfunc-
tion in RA patients.
Methods: Eleven anti-IL-6-naive RA patients (mean age 51.64 1.44
years; disease duration 11.36 2.5 years) with high DAS28 (> 5.1)
despite treatment with stable doses of conventional DMARDs were
investigated. Inflammatory disease activity [DAS28 and HAQ-Disability
Index (HAQ-DI) scores, ESR and CRP], serum nitrite concentration,
serum thiobarbituric acid reactive substances (TBARS) concentration,
and endothelium-dependent and -independent vasodilation of the
brachial artery were measured before and after 12 weeks of therapy
with tocilizumab 8 mg/kg intravenous infusion every 4 weeks. Serum
nitrite levels and FMD were also estimated in 10 age- and sex-
matched healthy controls.
Results: In healthy volunteers, mean serum nitrite level was
5.00.11 mmol/l. Serum nitrite levels in RA patients at baseline were
significantly higher as compared with healthy volunteers (P<0.01).
Level of serum nitrite significantly decreased from 7.410.18 to
6.130.19 (P<0.001), and FMD from 8.21 0.88% to 14.600.96 %
(P<0.001). ESR from 57.458.9 to 25.275.11 mm in the first hour
(P¼0.005), and CRP from 34.878.01 to 13.38 3.60 mg/dl
(P¼0.004) after treatment. DAS28 and HAQ-DI scores were signifi-
cantly reduced, from 6.590.24 to 4.470.24 (P¼ 0.005) and from
2.170.14 to 1.08 0.09, respectively with tocilizumab in RA patients.
There was a significant correlation of serum nitrite with FMD, CRP and
DAS28 both at baseline (P<0.05) and after 12 weeks therapy
(P<0.05) with tocilizumab in RA patients.
Conclusions: Nitrite production is enhanced to a greater extent in
patients with RA compared with controls and decrease in nitrite level
TABLE 1. Efficacy over time in patients on TCZ monotherapy
Weeka 0b 24c 72 120 168 192 216 240
n¼ 139 n¼138 n¼ 126 n¼ 121 n¼ 113 n¼ 108 n¼ 102 n¼ 90
SJC (66 joints), mean (S.D.) 19.0 (10.36) 4.8 (6.04) 2.7 (4.68) 1.8 (3.09) 2.1 (3.74) 1.7 (3.36) 1.5 (3.13) 1.8 (3.37)
TJC (68 joints), mean (S.D.) 32.5 (14.39) 10.5 (12.48) 6.2 (8.40) 4.8 (7.47) 4.2 (5.38) 3.7 (5.34) 4.0 (5.61) 3.8 (6.70)
n¼ 138 n¼137 n¼ 121 n¼ 115 n¼ 111 n¼ 107 n¼ 100 n¼ 87
DAS28 <2.6, n (%) 0 (0) 55 (40.1) 65 (53.7) 69 (60.0) 70 (63.1) 73 (68.2) 62 (62.0) 58 (66.7)
DAS28 3.2, n (%) 0 (0) 74 (51.8) 90 (74.4) 89 (77.4) 84 (75.7) 82 (76.6) 76 (76.0) 68 (78.2)
n¼ 138 n¼138 n¼ 124 n¼ 121 n¼ 112 n¼ 109 n¼ 103 n¼ 90
CDAI remission (2.8), n (%) 0 (0) 23 (16.7) 36 (29.0) 52 (43.0) 43 (38.4) 43 (39.4) 39 (37.9) 37 (41.1)
CDAI low disease activity (10), n (%) 0 (0) 66 (47.8) 77 (62.1) 85 (70.2) 77 (68.8) 84 (77.1) 80 (77.7) 72 (80.0)
TJC and SJC: missing data handled using LOCF method. Physician/patient global assessments: no imputation of missing post-baseline values performed.
aAssessed number of patients decreased over time. bBaseline in AMBITION. cLTE entry.
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after the treatment is associated with improvement in disease activity
and improvement of endothelial dysfunction. Serum nitrite level may
not only act as good predictor of inflammatory disease activity but also
predicts response to therapy in RA.
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Background: Novel foot orthoses (FOs) were functionally optimized
using patient-specific dynamic foot function data and produced using
additive manufacturing (AM) techniques. Selected plantar foot pres-
sure and 3 dimensional (3-D) motion analysis parameters mapped to
critical early stage foot impairments in an RA population were
developed for computer aided (CAD) FO design. Two AM techniques
[selective laser sintering (SLS) and fused deposition modelling (FDM)]
were used to manufacture personalized orthoses (PFOs) based on
identical CAD designs. PFOs were developed and tested in compar-
ison with standardized, hand-manufactured prescribed custom FOs
(SFOs) and shod for mode-of-action and patient experience.
Methods: FOs were tested in random order for a period of 7 days in a
series of 15 patients with early RA of< 2 years duration. Mode-of-
action was determined from 3-D kinematic and kinetic analyses and
plantar pressure distribution. Patient experience monitored FO
comfort, fit and short-term symptom and activity benefits were
determined through a series of Numerical Rating Scales (NRS) and
5-point Likert scales.
Results: Motion control was significantly greater for selected
mechanical variables in SLS or FDM FOs in comparison with SFOs
(Table 1). Peak internal dorsiflexion and inversion ankle complex
moments indicate no significant differences between test conditions
(P¼0.269 and P¼ 0.428 respectively). No significant differences
between PFOs and SFOs for plantar pressure distribution were
observed. SLS PFOs decreased medial and lateral forefoot peak
pressure in comparison with shod (P¼0.018 and P¼0.022 respec-
tively). Patient reported device comfort scores (range 0–10) were
equivalent (P¼0.517) with mean S.D. scores of 6.1 (2.0), 6.4 (2.3) and
7.0 (2.4) for SFO, FDM and SLS FOs respectively. Device fit scores
were also equivalent (P¼0.633) with mean S.D. scores of 6.6 (2.4),
7.3 (1.6) and 7.5 (2.1) for SFO, FDM and SLS FOs respectively. Short-
term symptom benefits and activity levels were significantly better in
SLS in comparison with SFOs devices (P¼0.025 and P¼ 0.046
respectively). Both SLS and FDM devices were subject-rated as more
effective than SFOs (P¼0.014, P¼0.009). No adverse reactions were
reported.
Conclusions: PFOs designed to optimize foot function demonstrate
better mechanical mode-of-action than SFOs for early RA-associated
foot impairments. Short-term use provides a safe and optimal patient
experience.
TABLE 1. Selected mechanical function variables with differences
Variable Comparison Mean/median
differences
(S.E.)
95%
CI
P-value
Peak forefoot
inversion
SLS-SFO –1.8 (0.4) –2.9, –0.6 0.000
Mean forefoot
inversion
SLS-SFO 0.7 (0.3) 0.0, 1.4 0.036
Peak rearfoot
dorsiflexion
SLS-SFO
FDM-SFO
1.4 (0.3) 1.5 (0.4) 0.4, 2.4 0.3, 2.6 0.003 0.010
Mean rearfoot
dorsiflexion
FDM-SFO –0.7 - 0.014
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100. COMPARATIVE EFFICACY OF BIOLOGICS AS
MONOTHERAPY AND IN COMBINATION WITH
METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS
WITH AN INADEQUATE RESPONSE TO CONVENTIONAL
DMARDS: A NETWORK META-ANALYSIS
Felicity Buckley1, Axel Finckh2, Tom W. Huizinga3,
Fred Dejonckheere4 and Jeroen P. Jansen1
1Consultancy, MAPI Consultancy, Boston, MA, USA,
2Rheumatology, University Hospital of Geneva, Geneva, Switzerland,
3Rheumatology, Leiden University Medical Centre, Leiden,
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Background: A number of (network) meta-analyses indirectly com-
pare the efficacy of biologic agents for RA. However, comparisons of
the efficacy of a biologic agent as monotherapy vs a biologic agent
combined with DMARDs are rare and none include all currently
approved biologic agents.
Methods: A systematic literature review was undertaken to identify
RCTs that assessed biologic agents as monotherapy or in combination
with DMARDs in adult RA patients with an inadequate response to
traditional DMARDs (DMARD-IR). 22 RCTs were included. Bayesian
network meta-analysis models were used to simultaneously synthe-
sise the results of the included studies and to obtain the effect
estimates of the biologic agents in their usual dose, alone and
combined with MTX in terms of ACR20/50/70 response at 24 weeks vs
placebo. As demonstrated previously, the effects of anti-tumour
necrosis factor therapies (aTNFs) were assumed to be exchangeable.
Given this, and the limited data identified for these therapies as
monotherapy in DMARD-IR patients, aTNF data were pooled.
Results: Using random effects modelling, in this DMARD-IR popula-
tion, tocilizumab (TCZ)þMTX was shown to be comparable to other
biologicsþMTX for ACR20/50/70 response. For monotherapies, the
probability of ACR20/50/70 response for TCZ was found to be greater
than for aTNFs. With TCZ as monotherapy, an ACR20/50/70 response
similar to that of TCZþMTX was observed ([RR 0.98 (95% credible
interval [CrI]: 0.70, 1.71)], [RR 0.92 [95% CrI: 0.62, 1.56)], and [RR 1.04
(95% CrI: 0.58, 2.08)], respectively). aTNFs as monotherapy were likely
to be less effective than aTNFsþMTX in terms of ACR20 and ACR50
response ([RR 0.71 (95% CrI: 0.48, 1.64)] and [RR 0.52 (95% CrI: 0.3
1.25)], respectively).
Conclusions: Based on a network meta-analysis involving indirect
comparison of trial findings, it was observed that for DMARD-IR
patients: the efficacy of TCZþMTX was in line with the efficacy of
other biologic agentsþMTX. In monotherapy, TCZ was associated
with a higher ACR response than was observed with aTNF. ACR
response of TCZ as monotherapy was similar to that of TCZþMTX,
whereas aTNF as monotherapy was likely to show a lower ACR
response than aTNFþMTX.
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101. LONG-TERM SAFETY OF TOCILIZUMAB IN RA
PATIENTS TREATED FOR A MEAN DURATION OF 3.7 YEARS
Mark Genovese1, Anthony Sebba2, Andrea Rubbert-Roth3, Juan
J. Scali4, Rieke Alten5, Joel M. Kremer6, Laura Pitts7, Emma Vernon7
and Ronald F. van Vollenhoven8
1Immunology and Rheumatology, Stanford University Medical
Centre, Palo Alto, CA, 2Rheumatology, University of South Florida,
Tampa, FL, USA, 3Internal Medicine, University of Cologne, Cologne,
Germany, 4Rheumatology, Durand University Hospital, Buenos Aires,
Argentina, 5Rheumatology, Schlosspark Klinik, University Medicine
Berlin, Berlin, Germany, 6Rheumatology, Albany Medical College,
Albany, NY, USA, 7Medical, Roche Products Ltd, Welwyn Garden
City, UK and 8Medicine, Karolinska Institute, Stockholm, Sweden
Background: Tocilizumab (TCZ) has demonstrated efficacy in
improving signs/symptoms, reducing joint damage and improving
physical function in RA patients. This analysis assessed the long-term
safety of TCZ in adult RA patients (up to 5.8 years (y) TCZ exposure).
Methods: Safety data were pooled for all patients who received 1
TCZ dose in 5 placebo-controlled trials (OPTION, TOWARD, RADIATE,
AMBITION and LITHE), a clinical pharmacology study and long-term
extension studies.
Results: 4009 patients were included with a mean (median [range])
treatment duration of 3.7 (4.6 [0.0–5.8]) y and total observation time
14,994 pt-y (PY). Over time, rates of serious adverse events (SAEs),
serious infections, myocardial infarction (MI) SAEs, stroke SAEs,
hepatic SAEs and gastrointestinal (GI) perforations were stable (Table
1). The overall rate of AEs leading to withdrawal was 5.0/100PY (95%
CI 4.7, 5.4). Infections, laboratory abnormalities and neoplasms were
the most common AEs leading to withdrawal (0.97/100PY, 0.89/100PY
and 0.80/100PY). 8 patients withdrew because of anaphylaxis events.
Rates/100PY (95% CI) were 14.6 (14.0, 15.3) for SAEs and 0.57 (0.45,
0.70) for deaths. The most common SAEs were infections (4.5/100 PY
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[95% CI 4.1, 4.8)]; the most common serious infection was pneumonia
(0.95/100 PY; 95% CI 0.80, 1.12). Overall rates/100PY (95% CI) of MI
SAEs, stroke SAEs and hepatic SAEs were 0.25 (0.18, 0.35), 0.31
(0.23, 0.42), and 0.04 (0.01, 0.09) respectively. The GI perforation rate
was 0.20/100PY (95% CI 0.13, 0.29). There were 194 confirmed
malignancies, including 65 non-melanoma skin cancer (NMSC) cases
(overall rate/100PY (95% CI) of 1.29 (1.12, 1.49); excluding NMSC:
0.86 (0.72, 1.02). Standardized incidence ratio for malignancies (all
sites) was 1.19 (0.99, 1.42).
Conclusions: The safety profile of TCZ remained stable over a mean
treatment duration of 3.7 y and no new safety signals emerged. AE
rates described are consistent with those reported in the RA
population and the overall rate of malignancies does not exceed
reported background rates.
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102. DOSE REDUCTION IN RITUXIMAB RETREATMENT MAY
DELAY ACHIEVEMENT OF OPTIMAL RESPONSES
Mohammed I. Sharif1, Sudipto Das1, Paul Emery1, Helen Maciver1,
Wendy Shingler1, Philip Helliwell1, Katharina Sokoll1 and
Edward M. Vital1
1Rheumatology, East Surrey Hospital, Surrey, 2University of Leeds,
Leeds and 3Rheumatology, Bradford Teaching Hospital, Bradford,
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Background: The best long-term treatment strategy for rituximab has
not been established. Retreatment at a fixed interval of 6 months
maintains stable disease activity1 and half-dose is equally effective in
first-cycle responders1. In first-cycle non- or moderate responders,
responses may improve further after a second cycle at full dose2,3.
We used a strategy of fixed 6-monthly retreatment at half-dose
following an initial full dose cycle in responders and non-responders,
and looked for changes in clinical response.
Methods: Patients received 2 x 1000 mg rituximab at month 0 (C1), 2 x
500 mg rituximab at month 6 (C2) and 2 x 500 mg at month 12 (C3)
regardless of C1 response. All patients were positive for RF and/or
anti-CCP. 17/41 were taking concomitant MTX and 9/41 other
DMARDs. All rituximab cycles were given with 2 x 100 mg methyl-
prednisolone. Two patients were taking concomitant oral predniso-
lone. DAS28 was measured at baseline and at 3–6 months after each
cycle and compared with baseline of the first cycle.
Results: To date, 41 patients received C1, 34 C2, 17 C3 and 14 C4
with outcome data. For all patients, mean (S.D.) DAS28 at baseline and
after C1, C2 and C3 were 6.15 (0.74), 4.14 (1.10), 3.82 (1.14) and 3.13
(1.06) respectively. EULAR Non/Moderate/Good responses were
achieved by 5, 28 and 8/41 patients (12/68/20%) in C1; 5, 18 and
11/34 patients (15/53/33%) in C2; 1, 6, 10/17 patients (6/35/59%) in
C3; and 1, 3 and 10/14 patients in C4 (7/21/71%). 3/5 patients with
Non response in C1 responded to C2.
Proportions of patients with a change in EULAR response between
C1–C2 and C2–C3 was compared for the 17 patients who received
three cycles. For C1–C2: 53% patients maintained the same EULAR
response, 18% improved and 29% worsened. For C2–C3, 47%
maintained the same response, 41% improved and 12% worsened.
DAS28 for these patients is shown in Figure 1. There was no significant
difference between C1 and C2 and a trend to reduction in DAS28 after
C3 (P¼ 0.128, paired t-test).
Conclusions: Some C1 non-responders responded to retreatment
with half-dose at 6 months, but response rate across all patients was
similar. Incremental improvements in C1 non- or moderate responders
were seen more frequently after a second half-dose retreatment. This
suggests that dose reduction may delay achievement of optimal
responses in C1 non- or moderate responders, and these patients
should have two full-dose cycles before reducing doses. Future work
will analyse B-cell depletion in this cohort.
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TABLE 1. Event rate/100 PY (95% CI) per 12 month period
0–12 13–24 25–36 >36 months
AEs leading to
withdrawal
9.3 (8.3, 10.4) 4.5 (3.8, 5.3) 4.1 (3.4, 5.0) 3.2 (2.7, 3.7)
SAEs 16.1 (14.7, 17.4) 14.2 (12.9, 15.7) 15.7 (14.2, 17.2) 13.5 (12.5, 14.5)
Serious infections 4.6 (4.0, 5.4) 3.9 (3.3, 4.7) 5.4 (4.6, 6.3) 4.2 (3.7, 4.7)
MI SAEs 0.29 (0.14, 0.53) 0.17 (0.05, 0.39) 0.29 (0.12, 0.57) 0.26 (0.15, 0.43)
Stroke SAEs 0.43 (0.24, 0.71) 0.26 (0.11, 0.52) 0.29 (0.12, 0.57) 0.28 (0.16, 0.45)
Hepatic SAEs 0 0.10 (0.02, 0.29) 0.04 (0, 0.2) 0.03 (0, 0.13)
GI perforations 0.20 (0.08, 0.42) 0.13 (0.04, 0.34) 0.29 (0.12, 0.57) 0.19 (0.1, 0.34)
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